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Reversible protein phosphorylation plays a fundamental role in signal transduction. 
Protein phosphatases, protein kinases and some modular domains (SH2, PDB, etc) 
form key components of the highly complex human phosphoproteome network. 
Dysregulation of this network is known to cause many human diseases including 
cancer. The phosphotyrosine (pTyr) residue in a protein serves as one of the key 
recognition and binding elements for signaling proteins. Its hydrolytic instability and 
poor cell permeability has led to the development of many novel phosphate mimics. 
This thesis described several pTyr mimics, most of which possess suitable N- and C-
terminus for conjugation/incorporation into peptide/protein synthesis, including 1) 
isoxazole carboxylic acid-based mimics that possess better cell permeability and 
hydrolytic stability; 2) quinone methide-based mimics containing fluorogenic and 
self-immobilizing properties; 3) vinyl sulfonate-based mimics having irreversible 
covalent labeling reactivity. These small pTyr mimics were subsequently incorporated 
into either small molecules or peptides to provide expanded chemical tools for further 
chemical biology applications, such as bioimaging, FACS and activity based-profiling. 
Furthermore, we successfully explored the multi-component Ugi reaction for rapid 





List of Publications 
(2007 - 2012) 
 
1 Kalesh, K. A.; Shi, H.; Ge, J.; Yao, S. Q.* “The Use of Click Chemistry in the 
Emerging Field of Catalomics”, Org. Biol. Chem., 2010, 8, 1749-1762 
 
2 Ge, J.; Wu, H.; Yao, S. Q.* “An Unnatural Amino Acid That Mimics 
Phosphotyrosine”, Chem. Commum., 2010, 46, 2980-2982 
 
3 Wu, H.; Ge, J.; Yao, S. Q.* “High-Throughput Small Molecule Microarray 
Identify Inhibitory Binder Against 14-3-3 Protein”, Angew. Chem. Intl. Ed., 
2010, 49, 6528-6532 
 
4 Wu, H.; Ge, J.; Yang, P.-Y.; Yao, S. Q.* “A Peptide Aldehyde Microarray for 
High-Throughput Discovery of Cysteine Protease Inhibitors”, J. Am. Chem. 
Soc., 2011, 133, 1946-1954 
 
5 Wu, H.; Ge, J.; Yao, S. Q.* “Small Molecule Microarray: The First Decade 
and Beyond”, Chem. Commum., 2011, 47, 5664-5670 
 
6 Ge, J.; Li, L.; Yao, S. Q.* “A Self-Immobilizing and Fluorogenic Unnatural 




7 Ge, J.; Cheng, X.; Tan, L. P.; Yao, S. Q.* “Ugi Reaction-Assisted Rapid 
Assembly of Affinity-Based Probes against Protential Protein Tyrosine 
Phosphatase”, Chem. Commum., 2012, 48, 4453-4455 
 
8 Li, L.; Ge, J.; Wu, H.; Xu, Q. -H.; Yao, S.Q.* “Organelle-Specific Detection of 
Phosphatase Activities with Two-Photon Fluorogenic Probes in Cells and 
Tissues”, J. Am. Chem. Soc., 2012, Submitted 
 
9 Ge, J.; Cheng, X. -M.; Li L.; Yao, S. Q.* “Unexpected Phosphotyrosine 
Mimicking Probes Target Protein Disulfide Isomerase in Different Cell Lines”, 




List of Figures 
Figures Page 
1.1 Phosphorylation and dephosphorylation on Ser/Thr/Tyr catalyzed by Kinases 
and Phosphatases. 2 
1.2 Schematic representation of the catalytic mechanism of PTP1B. 6 
1.3 The effect of SH2 domains in SHP2 protein. 8 
1.4 Fluorogenic pTyr mimics. 10 
1.5 Caged pTyr mimics. 12 
1.6 Pmp and F2Pmp based inhibitors. 14 
1.7 PTP1B inhibitors with carboxylic acid-based pTyr bioisosteres. 15 
1.8 Different pTyr mimics-based binders of Grb2 SH2 domain. 16 
1.9 Improvement of the inhibition and cellular activity by discovering new pTyr 
mimics. 17 
1.10 Inhibitors containing pTyr bioisosteres. 18 
1.11 Irreversible pTyr mimics. 19 
1.12 Overview of some developed bioorthogonal reactions used in the tag-free 
approach. 20 
1.13 Proteome profiling with activity-based probes (ABPs) and affinity-based 
probes (AfBPs). 22 
1.14 Quinone methide-based approach. 24 
1.15 Bromobenzylphosphonate and vinyl sulfone/sulfonate based probes. 25 
2.1 Structures of pTyr, its bioisosteres and the one in this study. 29 
2.2 Molecular docking of I1 and I2. 33 
2.3 Coomassie gel of the purified STAT3 SH2 domain. 34 
2.4 IC50 of two inhibitors determined by FP experiments. 35 
xii 
 
2.5 IC50 graphs of I2 against PTP1B. 36 
2.6 LC profiling of hydrolytic stability test. 37 
2.7 T47D cell viability in the presence of the two inhibitors. 40 
3.1 Representative examples of previously reported fluorogenic PTP substrates, 2-
FMPT and Withers’ sugar probe. 43 
3.2 Overall working principle of the pTyr mimic 3-2 and its peptide probes. 45 
3.3 LC profiles and MS results of uncaging process. 50 
3.4 Time-dependent fluorescence measurements of UV-irradiated 3-2 and pER. 
 52 
3.5 Microplate-based enzymatic assay of PTP1B and other four enzymes. 53 
3.6 Labeling of PTP1B with different concentrations of compound 3-2’. 54 
3.7  Fluorescence gel of PTP1B-overexpressed bacterial lysates treated with 
uncaged 3-2 and 3-1. 55 
3.8 Indirect competition assay.  
3.9 MS profiling of PTP1B before and after incubation with uncaged 3-2. 57 
3.10 Comparison of PTP1B’s activity, with and without compound 3-1’ and 3-2’.59 
3.11 Histogram of flow cytometry analysis of dead cells after UV-irradiation. 60 
3.12 Density-plot of FACS analysis of HeLa cells treated with 3-1 and 3-2. 61 
3.13 FACS analysis of five cell lines.  63 
3.14 Fluorescence images of HeLa cells treated with different non-irradiated 
peptide probes. 64 
4.1 Structures of representative PTP1B/MptpB bidentate inhibitors. 67 
4.2 Chemical synthesis of the 25 AfBPs using Ugi reaction.  68 
4.3 The AfBP work flow. 70 
4.4 IC50 graphs of all 25 AfBPs against PTP1B and MptpB. 74 
xiii 
 
4.5 Optimization of labeling of pure PTPs. 78 
4.6 Affinity-based profiling of recombinant PTP1B and MptpB against the 25 
AfBPs. 80 
4.7 Results of proteome profing of P23 against MCF-7 lysate. 83 
5.1 Overall strategy of probe design. 87 
5.2 Synthetic schemes of four probes. 88 
5.3 The structure of Tri-N3. 89 
5.4 In situ proteome-profiling of different probes against MCF-7. 91 
5.5 Dose and time-dependent in situ proteome profilings. 92 
5.6 Organelle co-localization bioimaging experiemtns. 94 
5.7 Fluorescence image of MCF-7 pull-down experiments after 5-1. 96 
5.8 Immunofluorescence experiments were performed with anti-PDIA1. 97 
5.9 IC50 curves for 5-1 against PDI. 99 
5.10 Concentration-dependent labeling of pure PDI protein by 5-1. 100 
5.11 Labeling PDI with different pretreatment.  101 
5.12 In situ labeling results of four cell lines. 102 
5.13 In situ pull-down results of four cell lines. 103 
5.14 Effects of 5-1 on the cell proliferation of four cell lines. 104 
6.1 The analytical HPLC results of compound 2-6’. 111 
6.2 The LCMS results of compound I1. 112 




List of Tables 
Table  Page 
2.1  Opitmization of isoxazole ring formation under Cu(I)-catalyzed, 1.3-dipolar 
cycloaddition conditions. 31 
2.2  The results of cell permeability. 38 
3.1  Kinetic data of compound 3-1’ and 3-2’ with PTP1B. 58 
4.1  Summary of IC50 values of 25 AfBPs against PTP1B/MptpB. 75 
5.1  List of proteins identified from mass spectrometry of three specifc bands. 95 
6.1  Summary of AfBPs and their characterizations. 137 





List of Schemes 
 
Scheme Page 
2.1 Synthesis of 2-6
’
 - the Fmoc-protected form of 2-6. 31 
2.2 Solid-phase synthesis of I2. 32 
3.1 Chemical synthesis of 3-2. 46 
3.2 Chemical synthesis of 3-1. 47 
3.3 Fmoc-based SPPS of the three CPP-containing probes. 48 
4.1 Chemical synthesis of 4-1 and 4-2. 71 




List of Abbreviations and Symbols 
2-FMPT  2-Fluoromethyl phosphotyrosine 
ABP Activity based probe 
ABPP  Activity based protein profiling 
AfBP affinity-based probe 
AIDS Acquired immunodeficiency syndrome 
ALS Amyotrophic lateral sclerosis  
Boc tert-Butoxycarbonyl 
br Broad 
BSA Bovine serum albumin 
CBB  Coomassie brilliant blue-stained gel 
CC  Click chemistry 
CuAAC Cu(I)-catalyzed 1,3-dipolar cycloaddition 
CPP Cell-penetrating peptide 
Cs2CO3  Cesium carbonate 
C-terminus Carboxyl terminus 
CuI Copper(I) iodide 
DAST Diethylaminosulfur trifluoride 
DBU 1,8-Diazobicyclo[5.4.0]undec-7-ene 
DCM  Dichloromethane 
dd Doublet of doublets 
DIC N,N'-diisopropylcarbodiimide  




DIFMUP 6,8-Difluoro-4-methylumbelliferyl phosphate 
DMAP 4-Dimethylaminopyridine 
DMEM Dulbecco's Modified Eagle Medium  
DMF  Dimethylformamide 
DMSO Dimethylsulfoxide 
DSP Dual-specificity phosphatase 
DTT Dithiothreitol 
E. coli Escherichia coli 
EA/EtOAc Ethyl acetate 
EDC 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide·HCl 
EDT 1,2-ethanedithiol 
EDTA Ethylenediamine tetraacetic acid 
EGF Epidermal growth factor 
equiv Equivalent 
ER Endoplasmic Reticulum  
ESI Electron Spray Ionization 
Et Ethyl 
Et2O diethyl ether 
EtOH Ethanol 
F2Pmp Phosphonodifluoromethyl phenylalanine 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FL  Fluorescent gel 
Fmoc 9-Fluorenylmethoxycarbonyl 
FMPP 2-Fluoromethyl phenyl phosphate  
xviii 
 
FMT Fluoro-O-malonyltyrosine  
FP  Fluorescence polarization 
g Gram 
Grb2  Growth factor receptor-bound protein 2 
HATU  O-(7-azabenzotrizol-1-yl)-1,1,3,3-tetramethyluronium 
HBSS Hank's balanced salt solution 
HBTU  O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluorophosphate 
HCl  Hydrogen chloride 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human immunodeficiency virus 
HOAT  1-Hydroxy-7-azabenzotriazole 
HOBT  N-Hydroxybenzotriazole 
HPLC High performance liquid chromatography 
Hz Hertz 
IC50  Half the maximal inhibitory concentration 
IF Immunofluorescence 
K2CO3 potassium carbonate 
Kd Dissociation constant 
KM Michaelis constant 
KHCO3 potassium hydrogen carbonate 
LC Liquid chromatography 
LC-MS Liquid chromatography-mass spectrometry 
LiOH Lithium hydroxide 












MptpB Mycobacterium protein tyrosine phosphatase B 
MS Mass 
MUP Methyl Umbelliferone Phosphate 
MW Molecular weight 
Na2SO4. Sodium sulfate 
NaBH4 Sodium borohydride 
NaCl Sodium chloride 
NaHCO3 Sodium bicarbonate 
NaN3 Sodium azide 
NaOH Sodium hydroxide 
Ni-NTA Nickel-nitrilotriacetic acid 
nM Nanomolar 
NMR Nuclear magnetic resonance 
NPE 1-(2-nitrophenyl)ethyl  
N-terminus Amino terminus 




P loop phosphate-binding loop  
PBS Phosphate buffered saline 
pCAP Phosphocoumaryl amino propionic acid  
pCAPF 8-fluorocoumarin deviatioin of pCAP 
PDIA1 Protein disulfide isomerase A1 
PDIA4 Protein disulfide isomerase A4 
PDIA6 Protein disulfide isomerase A6 
PEG Polyethylene glycol 
pH Negative logarithm of the hydroxonium ion concentration 
Ph Phenyl 
PK Protein kinase 
Pmp Phosphonomethyl-phenylalanine  
PMS Phenazine methosulfate  
PPI Protein-protein interaction  
ppm Parts per million 
PP Protein phosphatase 
PTB Phosphotyrosine binding 
PTK Protein tyrosine kinase 
PTM Post-translational modification 
PTP1B Protein tyrosine phosphatase 1B 
PTP Protein tyrosine phosphatase 
pTyr. Phosphotyrosine 





S.D. Standard deviation 
sat. Saturated 
SDS-PAGE  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SH2 Src homology domain  
SHP1 Src homology region 2 domain-containing phosphatase-1 
SHP2 Src homology region 2 domain-containing phosphatase-2 
SPPS Solid phase peptide synthesis 
STAT Signal transducer and activator of transcription 
STS Staurosporine 
t Triplet 
TCPTP T-cell protein tyrosine phosphatase 
TB Tuberculosis 
TBAF Tetrabutylammonium fluoride 




tBuOH tert-Butyl alcohol 
TCEP Tri(2-carboxyethyl)phosphine 
TFA  Trifluoroacetic acid 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
TLC Thin layer chromatography 
TMS  Trimethylsilyl 
xxii 
 
TOF Time of flight 











C degree celsius 
λem Emission wavelength  
λex Exitation wavelength 




List of Amino Acids 
 
One Letter Three Letter Amino Acid 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
r D-Arg D-Arginine 
Fx - Cyclohexylalanine 
1 
 
Chapter 1 Introduction 
 
 The human genome project is regarded as a milestone in the journey toward 
deciphering the entire story of life. DNA is a unit of heredity in a living organism, but 
it could not fully interpret the whole life and living processes. Functional annotation 
and characterization of proteins have received much attention in recent years, since 
proteins play a critical role in virtually every biological process, including cell-cell 
communication, cell death and cell division. The large-scale study of proteins, 
particularly their structures and functions is called “proteomics”. Of special 
importance are enzymes, which as biocatalysts play fundamental roles in regulating 
almost every cellular processes and metabolic transformation. Dysfunctions of 
enzymes are known to cause major human diseases including cancers, AIDS and 
Parkinson diseases. Consequently, it is not surprising that enzymes account for more 
than 25% of all current drug targets.
1
  
 Enyzmes catalyze most post-translational modification (PTM) events in 
biological processes. The PTMs are regulatory processes by the chemical 
modification of a protein after its translation, usually through the covalent addition of 
a small molecule to one of the amino acid residues.
2
 Among different posttranstional 
events involved in cellular signaling pathways, phosphorylation/dephosphorylation of 
a protein is a key reversible modification that regulates protein activity, localization, 
degradation and complex formation. The identification and characterization of 
proteins containing phosphate groups are named phosphoproteomics
2c
, a branch of 
proteomics. The phosphoproteomics network is extremely complex with a 
composition of around 500 mammalian protein kinases
3














, etc.), which interact with phosphorylated proteins. More than 30% of all 
human proteins are estimated to be phosphorylated. Abnormal levels of protein 
phosphorylation are linked to a wide range of diseases. Consequently, proteins 
involved in the phosphoproteomics network (e.g. kinases, phophatases, 
phosphoserine/threonine/tyrosine binding proteins) have become attractive targets for 
therapeutic developments.
3, 4
 The tyrosine residue is one of the important sites which 
could be tagged with a phosphate group by protein kinases, referred to as 
phosphotyrosine. This chapter will provide a brief overview of some phosphotyrosine 









1.1 Protein Tyrosine Phosphatases 
 Reversible protein phosphorylation and dephosphorylation reactions (shown in 
Figure 1.1) are catalyzed by protein kinases (PKs), which are responsible for 
phosphorylation, and protein phosphatases (PPs), which govern protein 
dephosphorylation, respectively. There are two main classes of protein phosphatases 
based on their structure and substrate specificity, namely protein serine/threonine 
phosphatases (PSTPs) and protein tyrosine phosphatases (PTPs). Among these 
phosphatases, PTPs, which catalyze the dephosphorylation of pTyr residues in 
proteins, are a structurally diverse and highly specific family of enzymes. There are a 
total of 107 PTPs encoded in the human genome. Evidences have shown that most 
PTPs are related to human diseases
9
, for example, PTP1B acts as a negative regulator 
of the insulin and leptin receptor pathways, CD45 is associated with autoimmune 
diseases and LAR downregulates signaling from multiple receptor tyrosine kinases. 
Consequently, the development of inhibitors against PTPs is a proven approach in the 




1.1.1 PTP family 
 The PTP super-family could be broadly categorized into at least four 
subfamilies: 1) classical PTPs, 2) dual-specificity phosphatases (DSPs), 3) Cdc25 
phosphatases, and 4) low-molecular-weight (LMW) PTPs.
10
 The classical PTPs (~ 38 
members) are specific for phosphotyrosine substrates and are sub-divided into non-
receptor and receptor-like forms based on their subcellular localizations. The non-
receptor PTPs such as PTP1B, TCPTP, SHP1 and SHP2 are non-transmembrane 
PTPs which have other extra sequences for specific subcellular localization or binding 
target proteins. Receptor-like PTPs have a single transmembrane domain and other 
4 
 
extracellular domains. These kinds of PTPs may have one or two catalytic domains.
9a
 
The second catalytic domain is normally inactive but plays a role in regulating the 
activity, specificity and stability of the PTPs. In contrast to the classic PTPs, dual-
specificity phosphatases dephosphorylate not only on pTyr but also on pSer/pThr 
residues in proteins.
11
 Cdc25 phosphatases which could also dephosphorylate both 
pTyr and pThr residues, have different primary and tertiary structures and are hence 
grouped differently.
12
 The overexpression of Cdc25 has been detected in multiple 
cancers and correlated with poor prognosis. LMW PTPs are a family of 18 kD 
proteins involved in cell growth regulation and share no significant differences except 




1.1.2 Structure of PTP catalytic domain and mechanism of PTP catalysis 
 One of the key features to define the PTP family is their conserved catalytic 
domain (active site) which contains signature motif (H/V)C(X)5R(S/T).
4d, 10b, 14
 This 
motif is located in the phosphate-binding loop (P loop), where the cysteine residue 
acts as a nucleophile and reacts with the phosphate head during catalysis. The arginine 
residue functions in both binding to the substrate and stabilizing the phosphoenzyme 
intermediates. There are other conserved loops, such as the pTyr recognition loop and 
WPD (Trp-Pro-Asp) loop. The recognition loop is created to selectively target pTyr as 
its substrate and not pSer and pThr residues in the target protein. The WPD loop 
contains a general acid-base catalyst (Asp) which takes part in the dephosphorylation 
reaction and could also affect the conformation change of PTPs. Upon binding to the 
substrate, the WPD loop closes over the phenyl ring of the tyrosine residue, holding it 
as a tight binding pocket to facilitate subsequent reactions. Mutations in this loop, 
5 
 
such as the W354A mutation in Yersinia PTP and the P425A mutation in SHP1, are 
known to attenuate or even disable the PTP’s’ enzymatic activity.  
 The general mechanism of PTP catalysis has been explained with the aid of 
PTP structural information.
15
 PTP1B, one of the best studied PTPs and a novel target 
for type 2 diabetes, is used as a model to illustrate the mechanism (Figure 1.2). The 
phosphate head of pTyr is first stabilized by the positive charges in Arg221 in the P 
loop. Upon binding, as mentioned above, PTP1B changes its conformation and closes 
the WPD loop to further stable the interaction. Asp181 in the WPD loop forms a 
hydrogen bond with the phenolic oxygen of pTyr. At this moment, the Cys215 serves 
as a nucleophile and attack pTyr in the P loop, with Asp181 acting as a general acid 
by protonation of the leaving group on the substrate.
16
 Subsequently, a water molecule 
attacks the thiophosphoryl intermediate, liberating an inorganic phosphate and 
regenerating the active enzyme.
16 
In this step, Asp181 residue acts as a general base 

















1.2 SH2 domains 
 The Src homology domains (SH2 domains) originally identified in numerous 
oncoproteins, such as Src and Fps, recognize pTyr and serve as the prototype for 
phosphorylation-dependent protein-protein interaction (PPI) modules that organize 
the multi-protein complexes in the cell signaling pathway.
18
 In recent years, SH2 




 SH2 domains are relative small protein modules with a sequence of 
approximately 100 amino acids. The human genome encodes 116 SH2 domains in 
approximately the same number of proteins. The basic structure of SH2 domains 
contains a central anti-parallel β-sheet surrounded by two α-helices, like a sandwich. 
They have a conserved pocket
20
 which could specifically recognize pTyr. 
Furthermore, researchers found that there is the so-called “specificity determining 
region” which recognizes several additional residues, three to five amino acids to the 




 In the cell, SH2 domains are usually a part of a protein possessing other 
domains such as the catalytic domain and other binding modules. SH2 domain-
containing proteins participate in a wide variety of intracellular processes (SAP with 
signal regulation
21
, c-Cbl with ubiquitination
22
, SHP1 and SHP2 with 
dephosphorylation
23
, Src and Fps with phoshorylation
20, 24
). Mutations within the SH2 
domain of several proteins have been implicated with defects in signaling pathways 
and cause diseases such as Noonan’s syndrome (SHP2) and the X-linked 
lymphoproliferative syndrome (SAP). For example, SHP2 (which contains a PTP 
domain and two SH2 domains) is a PTP with a proven oncogenic function. As 
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illustrated in Figure 1.3, SHP2 is normally endogenously expressed in mammalian 
cells in a low-activity state masked by the N-terminal SH2 domain which binds 
intramolecularly to the PTP domain. When cell membrane receptors are activated, 
two of the phosphorylated tyrosines within the SHP2-binding domain of these 
proteins interact with the two SH2 domains in SHP2. Subsequently the conformation 
of SHP2 is changed, which leads to complete restoration of the full enzymatic activity 
in SHP2. As a consequence, activated SHP2 dephosphorylates substrates which play 
important roles in various signal transduction processes. Mutation of SHP2, especially 
in the N-terminal SH2 domain, could cause hyperactivation of its catalytic activity 




Figure 1.3 The effect of SH2 domains in SHP2 protein. In the inactive state, SHP2 is kept 
silence by interaction of the N-terminal SH2 domain with the PTP catalytic domain. a) Self-
control releasing. In the C-terminal tail, both Y542 and Y580 are phosphorylated. 
Subsequently, the phosphorylated tail binds to two SH2 domain and it leads to the activation 
of SHP2; b) SHP2-binding protein. Activation of surface receptors and subsequent tyrosine 
phosphorylation of binding sites in receptor-tyrsoine kinases or some scaffolding adapter 
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proteins for the two SH2 domains, leads to recruitment of SHP2; c) Mutation of N-terminal 
SH2 domain. In Noonan syndrome, mutations in SHP2 impair the inhibitory interaction of 
two domains, leading to decrease the binding affinity of two domains and increase activity of 
SHP2. 
 
1.3 Mimics of pTyr 
 As discussed above, the addition of a phosphate group to a protein or other 
organic molecules is important in many biological processes. Specifically, the pTyr 
moiety serves as a critical affinity element as it is the key recognition and binding part 
for the phosphoproteomic network. Up to date, various chemical biology tools have 
been developed for the study of pTyr-based proteins. One common strategy is the 
creation of novel types of pTyr mimics. The potential mimics could be used in the 
rational design of inhibitors/binders, with greater pharmaceutical impacts, to achieve 
specific controls of intracellular pathways and to investigate the roles of targets. In 
addition, pTyr mimics could possess both the N- and C-terminus similar to natural 
amino acids, thus enabling their easy incorporation into peptides and even proteins 
using native chemical ligation
26
 or nonsense suppression technology
27
. In the next 
sections, four types of pTyr mimics, namely the fluorogenic pTyr mimics, caged pTyr, 
reversible non-hydrolyzable pTyr mimics and irreversible pTyr mimics, will be 
discussed. Subsequently, we will highlight the application of activity-based protein 
profiling (ABPP), a relatively new method and its successful contributions in the 
discovery of new probes for detecting PTPs. 
 
1.3.1 Fluorogenic mimics of pTyr  
 Fluorogenic compounds generally exhibit low or no fluorescence until 
enzymatic reaction occurs. The common fluorophores used in the design of 
10 
 
fluorogenic compounds include coumarin, fluorescein and rhodamines, which could 
form ethers, amides or chemically reduced dyes. Such derivatives have a very weak 
fluorescent intensity relative to their hydrolyzed/oxidized products, which are phenol, 
anilines or the oxidized fluorophores. Taking PTPs fluorogenic substrates as an 
example (Figure 1.4), the enzyme recognizing phosphate head group is conjugated 
with the phenol moiety of the fluorophore. This modification could reduce the 
availability of lone pairs in the fluorophore’s π system. Upon PTPs’ hydrolysis, the 
head is released from the fluorophore, leading to concomitant the emission of the 
fluorescence. The changes in the intensity of fluorescence at certain wavelength could 
be used to monitor the enzyme activity. Therefore, they are widely used in the 







Figure 1.4 Fluorogenic pTyr mimics. left: principle of PTP-mediated fluorogenic substrates; 
right:a) Some known PTP fluorogenic substrates; b) Some fluorogenic pTyr mimics.  
 
 Many PTPs’ fluorogenic substrates such as FDP, ELF 97, MUP29, and 
DIFMUP
30
 (shown in Figure 1.4) are developed based on the hydrolysis of the 
phosphate head of tyrosine residue by PTPs. In particular, DIFMUP (pKa = 4.9, Φ = 
0.89), which is widely used in inhibition assay, has a low pKa and higher fluorescent 
11 
 
quantum yield than that of MUP (pKa = 7.8, Φ = 0.63), thus making it a suitable 
substrate under acidic pH conditions. Additionally, it is a non-fluorescent compound 
and only generates the fluorescent DIFMU (λex = 358 nm, λem = 450 nm) upon 
hydrolysis by PTPs. DIFMUP-based assay provides a general and sensitive solution 
assay for fast and accurate exploration of the binding modes between enzymes and 
inhibitors. However, DIFMUP does not work well on certain members of the PTP 
family, such as SHP2 (Km = 104 µM, Kcat = 1.3 s
-1
). Barrios and co-workers reported a 
fluorogenic phosphocoumaryl amino propionic acid (pCAP), which is a coumarin 
based fluorogenic pTyr mimic.
31
 Subsequently, the incorporation of pCAP into 
different peptide-based PTP substrates allows enzymatic detection of most PTPs with 
high specificity and good sensitivity 
 To overcome the pH sensitivity of simple coumarins, the same group designed 
a fluorinated analog of pCAP (pCAPF).
32 
Additionally, they replaced propionic acid 
in the parental compound with butanoic acid to have a better fit for the large catalytic 
pockets in PTPs. The pCAPF-based peptides are more sensitive upon hydrolysis when 
compared to the original version, but have smaller turnover numbers. These 
fluorogenic mimics have potential applications in large-scale profiling of PTP 
activities using a combinatorial peptide library and to provide the fingerprint of each 
PTP. 
 
1.3.2 Caged pTyr 
 In chemical biology terms, a “caged molecule” is a compound whose function 
is masked by a chemical protecting group.
33
 The uncaging process triggered by 
chemical or physical means removes the protecting group and restores its intrinsic 
activity. Caged compounds allow the spatial and temporal control over the release of 
12 
 
reactive functions in target molecules, thus enabling the study of complex cellular 
processes in “real time” for the elucidation of their pathways more accurately. The 
photo-protecting group is often used as the cage as lights could be precisely and easily 
manipulated. Furthermore, with the development of lasers and microscopes, the 
uncaging process by light directed to a specific area, duration and intensity of 
irradiation can be controlled.
33b, 33c
 The straightforward design of caged pTyr involves 
protecting one or two phosphate oxygens with photo-removable protecting groups. 
Upon removal of the caging group by photolysis, the masked phosphorylated tyrosine 




Figure 1.5 Caged pTyr mimics. a) Caging and uncaging of thiophosphotyrosine peptides; b) 
Two different caging groups; c) Native chemical ligation joins fragments of Paxilin (38-557) 
with a paxillin thioester containing a caged pTyr at position 31 to generate full length paxillin. 
 
 In one of the earliest examples using the caged system, Bayley and co-workers 
reported the synthesis of nitrobenzyl- and p-hydoxyphenacyl caged 
thiophosphotyrosine incorporated peptides (Figure 1.5a).
34
 The peptides were first 
thiophosphorylated by their cognate tyrosine kinases under divalent transition metal 
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buffer. This is, followed by the reaction of the thiophosphate sulfur with electrophilic 
reagents (2-nitrobenzyl bromide or p-hydroxyphenacyl bromide) to generate new 
photocaged substrates (Figure 1.5a). The caged peptides showed no binding to SH2 
domain, however, upon by UV irradiation, the initial affinity is restored. 
 Imperiali and co-workers demonstrated the successful synthesis of 1-(2-
nitrophenyl)ethyl (NPE)-based caged pTyr (1-1) building block for the use in Fmoc-
based solid-phase peptide synthesis.
35 
NPE caging group could be removed with far 
UV light which is less harmful to cells. Semi-synthesis (native chemical ligation) was 
then used to install the caged pTyr residue into paxillin which could serve as a tool to 
investigate the influence of Tyr31-paxillin phosphorylation on cellular migration.
36a
 
Similar attempts were made by the Becker group to incorporate the caged pTyr in 
recombinant STAT6, and demonstrating that the movement and translocation of 
STAT6 is regulated by the phosphorylation of its Tyr641.
36b
 The Nagamune group 
has recently developed a new mimic (1-2) with a two-photon uncaging group (6-
bromo-7-hydroxycoumarin-4-ylmethyl).
37 
The two-photon uncaging approach is 




1.3.3 Reversible non-hydrolyzable mimics 
 The phosphate group is tetrahedral in geometry and dianionic at physiological 
pH. The charged phosphate group is not suitable and has poor bioavailability due to (1) 
the low cell permeability and (2) the ease of hydrolysis of the phosphoryl group by 
endogenous phosphatases. Hence the development of phosphate mimics has been 
focused on the introduction of a non-hydrolyzable bond and the use of groups with 
fewer charges, yet maintaining the affinity to target proteins.  
14 
 
 One of the most obvious approaches in the design of bioisosteres is to replace 
the benzylic oxygen atom of pTyr with a methylene group, to achieve a hydrolytically 
stable phosphonomethyl-phenylalanine (Pmp) derivative.
39
 The resulting phosphonate 
has a higher ionization constant (pKa2 = 7.1) compared to the normal phosphonate 
(pKa2 = 5.7), thereby resulting a different ionization state in neutral pH. However, the 
absence of the hydrogen bonding ability in the methylene group in turn causes Pmp to 
show less binding affinity. 
 
 
Figure 1.6 Pmp and F2Pmp based inhibitors. 
 
 Subsequently, the Burke group in 1992 synthesized a new Pmp analog. They 
introduced two fluorine atoms at α-methylene position.40 The fluoro substituents 
lower phosphanate pKa values and potentially afford hydrogen-bonding interactions 
similar to the phosphoryl ester oxygen. This increases the binding affinity by several 
orders of magnitude. As shown in Figure 1.6a, phosphopeptide Ac-pTyr-Glu-Glu-Ile-
15 
 
Glu-OH is a known Src SH2 domain binder (IC50 = 0.64 ± 0.04 µM). The 
investigation on several pTyr replacements found that the F2Pmp mimic (1-5) 
maintains the binding affinity (3-fold less potent compared to the parent peptide 1-3), 




It is worth to 
noted that, to date, the Lawrence and Zhang groups reported the use of a 
combinatorial high-throughput screening method and furnished a F2Pmp based small 
inhibitor 1-6 exhibiting notable selectivity in favor of PTP1B (Ki = 2.4 nM) against a 
panel of twelve other PTPs including TCPTP.
42
 However, the bioavailability of 1-6 
due to the charged phosphate group is still a limitation. To enhance the cellular 
activity, derivatives of 1-6 were developed, including coupling a cell permeable 
peptide tag (D-Arg8, 1-6a), incorporating a highly lipophilic fatty acid (1-6b) and 
synthesizing a prodrug (1-7). These modifications have some success to introduce 
phosphorus-based therapeutics, while, non-phosphorus-based mimics could also 




Figure 1.7 PTP1B inhibitors with carboxylic acid-based pTyr bioisosteres. 
 
 Consequently, pTyr mimics with combinations of polar groups including 
mono- and di- anionic groups were generated to maximally maintain phosphate-like 
electrostatic interactions and still obtain higher cell bioavaibility. For example, 
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compound 1-8 was found to be a potent inhibitor of PTP1B and has two carboxylic 
acids as a phosphate bioisostere.
44
 However, its low cell permeability limits its future 
therapeutic development. The same group further developed a singly charged 
compound 1-9
 
with reasonable inhibitory (Ki = 9 µM), good selectivity for PTP1B 
over most other phosphatases and more importantly, higher cell permeability.
45
 
 The Burke group have spearheaded the synthesis of numerous mono and 
dicarboxylic acid-based pTyr replacements as shown in Figure 1.8, including O-
malonyltyrosine (OMT, 1-10), fluoro-O-malonyltyrosine (FMT, 1-17) and F2Pmp (1-
12).
46
 Compounds (1-14, 1-16) with mono carboxylic acid due to lower the binding 
affinity show less potency than dicarboxylic acid-based analogues (1-10, 1-15, 1-17). 
Compound 1-15 with the dicarboxylic acid modification (2.5-fold decreases) 
maintains similar hydrogen-bonding interactions with Grb2 SH2 domain compared to 








 Another study reported various modifications to a small molecular 
peptidomimetic PTP1B inhibitor with O-carboxymethyl salicylic acid moiety 1-18 by 
the Bleasdale group.
47
 Due to the low cell permeability, one carboxylic acid moiety 
was replaced by a tetrazole unit as a carboxyl group. The resulting analogue 1-19 
showed the comparable potency to the dicarboxylic acid analogue against PTP1B. 
Both compounds showed a similar selectivity over LAR and SHP-2. The X-ray 
crystallographic studies also confirmed that the tetrazole-containing 1-19 bound in a 
similar manner in PTP1B active site as the dicarboxylic acid analogue 1-18. 
Furthermore, 1-19 showed the modest enhancement of insulin-stimulated 2-




Figure 1.9 Improvement of PTP inhibition and cellular activity by discovering new pTyr 
mimics. 
 
 In a more recent analysis, from the structure-activity relationship study, 1,2,5-





isothiazolidinone group was used in the synthesis of PTP1B inhibitors 1-20 (IC50 = 
190 nM)
48a
 and 1-21 (IC50 = 40 nM)
48b
, demonstrating that the utility of this scaffold 




Figure 1.10 Inhibitors containing pTyr bioisosteres. 
 
1.3.4 Irreversible pTyr mimics 
 The active site of the PTP family is highly conserved and contains a highly 
nucleophilic Cys residue as described above. Irreversible pTyr mimics always have a 
reactive group that could be attacked by the Cys residue, therefore resulting in 
irreversible inhibitions. There are few examples that the mimics contain N- and C- 
terminal modifications. Other pTyr mimics without the properties of amino acids have 
also been developed and widely used in activity-based probe profiling which will be 
discussed later (Chapter 1.4).  





 is also a potential bioisosteric match for 
biological O-phosphate (ROPO3
-2
). This mimic reacts effectively and irreversibly with 
the PTPs by formation of a covalent selenosulfide adduct. It inactivates YopH as well 
as PTP1B, VHR and VHX. It gives the potential application for seleninate based 
19 
 
inhibitors to study the physiological functions of PTPs. The Yao group developed the 
quinone methide-based unnatural amino acid (Figure 1.11, the mechanism was 
described in Figure 1.14) containing a 2-fluoromethyl phenyl phosphate (2-FMPP) 
and incorporated it into several peptide-based substrates of PTPs. The peptide-based 






Figure 1.11 Irreversible pTyr mimics. a) Seleninate based mimics b) Quinone methide based 
mimics. 
 
1.4 Activity-based protein profiling (ABPP) 
 Activity based protein profiling, pioneered by the Cravatt group, is one of 
most efficient ways to better understand both in vitro and in vivo enzymatic activities 
of a class of enzymes from a crude proteome.
51 
The strategy uses active site-directed 
mechanism-based probes, which normally have three key elements: 1) an active site-
targeting reactive group (warhead) that directs the probe to the active site and 
covalently reacts with the protein; 2) a reporter group, typically a fluorophore or 
biotin for visualization and identification of labeled proteins; 3) a linker which gives 
the space between reporter and warhead (Figure 1.12). To date, many ABPs have 











Figure 1.12 Overview of some developed bioorthogonal reactions used in the tag-free 
approach. 
 
 However, the bulky reporter group could affect the probe’s cellular 
distribution and decrease its cell permeability. The groups of Cravatt and Overkleeft 
independently developed strategies which used copper(I)-catalyzed azide-alkyne 
[3+2] cycloaddition (CuAAC, click chemistry) to incorporate the reporter group only 
after the labeling of the enzyme has occurred so as to avoid the influence of the 
reporter in the enzyme-probe interaction.
54 
This cycloaddition reaction is one of the 
several types of bioorthogonal ligation reactions (a term coined by C. R. Bertozzi in 
2003
57a
) that exist in the literature. These reactions normally have functional groups 
which could be inserted into a probe structure while minimizing interference with 
native biochemical processes and avoiding cross-reactivity with other endogenous 
biomolecules. Ideally, the reactions are biocompatible and not toxic. The Bertozzi 
group has developed mono and difluorinated cyclooctyne reagents possessing ring 
strains and electron-withdrawing fluorines to promote the rate of the cycloaddition 
reaction with an azide without the normally cytotoxic copper catalyst.
55
 With these 
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new substituted cyclooctynes, the authors were able to successfully image the 
dynamic processes of protein glycosylation in animals.
56
 New bioorthogonal ligation 
reactions
57
, with faster rates and less toxicity, including those based on the Diels-
Alder reaction between a tetrazine and a trans-cyclootene are currently being 






Figure 1.13 Proteome profiling with activity-based probes (ABPs) and affinity-based probes (AfBPs). a) Original activity-based probe, it contains warhead, 
linker and reporter, after covalent labeling, could be directly analyzed by SDS-PAGE. b) First generation of a), tag-free activity-based probe, it replaces the 
big report group with a small alkyne. After covalent labeling, click chemistry subsequently is carried on adding the reporter group. c) AfBPs, another branch 
of ABPs, it contains warhead, reporter and photo-cross group. After binding with targets, probes are then covalently bond with targets under UV-irradiation. d) 
Tag-free version of AfBPs. 
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 Furthermore, instead of using known reactive groups-based scaffolds for the 
development of probes against proteins, an alternative approach, so-called affinity-
based probes (AfBP, Figure 1.13) based on reversible inhibitors and binders was 
generated.
59
 The key components of AfBPs include an inhibitor/binder as a core 
group, which provides tight and specific binding to the target proteins and a photo-
cross unit
60
, including benzophenone, aryl azide and diazirine group, which, upon UV 
irradiation, provides a covalent linkage between the probe and the target. This 
approach is potentially more appealing and much more powerful since there are 
various inhibitors and binders of interested proteins readily available.
61
 Furthermore, 
this approach could be amenable to the study of the cellular off-targets of many 
existing reversible drugs/drug candidates. The Yao group reported AfBP-like 
modification of Dasatinib, a dual Src/Abl inhibitor, which is capable of proteome-




1.4.1 Activity based probes for PTPs 
 In recent years, there has been a growing trend to develop activity based PTP 
probes. Lo et al. first explored small molecules containing a 2-FMPP moiety which 
serves as a phosphate mimic.
62
 Upon hydrolysis by PTPs, the probe generates a highly 
reactive quinone methide intermediate which subsequently alkylates the nucleophiles 
present in the active site of PTP (Figure 1.14). Furthermore, they found that six 
cysteine residues of PTP1B could be labeled by the probes thereby suggesting a lack 
of specificity of the reactive intermediate. The Yao group further developed 1-22 and 
1-23 and demonstrated that these probes specifically label phosphatases (both PTP 
and alkaline phosphatase) over other enzymes like proteases and lipases in an activity-
based manner.
63b
 Although quinone methide based probes have been successfully 
used to profile PTPs, the diffusible and highly reactive nature of the intermediates 
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lead to poor PTP specificity and cross-reactivity in the crude proteome, making these 
probes unsuitable for ABPP application.
63
 The issue has been partially solved by Li 
and colleagues who reported a probe 1-24 with a short peptide based on EGF receptor 
(a known substrate of PTP1B.).
63d
 As only PTP1B was tested in this literature, it 
remains unclear whether other PTPs could also be targeted. The Yao group 
synthesized a new quinone methide based unnatural amino acid and incorporated it 
into peptide-based probes which were chosen from the known substrates of PTPs.
50 
This design is better than 1-24 since the generation of quinone methide is directly 
based on PTPs’ activity, and not from other sources. From the result, the conjugation 
of the additional PTP substrate sequences improves the probe’s binding affinity as 
well as specificity and decreases the possibility of diffusion and cross-reactivity. 
 
 
Figure 1.14 Quinone methide-based approaches. a) Schematic representation of formation of 






Figure 1.15 Bromobenzylphosphonate and vinyl sulfone/sulfonate based probes. a) The 
structure of a biotinylated bromobenzylphosphonat probe and its proposal mechanism.; b) The 
structure of three vinyl sulfonate/sulfone based probes and the proposal mechanism. 
 
 Zhang et al. developed a probe with α-bromobenzylphosphate as a non-
hydrolyzable phosphate mimic (Figure 1.15a).
64
 This mimic is sufficiently 
electrophilic to react covalently with the Cys residue in the PTP active site (one 
possible mechanism was shown in Figure 1.15a). The probe was shown to target PTPs 
in a crude proteome and more specific than the quinone methide-based probes. 
However, the highly unstable nature of the probes renders it impractical for 
widespread applications in ABPP. Recently, the same group developed a new version 
of probes based on phenyl vinyl sulfone/sulfonate motif (Figure 1.15b).
65
 Through the 
Michael 1,4-addition, cysteine with low pKa in active site nucleophilic attacks on the 
vinylic position, resulting in the formation of a stable thioether bond. In the design, 
the phenyl ring also plays an important role in recognition. However, vinyl 
sulfone/sulfonate based probes are well known to targeting cysteine-utilizing proteins, 




 The design of new pTyr mimics and investigation of PTPs in cellular process 
is still a challenge. In this thesis, the main aim is to develop new pTyr mimics and to 
apply them in the development of new inhibitors or activity-based probes. In 
additional, a new high throughput reaction is carried out to assemble PTPs probes for 









 This chapter, we describe the successful design and chemical synthesis of novel 
unnatural amino acid which mimics phosphotyrosine (pTyr). By replacing the phosphate 
group in pTyr with an isoxazole carboxylic acid, a novel unnatural amino acid has been 
successfully synthesized. Subsequently, its incorporation into a known PPI (protein-
protein interaction) inhibitor of STAT3 protein (ISS 610) generated I2 which showed 




 Protein-protein interaction (PPI) mediates a large number of important regulatory 
pathways in cellular processes.
66
 Inappropriate interactions are known to cause many 
human diseases including cancer and obesity. Small molecule inhibitors capable of 
disrupting protein-protein interaction therefore offer unique opportunities in drug 
discovery, especially against less common therapeutic targets such as transcription 
factors.
67
 PPI inhibitors of STAT3 are such examples.
68
 The signal transducer and 
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activator of transcription (STAT) family of proteins, including STAT3, are mediators of 
cytokine and growth factor responses, and control cellular growth and differentiation, 
survival, development and inflammation.
69
 They are members of the Src homology 2 
(SH2) domain-containing proteins, which also include many other adaptor proteins, 
phosphatases (i.e. SHP1 and SHP2) and kinases (i.e. Src and Abl).
70
 SH2 domains are 
phosphotyrosine (pTyr)-binding protein domains made of ~ 100 amino acids.
69,71
 In 





 In the case of STAT3 inhibitors, it is known that the 
activation of STAT3 is initiated by the phosphorylation of a key tyrosine residue near its 
C-terminus, which triggers protein dimerization via SH2-pTyr interaction, resulting in 
subsequent nuclear translocation, binding to specific DNA-response elements and 
inducing gene transcription.
73
 Although there are several proteins in the STAT family, so 
far only STAT3 is shown to be expressed constitutively in a variety of cancer cells, 




Most SH2 domain-targeting inhibitors are pTyr containing peptides or 
peptidomimetics, in which the phosphotyrosyl group is the most critical element for 
molecular recognition/tight binding to the SH2 domain. However, its hydrolytic 
instability (mainly due to enzymatic hydrolysis by cellular protein tyrosine phosphatases 
or PTPs) and predominantly anionic nature at physiologic pH practically render the 
corresponding pTyr containing inhibitors to possess poor cell permeability and 
bioavailability. Numerous pTyr bioisosteres have been developed (Figure 2.1a),
19c, 72b,75
 
most of which, however, are either still highly charged (2-2a-c), or poor mimics ((2-3) - 
(2-5); therefore possess low SH2-biniding affinity). Herein, we report the design and 
chemical synthesis of a novel unnatural amino acid, 2-6 (Figure 2.1a), in which the 
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phosphate group in pTyr was replaced with a non-hydrolyzable isoxazole carboxylic acid. 
The isoxazole carboxylic acid was previously shown to be a good cell-permeable 
bioisostere of the phosphate, and has been incorporated into small molecule inhibitors of 
PTPs.
76, 77
 Our finding here represents the first example in which this moiety has been 
successfully introduced as the side-chain of an amino acid. We further show this 
unnatural amino acid could be readily incorporated into SH2 domain inhibitors, i.e. 
ISS610 (a previously reported STAT3 PPI inhibiton
68a,68c
), to give a new inhibitor I2 
which possesses more desirable pharmacological properties (cell permeability and 




Figure 2.1 Structures of pTyr, its bioisosteres and the one in this study. (a) Structures of pTyr 
(2-1), representative examples of previously reported pTyr bioisosteres (2-2 to 2-5), and the 
one developed from this study (2-6). (b) Structures of ISS 610 (a previously reported STAT3 
inhibitor
68a,68c
), and I2 (an improved version with incorporation of 2-6). 
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2.2 Synthesis of the unnatural amino acid  
 The Fmoc-protected form of the unnatural amino acid, 2-6
’
, was synthesized in 
several steps from the commercially available 4-Iodophenylalanine
78
, as shown in 
Scheme 2.1. Fmoc was chosen as the protecting group for the -amino group in 2-6’ so 
that it’s compatible with standard Fmoc-based solid-phase peptide synthesis. The 
isoxazole carboxylic acid side-chain was protected in the form of an ethyl ester as it is 
orthogonal to Fmoc chemistry and could be deprotected by LiOH.
77
 Briefly, the Fmoc-
protected methyl ester of 4-Iodophenylalanine, 2-7, was subjected to Sonogashira 
coupling conditions with Pd(PPh3)2Cl2/CuI in DMF, in the presence of TMS-protected 
acetylene, to give 2-8 in 84% yield. All three protecting groups were then removed by 
NaOH treatment, followed by Fmoc protection of the N--amino group to give 2-9 (65% 
yield in two steps). Subsequent protection of 2-9 in the form of an allyl ester gave 2-10 
(90% yield). Next, the key isoxazole ring in 2-11 was formed using a recently published 
procedure,
79, 80
 under the Cu(I)-catalyzed 1,3-dipolar cycloaddition conditions between 
the terminal alkyne in 2-10 and ethyl chlorooximidoacetate. Previously, it was found 
electron-deficient nitrile oxides in general react sluggishly.
79 
Attempts were therefore 
made to optimize the reaction conditions (Table 2.1); the best yield obtained was with 
CuSO4/sodium ascorbate in KHCO3 with (1:1) tBuOH/H2O cosolvent, giving 2-11 in 
21% and 23% yield in 1 d and 5 d, respectively. Finally, deprotection of the allyl group 
by Pd(PPh3)4/PhSiH3 
81 
afforded the Fmoc-protected unnatural amino acid precursor 2-6
’
. 
No sign of racemization was observed throughout the whole synthesis and in the final 






Scheme 2.1 Synthesis of 2-6
’
 - the Fmoc-protected form of 2-6. 
 





( A or B )
a
 














5 B THF 1 15 
a 
A: CuSO4/Sodium ascorbate/KHCO3 (0.05/0.1/4 eq.); B: triethylamine (2 eq.) 
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2.3 Solid-phase synthesis of inhibitors 
 Next, the two STAT3 PPI inhibitors, I1 and I2 (Figure 2.1), were synthesized. 
I1, or ISS 610, is a peptidomimetic inhibitor derived from the STAT3 SH2 domain-
binding pTyr (Y*) peptide PY*LKTK.
68a
 ISS 610 inhibits STAT3:STAT3 dimmer 
(IC50 = 42 M from a DNA-binding assay
68a
) and was shown to induce cell growth 
inhibition and apoptosis of human cancer cells that harbor constitutively active 
STAT3, including MDA-MB-435 and MDA-MB-231 (human breast), NIH3T3 
(fibroblast) and T47D (human breast) cells.
68c
 ISS 610, however, has limited cell 
permeability and hydrolytic stability due to its pTyr group. We reasoned that 
replacing pTyr in ISS 610 with our newly developed unnatural amino acid 2-6 (giving 
I2) should improve both aspects, making I2 a potentially better STAT3 inhibitor for 
therapeutic intervention. Both inhibitors were synthesized conveniently using Fmoc-
based solid-phase peptide synthesis protocols (see Scheme 2.2 for synthesis of I2). 
Upon resin cleavage, the ethyl group was removed by LiOH treatment, delivering the 
final inhibitor I2 which was further purified by preparative HPLC to homogeneity (as 
judged by 
1
H NMR) before biological screenings.  
 
 
Scheme 2.2 Solid-phase synthesis of I2. 
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2.4 Biological experiments and discussion 
2.4.1 Docking Stimulations 
 At first, we did docking stimulations to gain insight view of the binding 
similarity between two inhibitors. Docking was carried out on an SGI IRIX 6.5 
workstation using the SYBYL7.2 suite installed with the FlexX docking software. 
The mol2 format of the two inhibitors I1 and I2 was prepared by Sybyl v7.2 (Tripos, 
Missouri, USA). STAT3 were obtained from the Protein Data Bank, entry 1BG1
82
. 
The docking sphere was set at 10 Å and centered on the Arg 609 residue as binding 
site. The docking was performed for 100 interactions and Figure 2.2 shows the most 
preferred conformations. Both phosphate of I1 and isoxazole carboxylic acid of I2 
interact with Arg595 of STAT3 SH2 domain. 
 
         
 
Figure 2.2 Molecular docking of I1 and I2. Right shown the hydrogen bond between Arg595 
and phosphate (I1, white dash bond) , isoxazole carboxylic acid (I2, yellow dash). 
 
2.4.2 Fluorescence polarization (FP) experiments 
2.4.2.1 Expression and purification of STAT3 SH2 domain 
 The clone containing the mammalian STAT3 SH2 domain was purchased 
from Open Biosystems (USA). The construct contains the SH2 domain cloned into a 
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modified pET28 bacterial expression vector. A 6x His tag is encoded for expression at 
the N-terminus which gives a final 68 kD fusion protein. The protein was expressed 
and purified according to protocols provided by the vendor.
83
 Figure 2.3 shows the 
coomassie gel of fractions containing the purified protein (shown as a band at the 
expected 68 kD position). Only sufficiently pure fractions were collected and used for 




Figure 2.3 Representative coomassie gel of the purified STAT3 SH2 domain (From left to 
right, different elution factions 1-4 and MW ladder). Only sufficiently pure fractions were 
pooled for subsequent FP experiments. 
 
2.4.2.2 Fluorescence polarization experiments 
 Fluorescence polarization (FP) experiments were carried out following the 
published procedures.
84
 Different concentrations of the inhibitors I1 and I2 (1 mM - 
7.8 μM) were first incubated with the protein (150 nM) for 30 min. Subsequently, the 
fluorescently labeled STAT3 peptide (Fluorescein-GY*LPQTV-NH2) was then added 
into each well (final conc: 10 nM). The fluorescence readings were then taken with a 
fluorescence plate reader (Tecan, USA) installed with 2 pairs of polarizers (λex: 485 ± 




the duplicates obtained from two independent assays. As shown in Figure 2.4, I2 (IC50 
= 144 ± 36 μM) was able to retain most of the binding affinity of I1 (IC50 = 83 ± 21 
μM) to STAT3,85 indicating our unnatural amino acid indeed serves as a good mimic 
of pTyr. Although I2 (similar to I1) is a rather poor inhibitor, future improvement 









I1 (IC50 = 83 M)










Figure 2.4 IC50 of two inhibitors determined by fluorescence polarization experiments 
 
2.4.3 Inhibition assays of PTP1B 
 Next, we carried on the inhibition assay of PTP1B by I2 to test the specificity 
of the inhibitor. The inhibition of I2 to PTP1B was assayed by measuring the rate of 
hydrolysis of the fluorogenic substrate, 6,8-difluoromethylumbellifery phosphate 
(DIFMUP, Invitrogen, USA) in 25 μL reaction volumes in black polypropylene flat-
bottom 384-well microtiter plates (Greiner, Germany).
77
 Briefly, a two-fold dilution 
series of I2, from approximately 2 mM to 125 μM (final concentrations) was 
prepared. PTP1B’s concentration is the same as STAT3 SH2 domain, 150 nM. The 
substrate concentration is 25 μM. As shown in Figure 2.5, little or no inhibition of 
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PTP1B by up to 2 mM of I2 was observed, indicating I2 is likely a specific inhibitor 
(binder) of the STAT3 SH2 domain.  
 















Figure 2.5 IC50 graphs of I2 against PTP1B 
 
2.4.4 Hydrolytic stability test 
 Since I1’s phosphate head is known to be hydrolysis by PTPs, we tested the 
stability of both compounds toward cellular PTPs. First, T47D cell lysate was 
prepared in PBS, pH 7.5 by disrupting their cell membranes using needle and syringe. 
1 µL of 5 mM I1 and I2 in DMSO was added into 100 µL 2 mg/mL cell lysate, 
respectively. After 15 h, the lysate was pipetted into Ultracel YM-3 (Millipore) and 
centrifuge (13000 rpm, 50 min) to get the filtrate and remove most of proteins (larger 
than 3 kD). Then, the composition of filtrate was analyzed by LCMS (Figure 2.6). 
From LCMS, after 15 h incubation, I2 was quite stable and still not hydrolyzed by 






a) untreated I1 
 
 I1 treated after 15 h 
 
b) untreated I2  
 
 I2 treated after 15 h
 
 
Figure 2.6 LC profiling of hydrolytic stability test. a) The LC profiling of treated I1. b) The 
LC profiling of treated I2. 
 
2.4.5 Cell permeability test 
 As phosphate head has another limitation (low cell permeability) and we 
modified the head to have one carboxylic acid, cell permeability test was continued to 
test whether the modification could improve the cell permeability. MDCK (Madin-
Darby canine kidney) cells86 were used for testing the cell permeability. MDCK was 




 per well insert, Millipore® 
#PSHT004R1) and cultured for 3 days before test. When cultures are confluent, 
remove media and rinse inserts with Hanks’ Balanced Salt Solution (HBSS, Gibco® 





























#14025). Transport assay donor solutions consisted of 50 µM I1, I2 and caffeine in 
transport medium containing 60 μM Lucifer Yellow (LY) and 1% DMSO. Transport 
assays were conducted using 75 μL of apical (AP) donor solution and 235 μL of 
basolateral (BL) acceptor solution (transport medium, pH 7.4, following manufacture 
descriptions of Millipore® #PSHT004R1). Monolayer was incubated with donor and 
acceptor solutions for 60 min at 37 °C, 95% humidity. After 60 min, the donor and 
acceptor solutions of each compound are collected and quantified by HPLC. Lucifer 
Yellow (LY) was quantified using a fluorescence 96-well plate reader (BioTek® 
Synergy 4 fluorescence plate reader at Ex = 485 nm and Em = 539 nm). Papp 
(apparent permeability) values were calculated according to the following equation: 










where dQ/dt is the permeability rate, C0 is the initial concentration in the donor 
compartment, and A is the surface area of the filter. Permeability rates were calculated 
by plotting the percent of initial AP drug mass (peak area) found in the BL 
compartment versus time and determining the slope of the line. Lucifer yellow (LY) 
results were used as an internal control for each monolayer to verify tight junction 
integrity during the entire assay period. Accordingly, LY Papp values were quantified 
from 60 min basolateral samples after background subtraction. As a quality control, 
results from MDCK monolayer with LY Papp > 30 nm/s were not used. From Table 
2.2, because I1 and the hydrolytic product have different cell permeability, the data of 
I1 is not available. I2 is shown quite reasonable cell permeability. 
 
Table 2.2 The results of cell permeability. 
 Positive control Negative control I1 I2 
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Caffeine / 50 µM + - - - 
Lucifer Yellow / 60 µM + + + + 
Compound / 50 µM - - + + 
DMSO 1% 1% 1% 1% 
Papp / nm·s
-1
 1217 n.d. N/A 876 
 n. d. : not determined. N/A: not available.   
 
2.4.6 Cell proliferation 
 Subsequently I1 and I2 were tested for their inhibition activity against the 
T47D cancer cell line in a cell proliferation assay. T47D cancer cell line was from the 
National Cancer Institute Developmental Therapeutics Program (NCI60 cell line 
panel). Cells were cultivated in a T25 flask in RPMI (Invitrogen, Carlsbad, CA) 
medium with 10% Fetal Bovine Serum (FBS, Gibco Invitrogen) and 100 U/mL 
Penicillin-Streptomycin (Thermo Scientific, Rockford, IL) and maintained in a 
humidified 37 
°
C incubator with 5 % CO2. Subsequently, trypsin with EDTA were 
used to detach cells detach from the flask. Cells were counted using Hemocytometer 
and seeded equally into each well of a 96-well plate. Each well contains around 
3000~4000 cells in culture medium with 10% FBS. After overnight culture, the 
medium was aspirated and then treated with different concentrations of I1 and I2 in 
DMSO (500 μM, 250 μM, 125 μM). Staurosporine (STS) was used as a positive 
control. The same volume of DMSO (final concentration in each well is 0.56%) was 
used as a negative control. After 2 days, the tetrazolium salt XTT solution (0.2 
mg/mL XTT, 250 µM phenazine methosulfate (PMS), Roche) was added to the cells. 
After incubating at 37 
°
C for 20 h, the absorbance was measured at 450 nm and 
background absorbance was measured at 650 nm using a Bioteck™ plate reader. Data 













A450nm and A650nm are the absorbance at 450 nm and the background absorbance at 
650 nm of the sample wells; a450nm and a650nm are the absorbance at 450 nm and the 
background absorbance at 650 nm of the control wells (which only contained 
DMSO). In the cell proliferation assay (Figure 2.7), we observed a corresponding 
dose-dependent inhibition of I2 towards T47D cells. More importantly under the same 
concentration (250 M), I2 was at least as effective as I1 (see bars labeled with * in 
Figure 2.7), suggesting that although I2 may have weaker binding towards the SH2 
domain of STAT3 in vitro than I1, its better cell permeability and hydrolytic stability 




Figure 2.7 Relative % of T47D cell viability in the presence of the two inhibitors, I2 (500 μM, 
250 μM & 125 μM) and I1 (250 μM). Negative control: DMSO only (0.56% final conc.). 






 In summary, we have synthesized a novel unnatural amino acid which mimics 
phosphotyrosine but possesses better cell permeability and hydrolytic stability. Its 
incorporation into a known STAT3 SH2 domain inhibitor has confirmed our design 
principle. Future work will focus on incorporation of this amino acid into other pTyr-
containing biologically active compounds. This new pTyr mimic, together with other 
newly developed approaches,
50, 87
 will provide expanded chemical tools for future studies 
of PTP biology. 
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Chapter 3 A self-immobilizing and fluorogenic unnatural 
amino acid that mimics phosphotyrosine 
Summary 
 
 This Chapter summarizes the designation and synthesis of the first self-
immobilizing and fluorogenic unnatural amino acid that mimics phosphotyrosine (pTyr). 
By using solid-phase peptide synthesis, it was subsequently incorporated into peptide-
based probes which found applications in bioimaging and fluorescence-activated cell 




 Reversible protein phosphorylation plays a fundamental role in signal 
transduction. Protein tyrosine phosphatases (PTPs; > 100 members in human), together 
with protein tyrosine kinases (PTKs), have an essential role in controlling this key cellular 
process and maintaining the intricate balance of the phosphoproteome network. Defective 
regulation of these enzymes has significant implications in human diseases.
4, 9
 Elevated 
levels of PTP activities are found in numerous tumor-associated cells and tissues.
9
 PTPs 
dephosphorylate proteins with a high degree of specificity inside the cell, although in 





Consequently, chemical and biological methods that report not only the global PTP 
activities, but more importantly the precise enzymatic activity of PTPs at single cellular 
and subcellular levels (and ultimately at the molecular level), may offer unprecedented 
views on how these enzymes work under physiological settings.
89
 Existing chemical tools 
have so far focused on the detection of PTP activities either in vitro or in situ using 
recombinant PTPs or cellular lysates.
62, 63, 64
 More recently, a small molecule-based 
imaging probe capable of detecting PTP activities in live cells has appeared.
90
 
Notwithstanding, most probes are not able to detect PTP enzymatic activities on the basis 
of their substrate, organelle or cell specificity.
90
 Herein, we have developed the first self-
immobilizing and fluorogenic unnatural amino acid, which, upon incorporation into 
suitable peptide sequences, gave rise to chemical probes suitable for cell-based analysis 
(e.g. imaging and FACS) of endogenous PTP activities, thus successfully addressing 




Figure 3.1 Representative examples of previously reported fluorogenic PTP substrates, 2-
FMPT and Withers’ sugar probe.  
 
 Existing fluorogenic substrates, such as difluoromethylumbelliferone 
phosphate (DiFMUP; Figure 3.1), are widely used to detect PTP activities in vitro but 





 Activity-based probes of PTPs have been developed with varied degrees of 
success, but they generally inhibit PTPs irreversibly and do not provide Turn-ON 
fluorescence readouts, and thereby are not suitable for cell-based imaging and FACS 
experiments.
.62, 63, 64
 An alternative strategy to minimize product diffusion is to, in the 
probe design, couple fluorescence release to an enzyme-probe covalent linkage.
90 
Based on this principle, Withers and co-workers recently reported self-immobilizing 
ﬂuorogenic imaging agents based on modiﬁed derivatives of coumarin glycosides 
(Figure 3.1) for histological and FACS studies of glycosidases.
92
 Inspired by this 
work, our newly developed unnatural amino acid (3-2 shown in Figure 3.2), is a 
modified version of the phosphorylated coumaryl amino acid 3-1’ (and the “caged” 
version 3-1; Figure 3.1), which was recently shown by Barrios and co-workers to be a 
close mimic of phosphotyrosine (pTyr).
31
 We had previously shown in a separate 
study of another novel pTyr mimic, 2-FMPT (Figure 3.1), that the introduction of a 
2-fluoromethyl group in the aromatic ring of pTyr does not disrupt PTP recognition, 
but upon dephosphorylation generates a highly reactive quinone methide intermediate 
which subsequently attaches itself covalently to the nearby PTP.
50
 2-FMPT, however, 
was not fluorogenic and cannot report PTP activities in real time in cells. Thus, our 
new pTyr mimic 3-2 not only is self-immobilizing and fluorogenic (i.e. like Wither’s 
sugar probe), also possesses both N- and C-terminus (as in the case of naturally 
occurring amino acids), allowing essential PTP-recognizing peptide elements to be 





Figure 3.2 Overall working principle of the pTyr mimic 3-2 and its peptide probes. With 
SPPS, PTP-recognizing elements or CPPs may be introduced into the probe. Upon UV-
irradiation to uncage the phosphate, the peptide binds to its intended PTP, and gets 
dephosphorylated. The ensuring charge delocalization followed by spontaneous elimination of 
–F generates the highly reactive quinone methide intermediate which, diffuses away from the 
enzyme active site before forming either covalent PTP-probe complex, or covalent complexes 
with nearby proteins (not shown). 
 
3.2 Synthesis of unnatural amino acid  
 Compound 3-2, the Fmoc-protected form of the unnatural amino acid, was 
synthesized in several steps from commercially available N-α-Fmoc-L-aspartic acid as 
shown in Scheme 3.1. A 2-nitrobenzyl photolabile protecting group was introduced in 
3-2 to facilitate chemical synthesis and at the same time provide temporal control over 
PTP-probe recognition.
50, 90, 93
 Briefly, the first four steps in the synthesis were based 
on previously reported procedures,
31
 with some modifications, giving the allyl-
protected coumaryl amino acid 3-6. Subsequently, formylation of 3-6 by Duff 
reaction gave 3-7 in moderate yield (25%).
94
 Next, phosphorylation with di(2-
nitrobenzyl) chlorophosphate under basic conditions provided 3-8 (46% yield), which 
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was reduced with NaBH4 (giving 3-9; 85% yield), followed by fluorination with 
DAST to give 3-10 (74% yield). Finally, the allyl group in 3-10 was removed by 
treatment with Pd(PPh3)4, giving 3-11 (90% yield). To obtain the new unnatural 





Scheme 3.1 Chemical synthesis of 3-2 
 
 Furthermore, we also synthesized 3-1 as a control of 3-2, since it is a 
fluorogenic substrate of PTP. There is no modification on the aromatic ring, it could 
not generate a reactive intermediate and continue on self-immobilizing function. The 
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synthesis (Scheme 3.2) of 3-1 began with 3-6. After phosphorylation with di(2-
nitrobenzyl) chlorophosphate under basic conditions and deprotection of allyl group 
provided 3-1-2 (45% yield). Followed by removing one of 2-nitrobenzyl group was 




Scheme 3.2 Chemical synthesis of 3-1 
 
3.3 Solid-phase synthesis of three localization peptides 
 To incorporate the unnatural amino acid into peptide-based probes, the 
precursor 3-11 was directly used in standard solid-phase peptide synthesis (SPPS) 
using Fmoc chemistry (Scheme 3.3). We chose to incorporate the self-immobilizing 
fluorogenic pTyr mimic into three different cell-penetrating peptides (CPPs), giving 






; Scheme 3.3). 
These localization peptides had previously been used to successfully deliver enzyme 
inhibitors into subcellular organelles of live cells.
98
 A flexible (Gly)4 linker was 
inserted between the CPPs and the unnatural amino acid to minimize potential 
interferences of PTP recognition by the CPPs. In the present work, we chose to focus 
on the prospect of these peptide-based probes as agents to study endogenous PTP 
activities through subcellular imaging and FACS experiments. In future, additional 
PTP-binding peptide fragments may be similarly introduced, by using the chemistry 






Scheme 3.3 Fmoc-based SPPS of the three CPP-containing probes. Reaction conditions: a) 
20 % piperidine in DMF; b) Fmoc-protected amino acid or acid (Palmitic acid), HOBT, 
HBTU, DIEA, DMF; c) compound 3-11, HOAT, HATU, DIEA, DMF; d) 2% DBU in DMF; e) 
acetic anhydride, DIEA, DCM; f) 1% TFA in DCM; g) TFA/TIS/H2O (95:2.5:2.5). 
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3.4 Biological experiments and discussion 
3.4.1 UV-initiated uncaging experiment 
 All the compounds and peptides we made have a photolabile protecting group, 
which could give better cell permeability and at the same time provide temporal 
control over PTP-probe recognition. So we first examined the photo- property of 
compound 3-2 and pER peptide (as a representative example). Briefly, compound 3-2 
(50 M) and pER peptide (50 µM), prepared in 25 mM Tris buffer with 50 mM NaCl 
at pH = 7.2, were photolyzed using a UVP CL-1000 Ultraviolet Crosslinker (500 
µJ/cm
2 
at 254 nm). The reaction was monitored by LCMS. It was established that 
nearly complete uncaging (> 95%) of the 2-nitrobenzyl group, giving the 
corresponding PTP-responsive adducts, could be achieved after 2 min under 500 
µJ/cm
2 
UV exposure (Figure 3.3). 
 




Before UV- irradiation 
  
 



















After UV- irradiation 
 
 
Figure 3.3 LC profiles and MS results of uncaging process. a) The LC profiles of 3-2 (50 µM) 
upon UV-irradiation for different lengths of time (0, 30 s, 60 s, 90 s and 120 s). All peaks 
were identified and confirmed based on LCMS results. b) HPLC profiles of 50 µM pER 
before (0 s) and after UV-irradiation (120 s). All peaks were identified and confirmed based 
on LCMS results. 
 































3.4.2 Dephosphorylation reaction with uncaged compound 
 Compound 3-2 (4 µM in 25 mM Tris buffer, 100 mM NaCl , pH = 7.26; final 
volume is 25 µL), which were first UV-irradiated, or “uncaged”, for different lengths 
of time. Subsequently, recombinant PTP1B (a human PTP involved in diabetes and 
obesity, 80 nM final conc.)
87b
 was added and the dephosphorylation reaction was 
monitored continuously over 2 h using a BioTek multi-mode fluorescence microplate 
reader (ex = 360 ± 10 nm; em = 460 ± 10 nm) (Figure 3.4a). Microplate experiments 
were also performed to compare the dephosphorylation of caged and uncaged pER 
peptide (Fig. 3.4b). Briefly, HeLa cells were lysed using a buffer containing 50 mM 
Tris, 150 mM NaCl 0.02 % NP-40, at pH = 8.0. The total lysate was collected and its 
protein concentration was determined using Bradford assay. In each reaction, 15 µg 
(protein content) of the lysates was used, together with pER (4 µM final conc.), either 
non-irradiated or UV-irradiated (120 s), in a 25 µL final reaction volume. The 
reaction was then continuously monitored over 2 h in the BioTek microplate reader as 
above described. The results are shown that the addition of recombinant PTP1B or 
lysates of HeLa cells (a cancer cell line with elevated PTP activities) led to a time-
dependent increase in fluorescence, with a concomitant release of the phosphate group. 
 




















































Figure 3.4 Time-dependent fluorescence measurements of UV-irradiated 3-2 and pER. a) 
Fluorescence measurements of 3-2, upon UV-irradiation (for 0, 30, 60, 90, 120s), then treated 
with PTP1B. b) pER (4 µM) in HeLa cell lysates. Control (): non-irradiated pER + lysates. 
The measurements were taken under coumarin channels (ex = 360 ± 10 nm; em = 460 ± 10 
nm) 
 
3.4.3 Enzyme specificity  
 Next, we carried out the microplate assays to test how selective the probe is 
towards PTPs. The microplate assays were performed in 384 wells. Compound 3-2 
(20 µM final conc.), which were uncaged by UV-irradiation. Subsequently, five 
enzymes (final 0.02 mg/mL) including recombinant PTP1B, recombinant glycosidase, 
recombinant Src (expressed and purified using the same protocol as reference 50), 
esterase (Fluka, No. 46069) and trypsin (Fluka, No. 93610) was added and the 
reaction was monitored continuously over 30 min using a BioTek multi-mode 
fluorescence microplate reader (ex = 360 ± 10 nm; em = 460 ± 10 nm). Results are 
shown in Figure 3.5, indicating our probe is only responsive towards PTPs as 


















Figure 3.5 Microplate-based enzymatic assay of PTP1B and other four enzymes. The assay 
was done with uncaged compound 3-2 as the fluorogenic enzyme substrate. 
 
3.4.4  Labeling experiments with pure PTP1B 
 In a recent study, it was found that the quinone methide generated in live cells 
underwent both self-quenching (> 90%; with aqueous media) and self-immobilizing (> 
10%; with nearby proteins) pathways,
90
 where the former produced a highly 
fluorescent diffusible dye molecule and the latter generated localized fluorescence. 
 First, we wondered whether the UV-irradiated 3-2, when treated with PTP1B, 
behaves similarly and produces covalent adducts with proteins nearby (Figure 3.2).
50
 
Labeling with recombinant PTP1B was carried out. In a 20 µL reaction, around 4 µg 
PTP1B was incubated with the uncaged compound 3-2 (final conc. 1 mM, 500 µM, 
200 µM and 100 µM) at room temperature for 2 h. The reactions were stopped by 
addition SDS loading dye, followed by heating at 95°C for 10 min. The mixture was 
resolved on a 10% SDS-PAGE gel and fluorescently labeled bands were 
photographed under UV light using CHEMI GENIUS Bio imaging system (Syngene). 
Results are shown in Figure 3.6. Most of 3-2’ upon treatments with PTP1B was 
converted to a diffusible small molecule dye (> 90%, a huge band at the front of the 
gel), while a small portion of it got self-immobilized to PTP1B. It indicated that 
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Figure 3.6 Labeling of PTP1B with different concentration of uncaged 3-2’ 
  
3.4.4 Labeling experiments with bacterial lysate 
 Next, labeling with bacterial lysate was continued. Both with and without 
inducing PTP1B expression Escherichia coli BL21 DE3 cell lysate was prepared in 
50 mM Tris buffer, 150 mM NaCl, 1% Triton X-100 pH = 7.26. Different 
concentrations of uncaged compound 3-1 and 3-2 were incubated with 30 µg lysate 
(protein content) for 2 h. Then the reaction was quenched by addition of SDS loading 
dye followed by heating at 95 °C for 10 min, then resolved on a 10% SDS-PAGE gel 
and photographed under UV light using CHEMI GENIUS Bio imaging system 
(Syngene). From the result, the majority of 3-2’ was still self-quenching (see free 
probe at the gel front; lane 1), a small amount of PTP1B and other cellular proteins 
were also labeled (caused by self-immobilization of 3-2’). Bariros’ coumaryl amino 
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acid 3-1’, which is a non self-immobilizing analog of 3-2’, was used as a negative 




Figure 3.7 Fluorescence gel (imaged under a UV transilluminator) of PTP1B-overexpressed 
bacterial lysate treated with uncaged 3-2 (1 mM; lane 1) and 3-1 (0.5 mM; lane 2). The 
corresponding coomassie gel was shown on the left. A small amount of covalent labeling 
between 3-2’ and PTP1B and other cellular proteins was observed. Most of 3-2’ was released 
as the highly fluorescent free probe (arrowed). 
 
3.4.5 Competitive gel analysis 
 Since the coumarin fluorescence in the probes could not be detected with our 
fluorescence gel scanner, we also used an indirect competition assay by labeling pre-
treated PTP1B (with either different amounts of uncaged 3-2, or the same amount of 
uncaged 3-2 incubated for different lengths of time) with a previously reported 
PTP1B peptide probe K3 (Rhodamine-GGKAVDGXVKPQ-NH2; X = 2-FMPT
50
). 
We still used uncaged 3-1 as a control for comparison; both dose- and time-dependent 
inhibitions of labeled PTP1B-K3 band were observed, but only at a very high 
concentration of the compound (Figure 3.8). In addition, similar inhibitory effect was 
observed for both compounds 3-1’ and 3-2’. These results indicated that although 
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some amount of uncaged 3-2 might have competed for covalent labeling of PTP1B 
with K3 to a certain extent, the majority of it failed to do so (likely as a result of self-
quenching). 
 
              
 
Figure 3.8 Indirect competition assay. Covalent labeling of PTP1B with K3, after PTP1B was 
pre-incubated with uncaged 3-1 or 3-2. (Left) Dose-dependent experiments: different 
concentrations of compound 3-1 and 3-2 (upon 300s UV-irradiation) were incubated with 
PTP1B (1 µg) for 1.5 h in 25 mM Tris buffer (containing 50 mM NaCl at pH = 7.26). 
Subsequently, K3 (final conc.: 20 µM) was added to the mixture and the reaction was further 
incubated for 1 h. Finally, the reaction was quenched by addition of 6x SDS loading dye 
followed by heating at 95 °C for 10 min, then resolved on a 12% SDS-PAGE gel and 
visualized by in-gel fluorescence scanning with Typhoon 9200 fluorescence gel scanner. 
(Right). Time-dependent experiments: 80 µM of compound 3-1 and 3-2 (upon 300s UV-
irradiation) were incubated with PTP1B (1 µg) for different lengths of time (0. 5, 15, 30, 45, 
60 min) in a 25 mM Tris buffer (containing 50 mM NaCl at pH = 7.26). Subsequently, K3 
(final conc.: 20 µM) was added to the mixture and the reaction was further incubated for 15 
min. Finally, the reaction was quenched by addition of 6x SDS loading dye followed by 
heating at 95°C for 10 min, then resolved on a 12% SDS-PAGE gel and visualized by in-gel 
fluorescence scanning. 
 
3.4.6 Mass spectrometry 
 PTP1B treated with uncaged 3-2 was further analyzed by mass spectrometry. 
25 µg of recombinated PTP1B was labeled by uncaged compound 3-2 (1:10, 






unlabelled PTP1B as a control, was analyzed with a micromass Q-TOF 2 tandem 
mass spectrometer (Figure 3.9); results indicated most of protein still retained its 





Figure 3.9 MS profiling of PTP1B before and after incubation with uncaged 3-2. 
 
3.4.7 Effects of the activities of PTP1B as a model 
 The assays were performed in Hepes buffer (25 mM Hepes, 0.05 M NaCl, 2.5 
mM EDTA and 0.02% Triton X-100, pH 7.5). The enzyme was incubated with 
different dilutions of compound 3-1’ and 3-2’ (final concentration: 250, 125, 62.5, 50, 
25, 12.5, 6.25, 1.25 µM). The dephosphorylation reaction was monitored continuously 
over 2 h using a BioTek multi-mode fluorescence microplate reader (ex = 360 ± 10 
mass









































nm; em = 460 ± 10 nm). Kinetic constants were computed by direct fits of the data to 
the Michaelis-Menton equation using a non-linear regression via GraphPad Prism 
software. The value was taken in mean ± S.D. in two sets of data with duplicate. From 
Table 3.1, Kcat and KM of the two compounds against PTP1B are similar, indicating 
small structural changes from 3-1’ to 3-2’ did not affect enzyme recognition. 
 
Table 3.1 Kinetic Data of compound 3-1’ and 3-2’ with PTP1B. 
 
 
3.4.8 Comparison of enzyme activities before and after probe reaction 
 Lastly, PTP1B treated with uncaged 3-2 was further analyzed by enzymatic 
assay to compare the activity of PTP1B before and after probe reaction. The assays 
were performed in Hepes buffer (25 mM Hepes, 0.05 M NaCl, 2.5 mM EDTA and 
0.02% Triton X-100, pH 7.5). PTP1B (2µg/mL final conc.) was incubated with 
compound 3-1’ and 3-2’ (0.2 µM final conc.). The control reaction is adding the same 
amount of water replacing compound 3-1’ or 3-2’. After 1 h incubation, DiFMUP (4 
µM final conc., Invitrogen, No. D6567) was then added. The dephosphorylation 
reaction was monitored continuously over 10 min using a BioTek multi-mode 
fluorescence microplate reader (ex = 360 ± 10 nm; em = 460 ± 10 nm). The kinetic 
curve was given after subtracting the background due to the dephosphorylation of 
compound 3-1’ and 3-2’. The results showed that PTP1B’s activity did not changed 
and still retained its original enzymatic activity after incubation, which also indicated 
 KM ( mM) kcat (s
-1
) Kcat/KM ( mM
-1∙s-1) 
Compound 3-1’ 0.77 ± 0.20 11.8 ± 2.4 15.2 ± 0.2 
Compound 3-2’ 1.1 ± 0.4 8.8 ± 2.6 7.9 ± 0.1 
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most of PTP1B is the reaction was not covalently labeled and the enzyme can still 




Figure 3.10 Comparison of PTP1B’s activity, with and without compound 3-1’ and 3-2’ 
labeling, indicates that, no significant decrease of activity was observed.  
 
3.4.9 FACS experiments 
 The self-immobilizing Turn-ON fluorescence properties of these new PTP 
probes make them suitable for FACS experiments.
92
 Flow Cytometry analysis was 
performed on a BD LSR II Bioanalyzer equipped with a 355 nm UV air-cooled laser. 
The data was analyzed using BD FACSDiva software. Cells were seeded in Nunc
TM
 
(Cat. No. 153066) 3.5 cm dishes and grown till ~90% confluence. Two sets of cells 
were prepared. One set of cells was UV-irradiated for 1 min. After pelleting the cells 
by centrifugation, discarding the supernatant and adding a fresh PBS buffer, 
Propidium iodide (PI, 2µM final conc.) was added and the cells were stained for 10 
min at room temperature. Then the cells were rinsed with 1x PBS and directly 
analyzed by flow cytometry. The results indicated that UV-treated cells and untreated 
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1-min UV irradiation on cells did not appear to have any noticeable morphology 




Figure 3.11 Histogram of flow Cytometry analysis of dead cells after 1 min UV-irradiation 
(five cell lines, MDCK, HEK293T, HepG2, HeLa, MCF-7). Red line: cells stained by PI; 
Blue line: UV-irradiated cells stained by PI. 
 
 HeLa cells were first incubated with 3-2 for 30 min, allowing sufficient time 
for the compound to enter the cells. Cells were subsequently UV-irradiated for 1 min 
then further incubated for 2 h. Upon washing with PBS (2x ), the cells were detached 
and finally fixed with 1% paraformaldehyde in PBS before being subjected to FACS 
analysis. Compound 3-1 was used as a negative control. As shown in Figure 3.12, we 
observed a noticeable increase in the number of highly fluorescently labeled cells, 
over both non-irradiated cells and cells treated with 3-1. The results clearly indicated 
that 3-2 was able to strongly and permanently “stain” the cells through its self-
immobilizing property. No leakage of 3-2 from the cells was observed (data not 
shown) even after repeated washing of cells. On the other hand, cells stained with 3-1 
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(the non self-immobilizing analog of 3-2) showed much weaker fluorescence, which 








Figure 3.12 a) Density-plot of FACS analysis of HeLa cells treated with 80 µM of 3-1 and 3-
2. Blank: only cells (without any added compounds). “– UV”: cells treated with compound 3-
2 but without UV-irradiation. UV + 3-1/3-2: cells treated with compound 3-1/3-2 followed by 
UV-irradiation. The boundary between two colors corresponds to the maximum fluorescence 
in the blank sample. b) FACS histogram of HeLa cells treated with 80 µM of uncaged 3-1 or 
3-2 (‘‘-UV’’ represents cells treated with non-irradiated 3-2, a negative control). 
 
 We next used 3-2 to detect PTP activities in a cell type-specific manner, in 
anticipation that most cancers have elevated PTP expression. For FACS experiments 
with normal and cancer cells, the cells were seeded in Nunc
TM
 (Cat. No. 153066) 3.5 
cm dishes and grown till ~90% confluence. Next, compound 3-2 (80 µM) was added 
Blank                                    - UV                           3-1 + UV                           3-2 + UV 
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and the cells were incubated further for 30 min. Upon UV-irradiation for 1 min, cells 
were further incubated for 2 h, then washed with PBS (2x ), detached from dishes, 
washed (with PBS), fixed with 1% paraformaldehyde in PBS for 10 min, then 
analyzed by FACS. While UV irradiation itself didn’t result in any apparent effect on 
the cells (Figure. 3.11), FACS analysis of 5 common mammalian cells, shown in 
Figure 3.13, indicated significantly higher fluorescence counts in cancer cells treated 





















Figure 3.13 FACS analysis of five cell lines. a) Density-plot of FACS analysis of five cell 
lines treated with 80 µM of compound 3-2. Blank: only cells (without any added compounds). 
The UV-irradiated samples were performed in duplicate (two right panels). The boundary 
between two colors corresponds to the maximum fluorescence in the blank sample. b) 
Summary of analysis of five cell lines. The data were extrapolated. Relative numbers of 
stained cells (by uncaged 3-2; 80 µM) from the FACS results of diﬀerent mammalian cells. 
 
3.4.10 Microscopy experiments 
 Finally, we showed that 3-2, upon incorporation into suitable peptide 
sequences, could be used for subcellular imaging of PTP activities in live cells. The 
cells were incubated with 20 µM of the peptide (either pMito, pMem or pER) in 
fresh Dulbecco's Modified Eagle Medium (DMEM). The cells were further incubated 
(1.5 h for pER and pMito, 30 min for pMem). Then the medium was refreshed. 
Upon UV-irradiation for 1.2 min, the cells were further incubated for 1.5 h. Next, 0.25 







 Plasma Membrane Stains C10045; 
MitoTracker
®
: Red CMXRos dye; all from Invitrogen). Upon further incubation 
according to the vendor’s protocols, the cells were washed with PBS (3x ), then fixed 
with 3.7% formaldehyde for 15 min at 37 °C. The stained cells were finally imaged 
with a Leica TCS SP5X confocal microscope system and processed with the Leica 
application suite advanced fluorescence (LAS AF).  
   
 
 
Figure 3.14 Fluorescence images of HeLa cells treated with different non-irradiated peptide 
probes (20 µM, 30 - 90 min incubation). Without UV-irradiation, the cells were directly 
imaged. No fluorescence was observed in any of the images, indicating the temporal control 
of our “caging” strategy. With UV-irradiated, further incubated (1.5 h) then imaged (in 
coumarin channel). ‘‘Overlay’’:images from the coumarin channel overlaid with the tracker 
channel. Excitation channel: peptide channel (405 nm Diode laser); tracker channel (white 
laser, 590 nm for ER-Tracker, 543 nm for CellMask, 554 nm for Mito-Tracker, respectively). 
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 Figure 3.14 (- UV) is the fluorescence images HeLa cells treated with different 
non-irradiated peptide probes (negative controls). The result shows the fluorescence 
images of HeLa cells treated with or without the different uncaged peptide probes. 
pMem, pER, and pMito, each containing a CPP, served to deliver our pTyr mimic to 
diﬀerent subcellular organelles (membrane, endoplasmic reticulum and mitochondria, 
respectively). Cells were subsequently imaged to detect subcellularly localized, 
endogenous PTP activities; all three peptides gave rise to strong ﬂuorescence signals 
only in their intended organelles, indicating successful delivery and subcellular 
imaging of PTPs. 
 
3.5 Conclusion 
 In conclusion, we have shown the utility of this newly developed, self-
immobilizing and ﬂuorogenic pTyr mimic in studying endogenous PTP activities 
using FACS and bioimaging experiments. Future work will focus on incorporation of 
this unnatural amino acid into peptides and proteins, to engineer the corresponding 
enzyme sensors capable of addressing the substrate speciﬁcity of individual PTPs. 
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Chapter 4  Ugi reaction-assisted rapid assembly of affinity-




 This chapter summarizes the development of a new method, the multi-component 
Ugi reaction to assemble a small library of affinity-based probes (AfBPs) that target 
potential protein tyrosine phosphatases (PTPs). The probes showed good inhibition and 
labelling of PTP1B and MptpB, and were subsequently used to label endogenous PTP1B 
in MCF-7 cancer cells. 
 
4.1 Introduction 
 Protein tyrosine phosphates (PTPs) are essential enzymes in the 
phosphoproteome networks. Dysregulation of these enzymes are implicated in a 
variety of human diseases.
 
For example, protein tyrosine phosphatase 1B (PTP1B) 
is a well-known negative regulator of the insulin pathway and its malfunction can 
cause diabetes and obesity.
98
 MptpB, another well-known protein tyrosine 
phosphatase encoded by Mycobacterium tuberculosis, is a promising target for 
new tuberculosis (TB) drugs (Figure 4.1).
99
 To better understand both the in vitro 
and in vivo enzymatic activities of PTPs, new chemical and biological methods 
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have emerged in recent years. Among them, strategies based on activity-based 
protein proﬁling (ABPP) are particularly appealing, as they enable sensitive 
detection of active PTPs present in a crude proteome.(Chapter 1 section 1.4) 
Depending on the design and the probes used, it is possible to profile different 
PTPs and obtain their substrate specificity.
50
 ABPP typically operates with small 
molecule activity-based probes (ABPs) derived either from suicide inhibitors or 
reversible inhibitors of the target enzyme, and in the later cases, these probes are 
more accurately referred to as affinity-based probes (AfBPs).
51, 100
 Compared to 
the traditional ABPs, AfBPs provide an easily accessible tool to most protein 
classes (including enzymes and non-enzymes) by conversion of reversible 
inhibitors into covalent protein-profiling probes with a suitable photo-cross linker 
and a reporter tag.
61, 101
 Many AfBPs have been developed so far against different 




Figure 4.1 Structures of representative PTP1B/MptpB bidentate inhibitors with the core 
group (in red) binding to the primary binding site and the peripheral group (in blue) binding 
to the secondary binding site of PTP. 
 
 Herein, we report the design and synthesis of AfBPs of PTPs. In order to 
obtain a sizeable panel of AfBPs suitable for substrate specificity profiling of 
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PTPs, we have used the multi-component reaction (MCR) to rapidly assemble 
these probes in a single step (Figure 4.2). To the best of our knowledge, this is the 




Figure 4.2 Chemical synthesis of the 25 AfBPs using Ugi reaction. The four components – 
the aldehyde 4-1 (in red), the isonitrile 4-2 (in green), the “clickable” 4-3 (in black) and the 25 
different diversity groups used 4a-y (in blue) - were shown, and the corresponding AfBPs 
were assembled in one-pot to give the 25 tBu-protected AfBPs, P1’ to P25’, which upon TFA 
treatment, gave the 25 final AfBPs, P1 to P25 (boxed). 
 
 Recently, it has been discovered that many PTPs, including PTP1B and 
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MptpB, possess a highly distinct secondary binding site in addition to their 
homologous primary active site where phosphotyrosine (pTyr) binds (Figure 
4.1).
88
 This thus makes it possible to develop bidentate inhibitors which could 
impart both potency and specificity against the target PTP (Figure 4.1).
76, 77, 102
 
Although MCR has been extensively used in drug discovery,
103
 including the 
synthesis of PTP inhibitors,
104
 its application for rapid assembly of AfBPs has not 
been explored. By carefully considering the structural property of previously 
developed bidentate PTP inhibitors (Figure 4.1), where a pTyr mimic (shown in 
red) is connected to a diversity group (shown in blue) through a suitable linker, we 
conceived an inhibitor-to-AfBP conversion could be conveniently made through 
the Ugi reaction using the following four components (Figure 4.2): 1) an aldehyde-
containing isoxazole carboxylic acid, 4-1, that mimics pTyr and anchors the AfBP 
to the PTP active site; 2) an amine-containing diversity component, 4a-y, which is 
readily accessible from commercially available amines and may bind to the 
secondary binding site of the PTP; 3) an isonitrile-containing benzophenone, 4-2, 
which upon UV irradiation would initiate covalent cross-linking between the PTP 
and the AfBP; 4) a terminal alkyne-containing carboxylic acid, 4-3, which serves 
as a clickable tag for subsequent in-gel fluorescence scanning and pull-down 
experiments by conjugation to suitable reporters (rhodamine-N3 or biotin-N3 in 
Figure 4.3) via the bioorthogonal click chemistry.
105
 Direct introduction of a 
fluorescent/biotin tag in the AfBP was not desirable as the bulky reporter might 
disrupt the binding between the PTP and the probe.
54
 In this study, a total of 25 
AfBPs targeting potential PTPs have been successfully assembled in a single step, 
and their ability for ABPP against recombinant PTPs and endogenous PTPs and 





Figure 4.3 The AfBP work flow. First, the enzymes were incubated with the probe for 30 min. 
After photolysis under UV for 20 min in an ice bath, the mixtures were subjected to the [3+2] 
click reaction for 2 h with TER-N3. Finally, the labeled reaction was separated by SDS-PAGE 
and visualized by in-gel fluorescence scanning. For pull-down/LC-MS/MS, Biotin-N3 was 
used in place of TER-N3. 
 
4.2 Synthesis of two components-aldehyde and isonitirile 
 The warhead aldehyde part (Scheme 4.1a, up) was prepared from p-
hydroxyacetophenone, which underwent allylation to get protected phenol 4-5. 
Subsequently, Claisen condensation with dimethyl malonate was processed to get 
the diketo product in 48% yield and following by cyclization to yield the isoxozale 
carboxylic methyl ester in 80% yield. Next methyl group was removed by LiOH to 
give compound 4-7 and protected t-butyl group using POCl3 and pyridine to obtain 
compound 4-8 in 75% yield of two steps. The final aldehyde 4-1 was obtained in 
81% yield after ozonolysis. The synthesis of the photo-cross linker part (Scheme 
4.1b) began from 4-methylbenzophenone. Bromination of the starting material was 
resulted bromomethyl benzophenone 4-9 in reasonable yield (78%). Substitution 
with NaN3, following with reduction using PPh3 was obtained the amine (4-11). 
Subsequently, 4-11 was coupled with the formamide linker, following by 





 In addition, we used 25 amines (4a-y) including aromatic 
amine, aliphatic amine with aromatic ring and hetero ring (Figure 4.2). 
 Next, as shown in Figure 4.2, the four-compound Ugi reaction with 4-1, 4-
2, 4-3 and one of the 25 amines (4a-y) was carried out in 1.5 mL tubes; upon 
optimizations, it was found the MCR reaction carried out with a co-solvent system 
of methanol and DMF (6:1) at room temperature for 9 h was sufficient to deliver 
high-quality products (P1’ to P25’) with consistent yields (~ 20-30% after HPLC 
purification). The desired probes, P1 to P25, in acceptable purity (> 85%) were 
obtained by further treatment with TFA/DCM (1:1) for 2 h and used directly for 
subsequent experiments. All the purification results were shown in Chapter 6. 
 
 
Scheme 4.1 Chemical synthesis of 4-1 and 4-2. 
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4.3 Biological experiments and discussion 
4.3.1 Inhibition assay 
 Prior to protein labeling studies, the probes were evaluated for their 
inhibition against recombinant PTP1B and MptpB in a standard enzymatic assay.  
The inhibition of MCR products to against protein tyrosine phosphatases (PTPs) 
was assessed by measuring the rate of hydrolysis of the fluorogenic substrate, 6,8-
difluoromethylumbellifery phosphate (DiFMUP, Invitrogen, USA) in 25 μL 
reaction volumes in black polypropylene flat-bottom 384-well microtiter plates 
(Greiner, Germany), using PTP1B and MptpB as model proteins. For IC50 studies, 
dose-dependent reactions were set up by varying the concentration of each 
inhibitor while maintaining a fixed enzyme and substrate concentration. Briefly, a 
two-fold dilution series of an inhibitor, from approximately 400 μM to 3.125 μM 
(final concentrations) was prepared. The reaction conditions are shown below: 
PTP1B (2 μg/mL) = 10 μL 
DiFMUP (10 μM) = 10 μL 
Inhibitor (Varied) = 5 μL (in 40% DMSO) 
Assay buffer (PTP1B) = 25 mM HEPES, 150 mM NaCl, 0.1 mg/mL BSA pH=7.5 
Assay buffer (MptpB) = 25 mM HEPES, 2.5 mM EDTA, 50 mM NaCl, 0.02% 
Triton-100, 2 mM DTT, pH = 7.4 
 
 Negative controls were performed in the absence of enzyme and positive 
controls were carried out in the presence of enzyme with DMSO (i.e. without 
inhibitor). The reactions were allowed to incubate at room temperature for 30 min 
before being initiated by addition of DIFMUP. The enzymatic reactions were 
immediately monitored with a Synergy™ 4 Multi-Mode Microplate Reader (BioTek, 
USA), at λex= 355 nm and λem= 460 nm for a period of 15 min. Each IC50 plot was 
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generated by averaging duplicates from two independent assays (Figure 4.4) and IC50 
values were summarized in Table 4.1. 
 Most AfBPs had IC50 values of ~10 μM against PTP1B, which was similar to 
the 5.7 µM (in Ki value) obtained from the original bidentate inhibitor (Figure 4.1),
77b
 
indicating that they likely bound to PTP1B at both the primary and secondary binding 
sites. Most probes possessed a greater inhibition against PTP1B than MptpB, 
indicating the isoxazole carboxylic acid moiety chosen fitted the active site of PTP1B 
better.
77b, 87a
 These results confirmed that most of our 25 AfBPs had moderate affinity 
against both PTP1B and MptpB, and therefore may be used for subsequent substrate 
specificity profiling/proteomic pull-down experiments 
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IC50 (μM) Probe 
ID 
IC50 (μM) 
PTP1B MptpB PTP1B MptpB 
P1 14.6 ± 2.4 24.6 ± 1.5 P14 10.3 ± 0.6 14.0 ± 0.8 
P2 8.2 ± 0.3 9.2 ± 0.2 P15 6.7 ± 0.5 16.8 ± 0.5 
P3 26.2 ± 3.7 33.0 ± 8.7 P16 17.0 ± 1.8 21.4 ± 2.9 
P4 20.1 ± 0.7 23.7 ± 2.0 P17 6.3 ± 0.7 12.2 ± 0.7 
P5 9.1 ± 0.1 11.5 ± 2.0 P18 13.7 ± 1.7 14.2 ± 2.4 
P6 6.3 ± 0.4 11.1 ± 1.8 P19 6.0 ± 0.5 5.8 ± 0.1 
P7 7.6 ± 0.5 11.2 ± 0.6 P20 7.1 ±1.2 8.3 ± 0.5 
P8 7.0 ± 0.8 8.8 ± 1.7 P21 4.6 ± 0.5 5.3 ± 0.5 
P9 21.5 ± 0.3 36.4 ± 14.2 P22 13.7 ± 0.7 > 80 
P10 42.6 ± 0.5 > 80 P23 7.0 ± 1.0 12.3 ± 1.9 
P11 30.5 ± 0.5 27.9 ± 4.1 P24 > 80 > 80 
P12 40.9 ± 7.7 53.8 ± 5.5 P25 11.4 ± 0.3 > 80 
P13 17.0 ± 2.2 23.0 ± 0.5    
 
4.4.2 Fingerprint profiling of PTP1B and MptpB 
4.4.2.1 Expression and purification of PTPs 
 PTP1B and MptpB containing His6-tag were expressed in E.coli strain BL21-
DE3, as previously described,
 
and purified from the lysates on Nickel-nitrilotriacetic 
acid (Ni-NTA) metal-affinity chromatography matrices (Qiagen) according to the 
manufacturer’s instructions. The purified proteins were then dialyzed against dialysis 
buffer and stored in 30% glycerol at -20 °C before use. (Dialysis buffer: PTP1B: 10 
mM Tris∙HCl, 25 mM NaCl, pH = 7.5; MptpB: 50 mM Tris∙HCl, 100 mM NaCl, pH 
= 7.4). Stock solutions of enzymes were prepared in final concentrations of 2-5 
mg/mL (in dialysis buffer). Stock solutions of the probes were prepared in DMSO and 
stored at before use. UV photolysis experiments were carried out using a B100A UV 
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lamp (UVP, USA). Fluorescence imaging was performed using a Typhoon 9410 
fluorescence gel scanner at λ = 533 nm and analyzed with the ImageQuant Software. 
 
4.3.2.2 General optimization for enzyme labeling 
 The enzyme stock solutions were diluted to 1 mg/mL. Generally 1 μL enzyme 
solution was added into 14 μL dialysis buffer solution with 1 μL probe and shaken at 
room temperature in the dark for 30 min. The mixture was next irradiated under the 
long-rang wavelength UV channel for 20 min on the ice. Subsequently, 1 μL of 
rhodamine-N3 and the click reagents (total 3 μL; see reference 107) were added into 
the solution (final solution contained CuSO4 (500 μM), TBTA liagnd (100 μM) and 
the reducing reagent (PTP1B: sodium ascorbate 250 μM; MptpB: DTT 500 μM)). The 
whole solution (total 20 μL) was shaken at room temperature for 2 h. The reaction 
was then quenched by addition of 4 μL of 6x SDS loading dye followed by boiling at 
95 °C for 10 min. The samples were analyzed on a 10% denaturing SDS-PAGE gel. 
The fluorescence was detected with the fluorescence gel scanner.  
 To determine the concentration-dependent labeling with varied amounts of the 
enzyme, 1 μL of MptpB (2000 ng, 1000 ng, 500 ng, 250 ng) was added into different 
reaction vessels, each containing 5 μM of the probe P15. The samples were then 
treated as mentioned above. To determine the concentration-dependent labeling with 
varied amounts of the probe P15, 1 μg of MptpB was incubated with the probe P15 
(20, 10, 5, 2.5, 1.25, 0.6, 0.3, 0 μM). The reaction was incubated for 30 min and 
treated as mentioned above. For UV- irradiation time-dependent experiments, 
identical reaction mixtures containing 1 μL of MptpB and 5 μM of the probe P15 
were similarly set up. The reactions were incubated at room temperature in the dark 
for 30 min. The mixtures were then irradiated for varied lengths of time (10, 15, 20, 
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30, 60 min) with long-wavelength UV light. Then the mixture was analyzed as 
mentioned above. As shown in Figure 4.5a and 4.5b, the labeling intensity increased 
with increasing probe or protein concentration. And with more UV-irradiation time 
which generates cross-link reaction, the intensity is also higher. 
 For labeling experiments with different click reagents and click reaction time, 
the reactions were prepared as mentioned above by using the probe P15. Varied 
amounts of CuSO4 (100, 200, 500 μM) were used. Then the mixture was treated as 
described above. Probes P12 and P17 were used to test the optimized amount of the 
ligand (TBTA, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) in the labeling of 
MptpB. Probe P15 was used to test the difference in the reducing agent (i.e. DTT vs 
sodium ascorbate) in the labeling reaction. Different amounts of sodium ascorbate 
(250, 500, 1000 μM) and DTT (125, 250, 500, 1000 μM) were used. All other 
conditions were similar as above mentioned. To optimize the click reaction time, after 
addition of the click reagent as mentioned above, the reaction was further incubated 
for 0.5, 1, 1.5, 2, and 3 h. After analyzing the results, we used higher copper 
concentration, with ligand and two different reducing reagents to label recombinant 
PTP1B and MptpB. 
 For heat-denaturing experiments, MptpB (in Tris buffer) was heated at 95
 
°C 
for 10 min and allowed to cool to room temperature. Each reaction was set up using 
1000 ng denatured and normal MptpB. Different probes (P13, P14, P19 and P20) 
were used. Other procedures were the same as above described. The labeling profiles 
of both the active and heat-denatured MptpB were compared (Figure 4.5h), 
confirming that successful labeling of PTPs by these AfBPs were indeed dependent 







Figure 4.5 Optimization of labeling of pure PTPs. a) Effect of probe P15 concentration on 
labeling intensity: MptpB was incubated with decreasing concentrations of P15 (final 
concentration: 20, 10, 5, 2.5, 1.25, 0.6, 0.3, and 0 μM, respectively); b) Effect of protein 
concentrations on labeling intensity: different MptpB concentrations (final concentration: 2, 1, 
0.5, and 0.25 μg, respectively); c) Effect of UV irradiation time on labeling intensity: MptpB 
was exposed to long-wavelength UV light for varying amounts of time (60, 30, 20, 15, 10 min, 
respectively); d) Effect of copper amount on labeling intensity: click reaction was carried out 
with increasing amounts of CuSO4 (final concentration: 100, 200, and 500 μM); e) Effect of 
TBTA ligand on labeling intensity: two different probes were incubated with or without the 
TBTA ligand (final concentration: 125 μM); f) Effect of reducing reagents on labeling 
intensity: MptpB was incubated with different concentrations of DTT (final concentration: 
125, 250, 500, and 1000 μM, respectively); PTP1B was incubated with different 
concentrations of sodium ascorbate (final concentration: 250, 500, and 1000 μM); g) Effect of 
click time on the labeling intensity: click reactions were carried with increasing time (3, 2.5, 2, 
1.5 and 0.5 h, respectively); h) Different probes (P13, P14, P19, and P20; final probe 




4.3.2.3 Affinity-based profiling of MptpB/PTP1B by using 25 AfBPs 
 After carrying out ABPP using recombinant PTP1B and MptpB by optimizing 
the protein labeling conditions (see above); it was found that 1 g of the protein, 
incubated with 5 M of the probe for 30 min, followed by 20 min of UV irradiation 
then 2 h of click chemistry with the reporter tag, gave the best labeling results. The 
labeling procedure was the same as mentioned above. One of the key advantages of 
our current approach is the rapid access to a large number of potential AfBPs using 
Ugi reaction, and in the present study, the 25 AfBPs obtained were immediately 
suitable for substrate specificity profiling against PTPs. As shown in Figure 4.6, the 
“fingerprint” generated for PTP1B and MptpB against the panel of AfBPs were 
unique, and may be used to further delineate different binding pockets present in 
PTPs. In the case of PTP1B, it appeared that probes having a small, hydrophobic 
diversity group (P1, P16, P17, P23, P24 and P25) gave the strongest fluorescence 
labeling. This is in good agreement with previously established structural information 








Figure 4.6 Affinity-based profiling of recombinant PTP1B and MptpB against the 25 AfBPs. The fluorescently labeled band was pseudo-colored in grey. 
PTP1B: protein 1 μg; probe 5 μM; dye 40 μM; Copper sulfate 500 μM; ligand 100 μM; sodium ascorbate 500 μM; UV time 20 min; click time 2 h. MptpB: 





4.3.4 In vitro labeling mammalian proteomes and pull-down/LC-MS/MS 
analysis 
 We next performed proteome profiling of MCF-7 mammalian cell lysates and 
large-scale pull-down/LC-MS/MS target identification experiments using the P23 
probe.
107
 P23 was chosen because of it good inhibition and strong labeling against 
PTP1B. Briefly, P23 (20 µM) was incubated with MCF-7 cell lysates (10 mg/10 mL 
in a chilled buffer of 50 mM Tris∙HCl, 150 mM NaCl, pH 8.0, 1.0% NP-40, 100 µM 
PMSF) for 20 min at room temperature. Then the samples were irradiated for 45 min 
under UV light. Subsequently, a small amount of the irradiated sample was treated 
with rhodamine-N3 (100 µM) and click reagent (1 mM CuSO4, 1 mM TCEP, 100 µM 
TBTA) for 3 h. Following acetone precipitation, washing (2x with methanol), 
resolubilization (in 1x SDS loading buffer) and heating (10 min at 95 °C), the sample 
was separated by SDS-PAGE (10% gel) and visualized by in-gel fluorescence 
scanning on a typhoon 9410 variable mode imager scanner. The fluorescent gel was 
shown in Figure 4.7. As shown in Figure 4.7a, in-gel fluorescence scanning of the 
labeled lysates indicated multiple cellular targets, one of which was subsequently 
confirmed to be endogenous PTP1B by western blot (labeled with “*” in Figure 4.7b) 
and LC-MS/MS analysis (Figure 4.7c) 
 The remaining labeled lysates (prior to click chemistry) were used for large-
scale pull-down/LC-MS analysis to identify other cellular targets of the probe. Briefly, 
the sample was treated with Biotin-N3 (100 µM) and click reagent (1 mM CuSO4, 1 
mM TCEP, 100 µM TBTA) for 3 h. Subsequently, it was acetone-precipitated, 
washed (2x methanol) and resolubilized in PBS (containing 0.1% SDS) with 
sonication. The sample was then incubated with avidin-agarose beads (Thermo 
Scientific) for 4 h at room temperature. After centrifugation, the supernatant was 
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removed and the beads were washed with washing buffers (3x with 1 M NaCl, 20 mM 
Tris∙HCl, 5 mM EDTA, 0.1% NP-40, pH = 7.3; 6x with 2 mM Tris∙HCl, 0.5 mM 
EDTA, 0.1% NP-40, pH = 7.3; 6x with 4 M urea, 10 mM Tris∙HCl, 1 mM EDTA, 0.1% 
NP-40, pH = 7.3; 2x with 2 mM Tris∙HCl, 0.5 mM EDTA, pH = 7.3). The beads were 
then boiled in 1x SDS loading buffer for 10 min. Samples were separated by SDS-
PAGE gels and stained by colloidal blue solution. Gel lanes corresponding to both 
DMSO- and probe-treated samples were then cut into small slices, respectively. Next, 
trypsin digestion (In-Gel Trypsin Digestion Kit, Pierce Co., USA) was performed for 
the whole pull-down proteins. Digested peptides were then extracted from the gel 
with 50% acetonitrile and 1% formic acid in H2O. Two samples was then dried in 
vacuo and stored at -20 °C for further LCMS analysis. Briefly, samples were analyzed 
as previously described.
 
The samples were resuspended in 0.1% formic acid in H2O. 
The peptides were separated and analyzed on a Shimadzu UFLC system (Shimadzu, 
Kyoto, Japan) coupled to an LTQ-FT Ultra (Thermo Electron, Germany). Peptides 





(Michrom BioResources, USA) and the raw data were analyzed using an in-house 
Mascot Server (version 2.2.07, Matrix Science, UK) with MS tolerance of 10 ppm 
and MS/MS tolerance of 0.8 Da. Two missed cleavage sites of trypsin were allowed. 
Carbamidomethylation (C) was set as a fixed modification. And oxidation (M) was 
set as variable modifications. After data analysis, a large number of proteins were 
identified from each LCMS experiments, many of which are non-specific binders and 
need to be removed. For those proteins with cores of < 50, they were automatically 
removed from the list. For those proteins that appeared in the negative run (pull-
down/LCMS experiments with DMSO only), they also were excluded from the list as 
well. Highly abundant proteins that commonly appeared in irrelevant pull-down 
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experiments were further removed. The final list was shown in Chapter 6, with 




Figure 4.7 Results of proteome profing of P23 against MCF-7 lysate. (a) Proteome profiling 
of P23 against MCF-7 cell lysates. (Left) In-gel fluorescence scanning. (Right) Western blot 
of the pulled-down sample after P23 labeling and clicked with Biotin-N3. (-) Netagive 
controls with DMSO. (*) labeled PTP1B which was subsequently confirned by WB (in Figure 
4.6b). (b) Target validation by pull-down/WB experiments. (c) A list of high-scoring proteins 
identified from in vitro pull-down/LC-MS experiments. For complete list, see Chapter 6, 
section 6.11 
 
 In addition to PTP1B, several other high-scoring proteins were listed (for 
complete list, see Chapter 6.11). Some of them (Cathepsin D and Prohibitin) were 
further validated to be true targets of P23 by pull-down/WB analysis (Figure 4.6b). 
Given the fact that most of our probes were moderate binders of PTP1B, it was not 





Information obtained from our current study would nevertheless be 
helpful in the design of more potent and specific AfBPs against PTPs in future. 
 
4.4 Conclusion 
 In summary, we have successfully used the multi-component Ugi reaction for 
rapid assembly of a panel of affinity-based probes targeting potential PTPs. The 
probes obtained, though moderate binders of PTP1B, were able to successfully label 
endogenous PTP1B in mammalian lysates. From this study, we have also identified 
some “off-targets” of these probes which will help in future design of better PTP 
probes. The marriage between MCR and ABPP will add another useful chemical tool 






Chapter 5 Unexpected phosphotyrosine mimicking probes 




 In this chapter, four clickable, phosphotyrosine mimics-, activity-based probes, 
which were derived from a known PTP1B inhibitor, have been synthesized and used 
in situ for profiling and identification of cellular targets in cell lines. Unexpectedly, 
protein disulfide isomerase was found as a major and selective target. 
 
5.1 Introduction 
 Protein tyrosine phosphates (PTPs), together with protein tyrosine kinases 
(PTKs) plays an essential role in maintaining the pTyr level in cellular events and 
regulating various fundamental cellular processes.
2
 Malfunction in PTP activity is 
related with a variety of human diseases, including cancer, diabetes and obesity, and 
autoimmune disorders.
4
 Many powerful chemical methods have been developed to 
integrate the analysis of PTPs in whole proteome.
10
 In particular, activity based probe 
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profiling (ABPP) is a very useful tool and have been applied in drug discovery, target 
identification and biomarker discovery.
51, 109 
ABPs for PTPs have already been 
developed based on PTP catalytic mechanism.
110
 However, due to the high conserved 
active site of PTPs, targeting an individual member of PTPs in crude proteome still 
needs to be addressed. 
 Herein, we designed and synthesized four activity-based probes based on a 
known PTP1B inhibitor (1-19, Figure 5.1)
41
 by replacing the phosphotyrosine (pTyr) 
mimetic head to some reactive groups, including phenyl vinyl sulfonates (PVS, 5-1 
and 5-2) and 2-fluoromethyl phenyl phosphate (FMPP, 5-3 and 5-4). FMPP moiety 
generates a highly reactive quinone methide intermediate upon PTP hydrolysis and 
subsequently immobilizes itself covalently to the nearby proteins.
50, 90, 111
 PVS, 
developed by Zhang group
65
, as a new pTyr mimic with better cell permeability, is an 
active site-directed and irreversible inactivation compound toward PTPs through 1,4-
Michael addition of cysteine in active site. Furthermore, the probe scaffold contains 
an alkyne handle, which serves a clickable tag for subsequent visualization, 
enrichment and identification of targets by conjugation to suitable reporters 
(trifunctional tag
54c, 112
) via the bioorthogonal click chemistry. Under consideration, 
since the aliphatic chain of 1-19 is out of the binding pocket and there is no hydrogen 
bond between the chain and protein, the minimal structural modification was 
established by introducing a C-C triple bond through replacing the terminal C-C 
single bond of this aliphatic chain. Furthermore, a photolabile protecting group was 
introduced into FMPP based probe 5-3 and 5-4 to improve the cell permeability and 
also provide temporal control by photolysis. Besides, compared with probes 5-1 and 
5-3, probes 5-2 and 5-4 were designed with the coumarin-based aromatic ring to 





Figure 5.1 Overall strategy of probe design. a) Structures of PTP1B inhibitor 1-19 and four 1-19-derived clickable probes (PVS-based probes 5-1 and 5-2, as 
well as 2-FMPP based probes 5-3 and 5-4). b) Workflow for in situ targeting profiling using probes. Protein visualization and identification is achieved by 






Figure 5.2 Synthetic schemes of four probes. 
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5.2 Synthesis of four probes 
 The synthetic scheme is shown in Figure 5.2. In brief, the aliphatic chain with 
the alkyne modification part was attached by amine and carboxylic acid coupling 
reaction using EDC, HOBT activation. The deprotection of Fmoc group was achieved 
using either piperidine or DBU. Subsequently, the addition of Boc-protected 
phenylaniline was also obtained by coupling reaction using EDC, HOBT activation. 
For probe 5-1 and 5-2, the vinyl sulfonate modification on phenol was obtained by 
nucleophilic substitution and elimination using 2-Chloro-1-ethanesulfonylchloride 
and triethylamine as a base.
65
 Probes 5-3 and 5-4 which are smaller than 5-10 and 5-
12 but also have better cell bioavailability were obtained by removing one of 2-
nitrobenzyl groups in 5-10 and 5-12 under TEA/thiophenol condition.  
 
 
Figure 5.3 The structure of Tri-N3. 
 
 The trifunctional tag (Figure 5.3) was also synthesized through routine 
acid/amine coupling reactions. The tag was containing three elements: 1) PEG azide, 
which is used for click reaction by reacting with the alkyne; 2) Rhodamine B dye, 
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which could be used for in-gel visualization; 2) Biotin, which is used for 
isolation/pull-down experiments. Combining with Rhodamine B dye and Biotin 
together, tracking the pull-down experiment could be done using fluorescent scanning 
which is faster and easier than Western blotting analysis. 
 
5.3 Biological experiments and discussion 
5.3.1 In situ proteomic profiling and in-gel fluorescence scanning 
 With the four probes in hand, we next assessed whether probes could be an 
effective probe in live cells. To analyze the cellular target profiling, we incubated 
probes with living MCF-7 cancer cells following the common procedure (see the flow 
in Figure 5.1).  
 Briefly, probes (5-1 and 5-2 in 5 µM, 5-3 and 5-4 in 20 µM, VS-1
114
 as a 
comparison) were directly treated with cell medium. Final DMSO concentration in 
labeling is less than 0.1%. The probes were stocked in DMSO, -20°C. For 5-1 and 5-2, 
cells were incubated for 2 h incubation. For 5-3 and 5-4, cells were first incubated 
with probes for 2 h, allowing sufficient time for them to enter the cells. Subsequently 
these cells were UV-irradiated for uncaging of the 2-nitrobenzyl group then further 
incubated for 2 h. 
 After incubation, the cells were washed with PBS three times and detached 
from the plates by scrapping or trypsin. Afterward, the cells were lysed in 300 µL 
buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 100 µM PMSF, pH = 8.0). To 
initial the click reaction, 4 equivalents of TER-azide (structure shown in Figure 4.3), 4 
equivalents of TBTA, 40 equivalents of TCEP and 40 equivalents of CuSO4 was 
added. The click reagent mixture was freshly prepared. The reaction was incubated at 
room temperature for 2 h with gentle shaking before termination by the addition of 5-
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fold volume prechilled acetone (incubation for at least 1 h at -20 °C). Precipitated 
proteins were subsequently collected by centrifugation (13, 000 rpm x 10 min at 4 °C). 
The supernatant was discarded and the residue pellet was washed with prechilled 
methanol, air-dried until the pellet started to shrink. Then the residue was resuspended 
in 1x standard SDS-loading buffer, sonicated 10 min and heated for 10 min at 95 °C 
with gentle mixing. Finally, the protein sample was loaded into 10% or 12% SDS-
PAGE gel, separated following by in-gel fluorescence scanning with a Typhoon 9410 





Figure 5.4 In situ proteome-profiling of different probes against MCF-7 (5-1 and 5-2: 5 µM; 
5-3 and 5-4: 20 µM; VS-1: 10 µM; 2 h incubation). FL = fluorescent gel. CBB = coomassie 





 In-gel fluorescent SDS-PAGE analysis of the labeled proteomes in Figure 5.4 
showed all the probes have some distinct fluorescently labeled bands compared with 
blank labeling (only DMSO, without any probe). Especially, 5-1 and 5-2 gave a very 
strong specific protein bands at a molecular weight of higher than 55 kD. Interestingly, 
it appears not a highest abundant protein.  
 Subsequently, dose- and time- dependent in situ labelling were carried on by 
varying the concentrations of 5-1 and incubation time. The results showed the specific 
fluorescent intensity to ~57 kD protein and other non-specific labeling increased with 
increasing concentrations of the probe (Figure 5.5 left). Furthermore, the prolifing did 




Figure 5.5 Dose and time-dependent in situ proteome profilings. a) Dose-dependent in situ 
proteome profiling of MCF-7 with 5-1 (different concentrations, 2 h incubation) resolved in 
10% SDS gel; b) Time-dependent in situ proteome profiling of MCF-7 with 5-1 (10 µM, 




5.3.2 Co-localization bioimaging 
 Then we also performed the fluorescence microscopy to visualize the 
localization of targets of probe. Briefly, MCF-7 cells were seeded in glass bottom 
dishes (CELLview
TM
, Cat. No. 627861) and grown till ~ 60% confluence. The cells 
were incubated with 20 µM 5-1 in fresh growth medium (200 µL). The cells were 
further incubated for 1 h. Then the cells were washed with PBS three times. 
Subsequently, cells were fixed with 3.7% formaldehyde in PBS for 20 min at 
37°C/CO2, washed twice again and permeabilized with 0.1% Triton X-100 in PBS for 
15 min at 37°C/CO2, washed twice again. Cell were then blocked with 2% BSA, 0.05% 
Tween-20 in PBS for 30 min at room temperature, washed twice with PBS and then 
subsequently treated with a freshly premixed click chemistry reaction in a 200 µL (10 
µM TER-PEG-azide, 200 µM TBTA 2 mM TCEP, 2 mM CuSO4 ) for 1 h at room 
temperature with gentle shaking. Cells were washed with 2x PBS, several times PBS 
containing 1% Tween-20 and 0.5 mM EDTA (until there was no small crystal under 
microscopy), 2x PBS, 2x methanol,  and 2x PBS. For ER-localization experiments, 





Invitrogen, 0.3 µM in final concentration) for 2 h, and washed with PBS twice. 
Continually, cells were incubated with nucleus stain (Hoechst, 0.2 µg/mL in final 
concentration) for 20 min and washed twice with PBS. Finally, the cells were 
washed ,imaged with a Leica TCS SP5X confocal microscope system and processed 






Figure 5.6 Organelle co-localization bioimaging experiemtns. Cellular imaging results of 
MCF-7 cells treated with 20 µM 5-1 or DMSO. Co-localization experiments were performed 
with ER and Nucleus tracker. Panel 1) and 5): Bright filed images of the corresponding cells; 
Panel 2) and 6) Probe clicked with TER-PEG-azide 543 nm Channel (pseudocolored in red); 
Panel 3) and 7) ER tracker (pseudocolored in green); Panel 4) and 8) Overlay images of 1), 2), 
3) and 5), 6), 7) together with  nucleus stain (pseudocolored in blue). All the images were 
acquired under the same settings. Excitation channel: Probe channel (white laser, 543 nm), 
ER-tracker (white laser, 488 nm), Hoechest (405 nm diode laser).  
 
 In Figure 5.6, minimal fluorescence was observed in samples treated with only 
DMSO. Whereas, in 5-1 treated cells, fluorescence signals were observed throughout 
the whole cell excluding the membrane. Most signals were co-localized with ER 
which indicated our target is probably localized in ER.  
 
5.3.3 Pull-down/LCMS/MS experiment  
 Subsequently, we performed large-scale proteomic analysis using 5-1 to 
identify potential cellular targets in MCF-7 cells by affinity pull-down/LC-MS/MS 
experiments, especially the specific labeled protein at ~57 kD. The targets were 
enriched and visualized using a trifunctional tag. The target-tag complexes were 
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isolated by using avidin beads and separated by SDS-PAGE. Through the fluorescent 
scanning and silver stain of the gel, 72kD, 57 kD and 48 kD bands “*” (Figure 5.7) 
were also precisely excised and subjected to in-gel tryptic digestion and mass 
spectrometry analysis. 
 LCMS results were obtained from above experiments with 5-1 as well as with 
DMSO as a negative control. For those proteins that appeared in the negative run 
(pull-down/LCMS experiments with DMSO only), they were excluded from the list. 
The result of ~ 48kD, 57 kD and 73 kD bands were shown in Table 5.1. From the data, 
the highest score of each bands (Figure 5.7) are protein disulfide isomerase A6 
(PDIA6. 48 kD), protein disulfide isomerase A1 (PDIA1, 57 kD), protein disulfide 
isomerase A4 (PDIA4, 73 kD), respectively. To confirm the results of the MS, we did 
the western blotting experiments with pull-down sample using PDIA1 antibody 
(Figure 5.6, right). The results again confirmed that the protein was indeed positively 
and specifically labeled by 5-1.  
 
Table 5.1 Protein identified by mass spectrometry of three specifc band (5-1-tagged band, 10 
µM) 
Name (gene protein) M.W. Score Peptide emPAI 
~ 48 kD band 
    
PDIA6 Protein disulfide-isomerase A6 48490 1854 72 1.46 
TUBB Tubulin beta polypeptide 48135 881 38 1.72 
ATP5B ATP synthase subunit beta 48083 383 27 0.91 
EEF1AL3 Putative elongation factor 1-alpha-like 3 50495 277 16 0.48 
PLIN3 Perilipin-3 47189 246 8 0.27 
~ 57 kD band 
    
P4HB Protein disulfide-isomerase 57081 4780 316 22.11 
PDIA3 Protein disulfide-isomerase A3 precursor 56747 287 16 1.08 
ATP5A1 ATP synthase subunit alpha, mitochondrial 
precursor 
59714 243 8 0.38 
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PHGDH D-3-phosphoglycerate dehydrogenase 56614 175 6 0.33 
CCT8 Uncharacterized protein CCT8 59741 88 2 0.06 
VISA Isoform 1 of Mitochondrial antiviral-signaling 
protein 
56493 62 3 0.12 
ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor 
56403 59 1 0.06 
DYNC1LI1 Cytoplasmic dynein 1 light intermediate 
chain 1 
56544 52 3 0.12 
~ 73 kD band     
PDIA4 Protein disulfide-isomerase A4 73229 4700 210 4.78 
HSPA5 glucose-regulated protein 72402 2072 91 2.39 
HSPA9 Stress-70 protein, mitochondrial 72641 289 12 0.22 




Figure 5.7 Fluorescence image of MCF-7 pull-down experiments after 5-1 (10 µM) labeling 
and clicking with trifunctional probe. “*” labeled bands were precisely cut and analyzed by 
mass spectroscopy. PDIA1 was subsequently confirmed by WB (right). Ctr = negative pull-
down assay with DMSO. 
 
5.3.4 Immunofluorescence 
 Immunofluorescence (IF) was also carried out to visualize the localization of 
PDIA1 and the overlapping with the probe. For immunefluorescent experiments, cells 
were still treated with 5-1, fixed, permeabilized and treated with TER-PEG-N3 
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following previously protocols (Chapter 5.3.2). Further cells were incubated with 
PDIA1 primary antibody (1: 200 in 2% BSA, Santa Cruz, sc-166474) for 1 h at room 
temperature, washed once with 2% BSA and twice with PBS, and then incubated with 
FITC-conjugated anti-mouse IgG secondary antibody (1:100 in 2% BSA, Santa Cruz, 
sc-2010), washed once with 2% BSA and twice with PBS. Finally, the cells were 
washed imaged with a Leica TCS SP5X confocal microscope system and processed 
with the Leica application suite advanced fluorescence (LAS AF).  
 The results are shown in Figure 5.8. DMSO treated cells has very faint signals. 
From Figure 5.8(8), IF signal of PDIA1 appears to mostly overlap with 5-1. Also, the 
colocalization indicated, beside the presence of PDIA1 as a target of 5-1, there are 
also other side targets. Together results of organelle colocalization and IF, most 
targets of 5-1 are distributed in ER where most of PDI family is localized. 





Figure 5.8 Immunofluorescence experiments were performed with anti-PDIA1 Cellular 
imaging results of MCF-7 cells treated with 20 µM 5-1 or DMSO. Panel 1) and 5): Bright 
filed images of the corresponding cells; Panel 2) and 6) Probe clicked with TER-PEG-azide 
543 nm Channel (pseudocolored in red); Panel 3) and 7) anti-PDI immnuofluorescent staining 
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(pseudocolored in green); Panel 4) and 8) Overlay images of 1), 2), 3) and 5), 6), 7) together 
with nucleus stain (pseudocolored in blue). All the images were acquired under the same 
setting. Excitation channel: Probe channel (white laser, 543 nm), FITC-tracker (white laser, 
488 nm), Hoechest (405 nm diode laser).  
 
5.3.5 Protein disulfide isomerase 
 Protein disulfide isomerase (PDIA1) is one of members in PDIs family.
114
 It is 
a characterized 57 kD oxidoreductase that localize in the ER as a chaperone protein. It 
facilitates the formation, breakage and rearrangement of disulfide bonds via catalysis 
of thiol-disulfide exchange. PDI has four structural thioredoxin-like domains (a, b, b’ 
and a’) with the catalytic CGHC motif present in a and a’ domains. The pKa of 
cysteine in active site is very low, around 4.6, which makes it as a good nucleophile 
and likely reacts with our probes. PDI could also reach the cell surface from ER 
though a regulatory pathway, with HIV virus infection.
115
 PDIs are involved in the 
recognition and repairment of abnormal proteins and their expression level is 
increased in patients with neurological disorders, including Parkinson’s disease116a 
and amyotrophic lateral sclerosis (ALS)
116b
. Recently, Stockwell group found that an 
inhibitor 16F16A could target PDIs (PDIA1 and PDIA3) and inhibit PDI in rat brain 
cells. And they also showed that inhibiting PDI activity in normal rat brain cells 




5.4.5.1 IC50-determination of 5-1 against protein disulfide isomerase (PDI)  
 In order to confirm the specific reactivity of PDI with 5-1, we did the dose-
dependency of 5-1 on PDI reductase activity using the insulin turbidometry assay. 
The inhibitor assay was carried out according to literature
117
 in 384-well plates. In 
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each well was contained 100 mM sodium phosphate and 0.2 mM EDTA, pH 7.0. 100 
ng PDI was first incubated with 10 µL buffer (with or without 200 µM DTT) for 30 
min. And then different concentrations of probes in buffer (40, 20, 10, 5, 2.5, 1.25, 
0.625, 0.3125 µM, 1% DMSO in final concentration, 10 µL) were then added. After 2 
h incubation, insulin (0.16 mM in final concentration) and dithiothreitol (1 mM in 
final concentration) was added into each well. The enzyme reaction was monitored at 
λabs = 650 nm on a Bioteck microplate (Germany). IC50 plot was shown in Figure 5.9. 
Addition of DTT before assay is known to increase PDI activity.
118
 The IC50 of 5-1 
without DTT (4.3 ± 1.1 µM) is slight higher than 5-1 with DTT incubation (3.3 ± 1.1 
µM). It appears that increasing PDI activity with DTT is more convenient for 5-1 to 
labeling with PDI and then cause higher inhibition. The hypothesis may also be 
approved by PDI labeling experiments. 
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5.4.5.2 Labeling experiment of PDI protein 
 Next, we did the dose-dependency by varying the concentration of 5-1 in the 
pure PDI labeling reaction. Different concentrations of 5-1 were incubated with 25 ng 
PDI for 2 h. After incubation, click cocktail reagents were then added. The mixtures 
were gently shaken for 2 h. SDS-loading buffer was then added and the solution was 
heated for 10 min at 95°C with gentle mixing. The proteins were resolved in a 10% 
SDS-PAGE gel and the labeled bands were visualized by in-gel fluorescence scanning. 
From Figure 5.10, as expected, continued increases in the fluorescence intensity of 




Figure 5.10 Concentration-dependent labeling of pure PDI protein by 5-1 (2 h incubation). 
FL = fluorescent gel. SS = silver stained gel. 
 
 Next, we went to test whether DTT, H2O2 and cystamine could affect the 
labeling efficiency. Cystamine, an organic disulfide, has been shown to decrease the 
PDI activity
119
 and could compete with a known PDI inhibitor (16F16A) for binding 
to PDI.
116c
 H2O2 is known to oxidize the cysteine.
120
 Three different concentrations of 
DTT (1000, 200, 50 µM in final concentration), H2O2 (10, 2, 0.5 mM in final 
concentration) and cystamine (1000, 200, 50 µM in final concentration) was 






concentration) was then added. After 2 h incubation, click cocktail was added to 
initial click reaction. The mixtures were incubated for 2 h. All the labeling reactions 
were quenched by addition of SDS-loading buffer followed by heating at 95 °C. The 
labeled proteins were resolved on a 10% SDS-PAGE gel and the labeled bands were 




Figure 5.11 Labeling of pretreatment of PDI with different concentrations of H2O2, DTT, 
cystamine by 5-1 (up: fluorescent gel; down: silver stain). 
 
 Subsequent fluorescent SDS-PAGE analysis also clearly shows an increase 
intensity of labeling PDI in the case of adding DTT, while pretreatment with either 
cystamine or H2O2, the labeling efficiency is decreasing. From the silver stain, PDI 
could be decomposed under cystamine and H2O2, which needs to be addressed. H2O2 
is oxidized cysteine of PDI which could nucleophilic attack with 5-1. Cystamine may 
react with cysteine of PDI and form a disulfide bond and this cysteine subsequently is 
lost its nucleophilic property. All these data indicated that our probe is possibly 




5.4.5 In situ proteomic profiling and pull-down experiments of different cell 
lines 
 We investigated in situ proteome profiling with different cell lines. We chose 
four cell lines (HepG2, HeLa, MCF-7 and HEK293T), containing normal and cancer 
cell lines. 10 µM 5-1 was incubated with different cell lines in DMEM medium for 2 
h. Then cells were lyzed and subject to CC reaction condition. After precipitation and 





Figure 5.12 a) in situ labeling of four cell lines (HEK293T, MCF-7, HeLa, HepG2) by 5-1 
(10 µM, 2 h incubation). b) Western blotting analysis of different cell lines with anti-PDIA1 
antibody. 
 
 Then pull-down experiments was done to analyze whether the labeling band is 
PDIA1. Different cell lines’ pull-down is also the same as the pull-down experiment 
of MCF-7 cell line using trifunctional tag. Subsequently, SDS-PAGE gel was 
analyzed by fluorescent scanning (Figure 5.13, left) and then transferred to a PVDF 
membrane to obtain anti-PDIA1 western results (Figure 5.13, right). 
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 From the results, ~ 57 kD band is still the specific labeling in different cell 
lines. It appears cancer cell lines have higher labeling intensity. Then western blotting 
for pull-down samples of four cell lines confirmed PDIA1 is the major target of 5-1 
against four cell lines. Subsequently, western blotting analyzed the amount of PDIA1 
in these labeled proteome samples. MCF-7 has more PDI in four cell lines and the 




Figure 5.13 In situ pull-down results of four cell lines. Left: Fluorescent gel of in situ pull-
down samples of four cell lines treated with 5-1 (5 µM, 2 h incubation) and Right: western 
blotting analysis of these samples with anti-PDI antibody. 
 
5.4.5 Cell proliferation-XTT assay 
 We measured the cytotoxic effect of 5-1 on the viability of four cell lines 
using XTT cell. HeLa, HepG2, MCF-7 and HEK293T cell lines were seeded in 96-
well plates at a concentration of 4000 cells per well. The cells were grown for 24 h 
before treatment with 5-1. After removing the growth medium by suction, different 
concentrations of 5-1 (40, 20, 10, 5, 2.5, 1, 0.5, 0.2, 0.1 µM) in growth medium (100 
µL, 1% DMSO) were added and the cells were incubated for 24 h at 37 °C/5% CO2. 
Subsequently, 50 µL (1 mg/mL XTT (Invitrogen), 0.025 mM PMS (Sigma)) solution 
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were added ant the mixture were incubated at 37 °C /5% CO2 for 6 h. The absorbance 
was measured at 450 nm and background absorbance was measured at 650 nm using a 
Bioteck
TM
 plate reader. Cells incubated with 1% DMSO served as positive control. 
Duplicates were conducted. IC50 plot was shown in Figure 5.14. Especially, more 
PDIA1 protein in the cells (Figure 5.11) showed stronger labeling intensity and higher 
cytotoxicity. It indicated that PDIA1 may play an important role in the viability of 
cells. 
 




HepG2  IC50 = 2.8  1.1 M
HeLa     IC50 = 3.2  1.1 M
MCF-7   IC50 = 2.3  1.0 M










Figure 5.14 Effect of 5-1 on the cell proliferation of four cell lines. 
 
5.5 Conclusion 
 In conclusion, we have successfully synthesized and evaluated inhibitor-
like probes with different phosphotyrosine mimetics. While subsequently in situ 
labelling results were surprising that our major target is PDI not PTPs. To my 
knowlegdement, it is the first time reported that a vinyl sulfonate based small 
molecular is specific labelled with PDI family in vivo. We believe that our probes 
give the new insight in developing new PDI inhibitors and also will be useful in 
understanding the functions of PDI family in cellular process. 
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Chapter 6 Experimental section 
 
6.1 General Information 
 All chemicals were purchased from commercial vendors and used without 
further purifications, unless otherwise noted. 
1
H NMR spectra and 
13
C NMR were 
recorded on Bruker 300 MHz, 500 MHz or DPX-300 NMR spectrometers. Chemical 
shifts are reported in parts per million referenced with respect to residual solvent 
(CDCl3 = 7.26 ppm and d6-DMSO = 2.5 ppm) or from internal standard 
tetramethylsilane (TMS = 0.00 ppm). The following abbreviation was used in 
reporting spectra: s = singlet, d = doublet, t = triplet, q = quarter, m = multiplet, dd = 
doublet of doublets. All solvents used were of HPLC grade, unless otherwise 
indicated. All reactions requiring anhydrous conditions were conducted under a 
nitrogen or argon atmosphere in flame-dried glasswares. Dimethylformamide was 
dried over calcium hydride and distilled under reduced pressure. Analytical thin layer 
chromatography was performed using Merck silica gel plates (0.25 mm thickness) 
with fluorescent indicator UV254. Spots were visualized by ultraviolet illumination, 
iodine staining, KMnO4 staining (for alkenes, aldehydes), Nindhydrin staining (for 
primary amines), or cerium molybdate staining. All LC profiles and mass spectra 
were recorded on Shimadzu LC-IT-TOF and LC-ESI systems equipped with an 
autosampler, using reverse-phase Phenomenex Luna 5 C18 (2) 100 Å 50 × 3.0 mm 
column. 0.1% formic acid/H2O and 0.1% formic acid/acetonitrile were used as eluents 
for the LC-ESI/MS system and 0.1% TFA/H2O and 0.1% TFA/acetonitrile for the 
LC-IT-TOF/MS. The flow rate for both was 0.6 ml/min. Solid-phase reactions were 
performed on an IRORI AccuTag
TM
 Combinatorial Chemistry System. 
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6.2 Synthesis of unnatural amino acid 2-6’ and relatives 
 
 
Methyl 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-iodophenyl) propanoate 
(2-7)  
Thionyl Chloride (15 mL) was added dropwise to 4-Iodo-L-phenylalanine (12 g, 41.3 
mmol, synthesized following reference 78) in a methanol (200 mL) solution at 0 
°
C. 
The yellow solution was refluxed for 2 h. The solution was evaporated and dissolved 
in a minimal amount of hot MeOH. Et2O was added to obtain the white product 
precipitation. The crude product was dissolved in NaHCO3 (sat.) and dichloromethane 
(DCM) (20 mL each). To this solution was added Fmoc-OSu (15.2 g, 45.4 mmol), 
followed by stirring for 5 h. DCM was evaporated in vacuo. The residue was 
extracted with EtOAc three times. The organic layer was combined, washed with 
brine and dried over Na2SO4. Flash column chromatography (9/1 to 3/1 
Hexane/EtOAc gradients) afforded the protected unnatural amino acid 2-7 as a white 
solid (15.2 g, 70 % in two steps). 
1
H-NMR (300 MHz, CDCl3) δ 7.78 (d, J = 7.38 Hz, 
2H), 7.55-7.61 (m, 4H), 7.41 (t, J = 7.40 Hz, 2H), 7.32 (t, J = 7.39 Hz, 2H), 6.81 (d, J 
= 7.89 Hz, 2H), 5.23 (d, J = 8.22 Hz, NH), 4.63-4.65 (1H, m), 4.34-4.50 (2H, m), 4.20 
(t, J = 6.42 Hz, 1H), 3.73 (s, 3H), 2.98-3.08 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 
171.6, 155.5, 143.6, 141.3, 137.6, 135.4, 131.2, 127.7, 127.1, 125.0, 120.0, 92.6, 66.8, 
54.5, 52.4, 47.14, 37.7. IT-TOF: m/z [M+H] 
+





Methyl 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-((trimethylsilyl)  
ethynyl)  phenyl)propanoate (2-8) 
DMF (25 mL) was degassed by bubbling with argon in a dry two-neck round bottle 
flask. Subsequently, compound 2-7 (1.2 g, 2.28 mmol) was added and the solution 
was stirred until it became homogenous. Pd(PPh3)2Cl2 (16 mg, 0.02 mmol) and CuI 
(18.9 mg, 0.1 mmol), DIEA (1.2 mL, 6.5 mmol) were subsequently added under an 
N2 atmosphere. Trimethylsilyl acetylene (0.63 mL, 4.56 mmol) was then added by a 
needled syringe. The reaction was heated at 45 
o
C for 3 h before being quenched by 
addition of an ammonium chloride solution and EtOAc. Then the aqueous phase was 
extracted with EtOAc. The combined organic phases were washed with brine and 
dried with Na2SO4. After removal of the solvent under reduced pressure, column 
chromatography on silica gel (1/9 to 1/6 EtOAc/Hexane gradients) afforded 2-8 as a 
light yellow solid (84 % yield).
 1
H-NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.38 Hz, 
2H), 7.53-7.55 (broad, 2H), 7.27-7.41 (m, 6H), 7.01 (d, J = 7.71 Hz, 2H), 5.27 (d, J = 
8.04 Hz, NH), 4.64 (m, 1H), 4.35-4.46 (m, 2H), 4.19 (t, J = 6.66 Hz, 1H), 3.69 (s, 3H), 
3.05-3.10 (m, 2H), 0.25 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ 171.6, 155.4, 143.7, 
141.3, 136.3, 132.1, 129.1, 127.7, 127.0, 125.0, 121.9, 120.0, 104.7, 94.4, 66.9, 54.6, 
52.3, 47.1, 38.1, -0.1. IT-TOF: m/z [M+Na] 
+









The compound 2-8 (2.0 g, 4 mmol) was dissolved in MeOH (10 mL) and cooled to 0 
o
C. NaOH (10 mL, 10 M) was added dropwise. After 5 h, the pH of the solution was 
adjusted to 8 using HCl and NaHCO3 (sat). Then to the mixture was added Fmoc-OSu 
(1.6 g, 4.8 mmol) followed by stirring overnight. MeOH was removed in vacuo and 
the aqueous layer was extracted with EtOAc. The combined organic phases were 
washed with brine and dried with Na2SO4. After removal of the solvent under reduced 
pressure, column chromatography on silica gel (9/1 Hexane/EtOAc to 9/1 
EtOAc/MeOH with 0.1 % acetic acid gradients) afforded 2-9 (1.07 g, 65 %) as a 
white solid. 
1
H-NMR (300 MHz, CD3OD) δ 7.78 (d, J = 7.38 Hz, 2H), 7.57 (d, J = 
7.41 Hz, 2H), 7.38 (t, J = 7.56 Hz, 4H), 7.26-7.31 (m, 2H), 7.11 (d, J = 8.04 Hz, 2H), 
4.13-4.41 (m, 4H), 3.42 (s, 1H), 2.90-3.24 (m, 2H). 
13
C-NMR (75 MHz, DMSO-d6) δ 
174.8, 158.3, 145.2, 142.5, 139.6, 133.0, 128.7, 128.1, 126.1, 122.1, 120.9, 84.3, 78.5, 
67.9, 56.5, 48.3, 38.3, 26.3. IT-TOF: m/z [M+Na] 
+





The compound 2-9 (0.75 g, 1.8 mmol) was dissolved in MeOH (10 mL). Cs2CO3 
(0.28 g, 0.85 mmol) was added over a period of 10 min. Subsequently, MeOH was 
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removed in vacuo. The residue was redissolved in DMF (20 mL). Allyl bromide (0.68 
g, 5.6 mmol) was added. After 1 h, DMF was distilled off under reduced pressure. 
Water was added and the solution was extracted with EtOAc. The combined organic 
phase was washed with brine, dried over Na2SO4 and concentrated. The crude product 
was purified by silica gel chromatography (EtOAc/Hexane gradients). The white 
product 2-10 was obtained in 90 % yield. 
1
H-NMR (300 MHz, CDCl3) δ 7.78 (d, J = 
7.41 Hz, 2H), 7.57 (d, J = 7.23 Hz, 2H), 7.39-7.43 (m, 4H), 7.32-7.34 (t, J = 7.40 Hz, 
2H), 7.06 (d, J = 7.86 Hz, 2H), 5.83-5.88 (m, 1H), 5.26-5.35 (m, 3H), 4.61-4.72 (m, 
3H), 4.35-4.50 (m, 2H), 4.21 (t, J = 6.82 Hz, 1H), 3.08-3.15 (m, 3H). 
13
C-NMR (75 
MHz, CDCl3) δ 170.9, 155.5, 143.8, 141.3, 136.6, 132.3, 131.2, 129.4, 127.7, 127.0, 
125.0, 121.0, 120.0, 119.3, 77.3, 83.3, 66.9, 66.2, 54.6, 47.2, 38.1. IT-TOF: m/z 
[M+Na] 
+







Method 1: Compound 2-10 (0.1 g, 0.22 mmol) and ethyl chlorooximidoacetate (33 
mg, 0.22 mmol) were dissolved in t-BuOH (5 mL). To the resulting solution, H2O was 
added, followed by sodium ascorbate (4.35 mg, 0.02 mmol), copper sulfate (2.75 mg, 
0.01 mmol) and finally KHCO3 (90 mg, 0.9 mmol). The reaction mixture was stirred 
at room temperature for 24 h. Upon evaporation of t-BuOH, the reaction was extract 
several times with EtOAc. The organic layers were then collected, dried over 
anhydrous Na2SO4 and filtered, and then the solvent was removed under reduced 
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pressure to yield a crude product. The product was purified by flash chromatography 
to yield 2-11 (21 %) as a white solid.  
Method 2: Compound 2-10 (0.5 g 1.1 mmol) and ethyl chlorooximidoacetate (0.25 g, 
1.6 mmol) were dissolved in THF (20 mL). Triethylamine (0.22 g, 2.2 mmol) was 
slowly added into solution. The mixture was stirred for 1 day. THF and TEA was 
evaporated and the residue redissolved in EtOAc. After washing with brine and 
drying over Na2SO4, the organic layer was evaporated. The crude product was 
purified by flash chromatography to obtain 2-11 (15%).  
1
H-NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.60 Hz, 2H), 7.70 (d, J = 7.60 Hz, 2H), 
7.55-7.57 (m, 2H), 7.40 (t, J = 7.40 Hz, 2H), 7.30 (t, J = 7.55 Hz, 2H), 7.21 (d, J = 
8.20 Hz, 2H), 5.85-5.91 (m, 1H), 5.26-5.38 (m, 3H), 4.70-4.74 (m, 1H), 4.63 (d, J = 
5.7 Hz, 1H), 4.47 (q, J = 7.55 Hz, 2H), 4.35-4.39 (m, 1H), 4.19 (t, J = 6.95 Hz, 1H), 
3.18 (dd, J = 13.87, 5.65 Hz, 2H), 1.45 (t, J = 6.96 Hz, 3H). 
13
C-NMR (125 MHz, 
CDCl3) δ 171.1, 170.8, 159.9, 156.9, 155.5, 143.7, 141.3, 138.9, 131.1, 130.1, 127.7, 
127.0, 126.0, 125.4, 125.0, 120.0, 119.4, 99.8, 66.8, 66.2, 62.2, 54.6, 47.1, 38.1, 14.1. 
IT-TOF: m/z [M+H] 
+




yl)phenyl)propanoic acid (2-6’) 81 
Compound 2-11 (20 mg, 0.03 mmol) was dissolved in DCM under an N2 atmosphere. 
Phenylsilane (8 mg, 0.07 mmol) and Pd(PPh3)4 (1.7 mg, 1.5 μmol) were added. After 
30 min, the solution became slightly dark and TLC was showed the reaction was 
finished. The solvent was removed under reduced pressure and the residue was 
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directly purified by flash chromatography to obtain compound 2-6’ (89 %). 1H-NMR 
(300 MHz, DMSO-d6) δ 13.1 (br, 1H), 7.86 (d, J = 7.23 Hz, 4H), 7.61-7.68 (m, 3H), 
7.37-7.45 (m, 5H), 7.25-7.31 (m, 2H), 4.39 (q, J = 6.9 Hz, 2H), 4.17-4.19 (m, 4H), 
2.91-3.19 (m, 2H), 1.35 (t, J = 7.05 Hz, 3H). 
13
C-NMR (75 MHz, DMSO-d6) δ 173.1, 
171.1, 159.4, 156.8, 155.9, 143.7, 141.4, 140.7, 130.1, 127.6, 127.0, 125.7, 125.2, 
124.3, 120.1, 100.4, 65.6, 61.2, 55.2, 46.5, 36.3, 14.0. HRMS calcd for C30H25N2O7: 
525.1662, found: 525.1647. 
 
Figure 6.1 The analytical HPLC results of compound 2-6’ 
 
6.3 Solid-phase synthesis of I1 and I2 
 
 
Inhibitor I1. Wang resin was used to synthesize the inhibitors. First, Wang resin (100 
mg, 0.05 mmol, and loading ~0.5 mmol/g) was previously swollen in DMF. Fmoc-
Leu-OH (4 equiv) was pre-activated using HOBT (4 equiv), HBTU (4 equiv), DIEA 
(8 equiv) in DMF. And the resins were added into the solution. The reaction was 
shaken for 4 h at room temperature. After that, the resin was washed with DMF (3x), 
DCM (3x) and DMF (3x). Next, Fmoc-protected amino functionalized resin was 
treated with 20% piperidine in DMF for 1 h at room temperature. The rein was 









washed with DMF (3x), DCM (3x) and DMF (3x). Fmoc-Tyr (HPO3Bzl)-OH were 
pre-activated by HOBT (4 equiv), HBTU (4 equiv), DIEA (8 equiv) in DMF. The 
resin was added into the solution and shaken at room temperature overnight. 
Subsequently, the resin was washed with DMF (3x), DCM (3x) and DMF (3x). 
Deprotection of the Fmoc group was carried out with 2% DBU in DMF for 2 h. And 
the resin was washed again. 4-Cyanobenzoic acid was coupled with the resin using 
HOBT (4 equiv), HBTU (4 equiv), and DIEA (8 equiv) in DMF overnight. The resin 
was then washed with DCM and MeOH before being dried in vacuo. The cocktail 
cleavage solution contains TFA/TIS/DCM (95:2.5:2.5). The resin was treated with the 
cocktail for 2.5 h, after which the resin was filtered off and the solvent was removed 
under reduced pressure. The resulting inhibitor was further purified by preparative 
HPLC.  
 
Figure 6.2 The LCMS results of compound I1 
 
 
Inhibitor I2. The inhibitor I2 was synthesized similarly as I1 following procedures as 
shown above. The unnatural amino acid, compound 2-6’, was coupled to the resin as 
follows. First, 2-6’ was pre-activated by HOBT (4 equiv), HBTU (4 equiv), DIEA (8 
equiv) in DMF. Then resin was added into the solution and the resulting mixture was 





SPD Ch1:214nm  
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shaken at room temperature overnight. Subsequently, the resin was washed with DMF 
(3x), DCM (3x) and DMF (3x). The deprotection of Fmoc group was carried on 2 % 
DBU in DMF for 2 h. And the resin was washed again. 4-Cyanobenzoic acid was 
coupled with the resin using HOBT (4 equiv), HBTU (4 equiv), and DIEA (8 equiv) 
in DMF overnight. The resin was washed, after coupling, with DMF (3x), DCM (3x) 
and DMF (3x). At the end of solid phase synthesis, the resin was washed with DCM 
and MeOH before being dried in vacuo. The inhibitor was cleaved off the resin by 
treatment with the cocktail mixture, TFA/TIS/DCM (95:2.5:2.5), for 2.5 h. After that, 
the resin was filtered off and the solvent was removed under reduced pressure to give 
the protected form of the final product (precursor). The final product was 
subsequently obtained by treating the precursor with LiOH (2 M) in THF for 2 h 
followed by purification with preparative HPLC. 
1
H-NMR (500 MHz, DMSO-d6) δ 
8.90 (d, J = 8.85 Hz, 1H), 8.42 (d, J = 8.20 Hz, 1H), 7.90-7.92 (m, 4H), 7.84 (d, J = 
8.20 Hz, 1H), 7.54 (d, J = 8.85 Hz, 2H), 7.34 (s, 1H), 4.81-4.84 (m, 1H), 4.25-4.29 (m, 
1H), 3.01-3.25 (m, 2H), 1.60-1.69 (m, 1H), 1.53-1.59(m, 2H), 0.89 (dd, J = 14.80, 
6.30 Hz, 6H) 
13
C-NMR (125 MHz, DMSO-d6) δ 173.9, 171.0, 164.9, 160.8, 157.7, 
141.4, 139.5, 137.9, 132.3, 130.0, 128.2, 125.6, 124.4, 118.3, 113.7, 100.4, 53.4, 50.4, 
36.9, 24.3, 22.8, 21.3. HRMS calcd C27H25N4O7: m/z [M+H] 
+
 calcd: 517.1724, found: 
517.1721. 
Based on the 
1
H NMR result, we found no sign of racemization in the final product I2, 
indicating that during the synthesis of the new amino acid 2-6’ and the final inhibitor 
I2, the two steps where base treatments were involved (2-8 to 2-9 in Scheme 2.1 and 






Figure 6.3 The analytical HPLC results of compound I2 
 
6.4 Solid-phase synthesis of SH2-binding peptide Fluorescein- 
GY*LPQTV-NH2 
Rink amide resin (100 mg, loading ~ 0.5 mmol/g) was first swollen in DMF and 
washed with DMF (2x). Before coupling, 20% piperidine in DMF was used to 
deprotect the Fmoc group for 1 h at RT. Subsequently, the resin was washed with 
several cylces of DMF and DCM. Fmoc-Val-OH (4 equiv) was pre-activated using 
HOBT (4 equiv), HBTU (4 equiv), DIEA (8 equiv) in DMF. The resin was put into 
the solution and shaken for 4 h. Next, the resin was washed with several cycles of 
DMF and DCM and treated with 20% piperidine to remove the Fmoc group prior to 
the next coupling. The cycle of coupling was repeated with Fmoc-Thr(OtBu)-OH, 
Fmoc-Gln(Trt)-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Tyr(HPO3Bzl)-OH, Fmoc-
Gly-OH. Final, the resin was coupled with 3’, 6’-diacetyl fluorescein (4 equiv). After 
washing, the acetyl protecting group was removed by treatment with 20% piperidine 
in DMF. Finally, the resin was washed with DMF (3x), DCM (3x and MeOH (3x) and 
dried thoroughly under reduced pressure. A solution of cleavage solution 
TFA/TIS/DCM (95:2.5:2.5) was added to the resin for 2 h. The resin was filtered off. 
The solvent was removed in vacuo. The peptide was purified by preparative HPLC. 
 







6.5 Synthesis of unnatural amino acid 3-2 and relatives 
 
 
(S)-1-allyl 4-tert-butyl 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)succinate (3-3) 
The compound FmocNH-Asp(O
t
Bu)-COOH (20.0 g, 48.6 mmol) was dissolved in 
MeOH (150 mL). Cs2CO3 (7.9 g, 24.3 mmol) was added into the solution and the 
reaction was stirred for 30 min. Subsequently, MeOH was removed in vacuo. The 
residue was redissolved in DMF (200 mL). Allyl bromide (8.4 mL, 72.9 mmol) was 
added dropwise and the reaction mixture was stirred overnight. DMF was removed 
under reduced pressure. Water was added and the solution was extracted with EtOAc. 
The combined organic phase was washed with water, 10% NaHCO3 and brine. The 
organic layer was dried over Na2SO4 and concentrated. The product 3-3 was obtained 
as a white solid (16.6 g, 95%). 
1
H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 7.5 Hz, 2H), 
7.62 (t, J = 7.1 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 5.97 (d, J = 
8.5 Hz, 1H), 5.87 - 5.96 (m, 1H), 5.34 (d, J = 17.2 Hz, 1H), 5.24 (d, J = 10.4 Hz, 1H), 
4.63 - 4.73 (m, 3H), 4.33 - 4.47 (m, 2H), 4.25 (t, J = 7.2 Hz, 1H), 2.90 (dd, J = 16.8, 
4.5 Hz, 2H), 1.47 (s, 9H). 
13
C NMR (125 MHz, CDCl3) δ 170.39, 169.71, 155.77, 
143.70, 141.06, 131.35, 127.48, 126.84, 124.95, 119.75, 118.46, 81.52, 67.02, 65.99, 
50.45, 46.88, 37.56, 27.79. IT-TOF: m/z [M+H] 
+







The compound 3-3 (10 g, 22.2 mmol) was dissolved in DCM : TFA (1:1, 80 mL) and 
the mixture was stirred at room temperature for 5 h. The solvent was then evaporated 
under reduced pressure and the residue was precipitated by addition of cold water 
(400 mL). The solution was stirring overnight. The resulting precipitate was filtered, 
dried to give the desired product as a white solid (8.4 g, 96%). 
1
H NMR (500 MHz, 
d6-DMSO) δ 7.87 (t, J = 7.8 Hz, 2H), 7.71 (d, J = 7.4 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 
7.33 (t, J = 7.3 Hz, 2H), 5.84 - 5.92 (m, 1H), 5.30 (d, J = 17.3 Hz, 1H), 5.19 (d, J = 
10.5 Hz, 1H), 4.59 (d, J = 5.1 Hz, 2H), 4.49 (dd, J = 13.7, 7.9 Hz, 1H), 4.29 - 4.36 (m, 
2H), 4.23 (t, J = 6.9 Hz, 1H), 2.73 (dd, J = 16.6, 6.8 Hz, 2H). 
13
C NMR (125 MHz, 
d6-DMSO) δ 171.44, 170.85, 155.88, 143.78, 140.75, 132.24, 127.65, 127.09, 125.20, 
120.11, 117.56, 65.80, 65.07, 50.60, 46.63, 35.90. IT-TOF: m/z [M+H] 
+
 calcd: 
396.145, found: 396.121. m/z [M+Na] 
+





Compound 3-4 (10 g, 25.3 mmol), Meldrum’s acid (4.7 g, 32.6 mmol) and DMAP 
(3.1 g, 25.3 mmol) in 100 mL DCM was cooled in an ice bath. To this reaction 
mixture, N,N'-diisopropylcarbodiimide (DIC) was added very slowly. The reaction 
mixture was allowed to stir around 5 h, or till the disappearance of the starting 
material was detected by TLC. The resulting solution was washed with 10% aqueous 
solution of KHSO4 (75 mL, 3x) and brine. The organic layer was dried over Na2SO4 
and evaporated in vacuo. The residue was dissolved in methanol/toluene (10:1). The 
solution was refluxed overnight. After evaporation of the solvent, the desired product 
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was obtained by recrystallization in hexane/EtOAc (10.1 g, 89%).
[1] 1
H NMR (500 
MHz, CDCl3) δ 7.74 (d, J = 7.5 Hz, 2H), 7.55 - 7.62 (m, 2H), 7.38 (t, J = 7.4 Hz, 2H), 
7.29 (t, J = 7.4 Hz, 2H), 5.96 (d, J = 7.1 Hz, 1H), 5.82 - 5.90 (m, 1H), 5.30 (d, J = 
17.2 Hz, 1H), 5.23 (d, J = 10.4 Hz, 1H), 4.61 - 4.67 (m, 3H), 4.29 - 4.42 (m, 2H), 4.21 
(t, J = 7.0 Hz, 1H), 3.68 (s, 3H), 3.46 (s, 2H), 3.22 (dd, J =  18.4, 4.4 Hz, 2H). 
13
C 
NMR (125 MHz, CDCl3) δ 200.48, 170.19, 166.74, 155.80, 143.61, 141.02, 131.27, 
127.47, 126.83, 124.92, 119.73, 118.48, 66.96, 66.08, 52.14, 49.68, 48.52, 46.83, 
44.26. IT-TOF: m/z [M+H] 
+





Compound 3-5 (8 g, 17.7 mmol) was dissolved in methanesulfonic acid (100 mL). 
The solution was cooled down in an ice bath. Resorcinol (1.95 g, 17.7 mmol) was 
added into the solution. The mixture was stirred in 4 °C for 4 h, when TLC showed 
the starting material was completely consumed. The reaction mixture was then slowly 
poured into ice water, and the resulting white precipitate was collected by vacuum 
filtration. Upon recrystallization in ethanol/water, the desired product was obtained 
(8.1 g, 90%).
 1
H NMR (500 MHz, d6-DMSO) δ 10.58 (s, 1H), 8.01 (d, J = 8.2 Hz, 1H), 
7.87 (d, J = 7.5 Hz, 2H), 7.60 - 7.65 (m, 3H), 7.40 (t, J = 7.3 Hz, 2H), 7.29 (q, J = 7.3 
Hz, 2H), 6.83 (d, J = 8.7  Hz, 1H), 6.74 (d, J = 2.0 Hz, 1H), 6.17 (s, 1H), 5.83 - 5.91 
(m, 1H), 5.29 (d, J = 17.2 Hz, 1H), 5.20 (d, J = 10.5 Hz, 1H), 4.60 (d, J = 4.0 Hz, 2H), 
4.42 - 4.45 (m, 1H), 4.17 - 4.20 (m, 2H), 4.19 (t, J = 6.9 Hz, 1H), 3.06 - 3.30 (m, 2H). 
13
C NMR (125 MHz, d6-DMSO) δ 170.71, 161.22, 159.98, 155.88, 155.09, 152.16, 
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143.64, 140.66, 132.08, 127.59, 127.01, 125.92, 125.07, 120.06, 117.83, 113.11, 
111.23, 110.88, 102.54, 65.78, 65.25, 52.80, 46.50, 32.36. IT-TOF: m/z [M+H] 
+
 





Compound 3-6 (5 g, 9.78 mmol) was added into acetic acid (50 mL). The mixture was 
heated to around 100 °C, until compound 3-6 was dissolved. Hexamine (4.1 g, 29.4 
mmol) was added slowly. Then the reaction was heated to 150 °C and stirred for 3 h. 
The solvent was removed in vacuo. 1 M HCl was added to the residue and the mixture 
was further stirred for 1 h. The solution was extracted with EtOAc (3x), washed with 
water and brine (2x). The organic layer was dried over Na2SO4 and concentrated. The 
product was obtained by purification with flash column chromatography (1.32 g, 
25%).
94 1
H NMR (500 MHz, CDCl3) δ 12.21 (s, 1H), 10.56 (s, 1H), 7.90 (d, J = 9.0 
Hz, 1H), 7.74 (d, J = 7.5 Hz, 2H), 7.54 (d, J = 7.3 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 
7.29 (t, J = 7.4 Hz, 2H), 6.88 (d, J = 9.0 Hz, 1H), 6.13 (s, 1H), 5.80 - 5.91 (m, 1H), 
5.66 (d, J = 7.6 Hz, 1H), 5.27 - 5.38 (m, 2H), 4.69 (dd, J = 13.9, 6.9 Hz, 1H), 4.63 (d, 
J = 5.8 Hz, 2H), 4.41 (d, J = 6.8 Hz, 2H), 4.17 (t, J = 6.7 Hz, 1H), 3.19 (d, J = 6.5 Hz, 
2H). 
13
C NMR (75 MHz, CDCl3) δ 193.10, 170.00, 165.22, 158.53, 156.29, 155.63, 
150.85, 143.41, 141.13, 132.58, 130.64, 127.69, 126.98, 124.80, 119.92, 114.51, 
113.11, 110.73, 108.69, 67.17, 66.67, 53.11, 46.85, 34.99. IT-TOF: m/z [M+H] 
+
 






To a suspension of di(2-nitrobenzyl) phosphate (1.22 g, 3.3 mmol) in distilled DCM 
(20 mL) was added two drops of DMF as a catalyst. Oxalyl chloride (2.12 g, 16.5 
mmol) was then added dropwise at room temperature to the mixture. The reaction was 
stirred for 1 h. Upon solvent removal in vacuo, the product obtained was directly used 
in the next step without further purification. Compound 3-7 (900 mg, 1.67 mmol; 
dissolved in 20 mL DCM) was added the above product (dissolved in DCM with ~1 
mg of DMAP) in an ice bath. Subsequently, triethylamine (0.86 g, 4.18 mmol) was 
added dropwise. The reaction mixture was stirred for 5 h until the starting material 
was completely consumed. Upon solvent removal in vacuo, the resulting residue was 
purified by flash column chromatography (1:1 hexane/EtOAc) to give 3-8 as a slightly 
yellow solid (1.34 g, 46%). 
1
H NMR (500 MHz, CDCl3) δ 10.61 (s, 1H), 8.11 (d, J = 
8.2 Hz, 2H), 8.02 (d, J = 8.5 Hz, 1H), 7.73 - 7.77 (m,  4H), 7.63 - 7.69 (m, 2H), 7.55 
(d, J = 7.4 Hz, 2H), 7.47 - 7.50 (m, 3H), 7.36 - 7.39 (m, 2H), 7.30 (td, J = 7.3, 3.1 Hz, 
2H), 6.27 (s, 1H), 5.80 - 5.90 (m, 1H), 5.74 (t, J = 7.1 Hz, 4H), 5.62 (d, J = 6.8 Hz, 
1H), 5.25 - 5.35 (m, 2H), 4.63 - 4.66 (m, 3H), 4.42 (d, J = 5.8 Hz, 2H), 4.18 (t, J = 6.6 
Hz, 1H), 3.21 - 3.22 (m, 2H). 
13
C NMR (125 MHz, CDCl3) δ 186.48, 170.62, 158.61, 
156.74, 156.42, 152.06, 150.62, 147.55, 144.21, 142.00, 134.82, 132.13, 131.32, 
131.07, 129.90, 129.51, 128.50, 127.80, 125.76, 125.57, 121.05, 120.72, 118.14, 
117.40, 116.79, 116.62, 68.11, 68.01, 67.57, 53.78, 47.76, 36.21. 
31
P NMR (121 MHz, 
CDCl3) δ -7.84. IT-TOF: m/z [M+CF3COO] 
-






Compound 3-8 (0.93 g, 1.0 mmol) was dissolved in DCM/Ethanol (1:1, 30 mL) and 
cooled to 0 C. NaBH4 (9.8 mg, 0.25 mmol) in 1 mL water was then added dropwise 
into the reaction. The reaction mixture was stirred at 0 C for 5 min. The reaction was 
quenched with 0.25 M HCl. The organic solvents were removed in vacuo. The residue 
was purified by flash column chromatography (1:1 hexane/EtOAc) to obtain 3-9 as a 
white solid (757 mg, 85%). 
1
H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 8.2 Hz, 2H), 
7.68 - 7.80 (m, 4H), 7.65 (t, J = 7.5 Hz, 2H), 7.55 (d, J = 7.0 Hz, 2H), 7.49 (t, J = 7.7 
Hz, 2H), 7.36 - 7.39(m, 2H), 7.27 - 7.34 (m, 3H), 6.23 (s, 1H), 5.78 - 5.89 (m, 1H), 
5.63 - 5.66 (m, 5H), 5.23 - 5.34 (m, 2H), 4.89 (s, 2H), 4.65 - 4.47 (m, 1H), 4.61 (d, J 
= 5.7 Hz, 2H), 4.39 (d, J = 6.7 Hz, 2H), 4.17 (t, J = 6.7 Hz, 1H), 3.22 (d, J = 6.4 Hz, 
2H). 
13
C NMR (125 MHz, CDCl3) δ 170.15, 159.28, 155.71, 153.26, 150.93, 150.23, 
146.89, 143.53, 141.28, 134.17, 131.20, 131.14, 130.73, 129.40, 128.86, 127.79, 
127.11, 125.15, 124.92, 121.49,  120.12, 120.01, 116.83, 115.85, 67.46, 67.32, 66.76, 
53.18, 47.07, 35.24. 
31
P NMR (121 MHz, CDCl3) δ -6.11. IT-TOF: m/z [M+H] 
+
 
calcd: 892.212, found: 892.171. m/z [M+CF3COO] 
-








Compound 3-9 (602 mg, 0.67 mmol) was dissolved into distilled DCM (15 mL) at 
0 °C. Diethylaminosulfur trifluoride (DAST, 218 mg, 1.35 mmol) was added slowly 
under an Ar atmosphere. The reaction was stirred for 10 min. The solvent was 
evaporated and the residue was purified by flash column chromatography to obtain 
compound 3-10 as a white foam solid (436 mg, 74%). 
1
H NMR (500 MHz, CDCl3) δ 
8.11 (d, J = 8.2 Hz, 2H), 7.86 (d, J = 8.5 Hz, 1H), 7.69 - 7.75 (m, 4H), 7.65 (td, J = 
7.8, 3.5 Hz, 2H), 7.55 (d, J = 7.0 Hz, 2H), 7.46 - 7.52 (m, 3H), 7.36 - 7.41 (m, 2H), 
7.29 - 7,32 (m, 2H), 6.24 (s, 1H), 5.78 - 5.89 (m, 1H), 5.71/5.61(d, J = 47.4 Hz, 2H, 
CH2F), 5.67 (dd, J = 7.7, 2.5 Hz, 4H), 5.58 (d, J = 7.4 Hz, 1H), 5.26 – 5.35 (m, 2H), 
4.68 (d, J = 6.9 Hz, 1H), 4.61 (d, J = 5.2 Hz, 2H), 4.41 (s, 2H), 4.18 (t, J = 6.7 Hz, 
1H), 3.22 (d, J = 6.2 Hz, 2H).
 13
C NMR (125 MHz, CDCl3) δ 170.07, 158.85, 155.68, 
153.35, 152.23, 150.08, 146.82, 143.51, 141.30, 134.16, 131.29, 131.23, 130.65, 
129.33, 128.69, 127.80, 127.12, 126.91, 125.14, 124.98, 120.20, 120.02, 116.45, 
116.08, 115.86, 115.74, 72.48 (d, J = 166.3 Hz, 1C, C-F), 67.32, 66.79, 53.15, 47.08, 
35.33. 
19
F NMR (282 MHz, CDCl3) δ -135.37 (t, J = 47.6 Hz, 1F).
 31
P NMR (121 
MHz, CDCl3) δ -7.03. IT-TOF: m/z [M+H] 
+
 calcd: 894.207, found: 894.131. m/z 
[M+CF3COO] 
-






phosphoryloxy)-8-(fluoromethyl)-2-oxo-2H-chromen-4-yl)propanoic acid (3-11) 
Compound 3-10 (220 mg, 0.25 mmol) was dissolved in DCM under an Ar atmosphere. 
Phenylsilane (107 mg, 1 mmol) and Pd(PPh3)4 (14 mg, 0.01 mmol) were added. After 
5 h, the solution became brown dark, with TLC showing the completion of the 
reaction. The solvent was removed in vacuo, and the resulting residue was purified by 
flash chromatography to give the desired product 3-11 (190 mg, 90%). 
1
H NMR (500 
MHz, d6-DMSO) δ 8.11 (dd, J = 8.1, 2.2 Hz, 2H), 7.96 (d, J = 7.2 Hz, 1H), 7.86 (dd, J 
= 8.0, 3.3 Hz, 2H), 7.74 - 7.78 (m, 2H), 7.68 - 7.70 (m, 2H), 7.58 - 7.64 (m, 4H), 7.43 
(d, J = 8.9 Hz, 1H), 7.38 (t, J = 6.5 Hz, 2H), 7.27 (q, J = 7.3 Hz, 2H), 6.45 (s, 1H), 
5.65 (d, J = 7.6 Hz, 4H), 5.57 (d, J = 47.8 Hz, 2H), 4.31 - 4.37 (m, 1H), 4.25 (d, J = 
7.1 Hz, 2H), 4.14 - 4.21 (m, 2H), 3.24 (ddd, J = 25.4, 14.7, 7.2 Hz, 2H). 
13
C NMR (75 
MHz, d6-DMSO) δ 173.41, 159.69, 157.02, 153.89, 153.17, 152.27, 147.93, 144.74, 
141.72, 135.33, 131.90, 131.80, 130.75, 130.08, 128.65, 128.05, 126.18, 125.97, 
121.12, 117.34, 116.83, 115.83, 115.70, 73.62 (d, J = 162.2 Hz, 1C, C-F), 67.92, 
66.80, 53.55, 47.61, 33.61. 
19
F NMR (282 MHz, d6-DMSO) δ -133.34 (t, J = 47.9 Hz, 
1F).
 31
P NMR (121 MHz, d6-DMSO) δ -6.93. IT-TOF: m/z [M-H] 
-







(2-nitrobenzyloxy)phosphoryloxy)-2-oxo-2H-chromen-4-yl)propanoic acid (3-2) 
Compound 3-11 (20 mg, 23 µmol) was dissolved in 1 mL DCM.  500 µL of 1 M 
thiophenol and triethylamine were subsequently added. After 1 h, the solvent was 
removed under reduced pressure. The residue was purified by preparative HPLC, 
giving the desired product 3-2 (10 mg, 60%). 
1
H NMR (500 MHz, d6-DMSO) δ 8.09 
(d, J = 8.1 Hz, 1H), 7.92 (d, J = 8.9 Hz, 1H), 7.86 (d, J = 7.8 Hz, 2H), 7.70 - 7.78 (m, 
2H), 7.62 (dd, J = 12.1, 7.6 Hz, 2H), 7.55 (t, J = 8.3 Hz, 1H), 7.47 (d, J = 8.9 Hz, 1H), 
7.39 (dd, J = 7.3, 5.2 Hz, 2H), 7.28 (q, J = 7.7 Hz, 2H), 6.38 (s, 1H), 5.55 (d, J = 47.9 
Hz, 2H), 5.42 (d, J = 7.9 Hz, 2H), 4.32 - 4.39 (m, 1H), 4.25 (d, J = 7.2 Hz, 2H), 4.18 
(t, J = 7.0 Hz, 1H), 3.23 (ddd, J = 25.2, 14.6, 7.3 Hz, 2H). 
13
C NMR (125 MHz, d6-
DMSO) δ 172.35, 158.89, 158.06, 155.90, 153.20, 152.93, 152.28, 146.69, 143.65, 
140.61, 134.06, 132.57, 132.51, 128.94, 128.59, 127.54, 127.10, 126.96, 125.10, 
124.64, 120.00, 116.00, 114.88, 114.31, 113.72, 73.27, 71.98, 65.69, 64.94, 52.47, 
46.51, 32.53. 
19
F NMR (282 MHz, d6-DMSO) δ -132.67 (t, J = 47.9 Hz, 1F).
 31
P 
NMR (121 MHz, d6-DMSO) δ -6.67. IT-TOF: m/z [M+H] 
+
 calcd: 719.144, found: 
719.118. m/z [M-H] 
-







phosphoryloxy)-2-oxo-2H-chromen-4-yl)propanoic acid (3-1-2) 
Prepared according to procedures for preparation of compound 3-8 using di(2-
nitrobenzyl) chlorophosphate [prepared from di(2-nitrobenzyl) phosphate (0.55 g, 1.5 
mmol)], compound 3-6 (0.38 g, 0.75 mmol), triethylamine (0.38 g, 1.88 mmol). The 
allyl group of the phosphorylated product was deprotected using Pd(PPh3)4 and 
PhSiH3, and purified by flash chromatography to give the desired product 3-1-2 (276 
mg, two steps in 45% yield). 
1
H NMR (500 MHz, d6-DMSO) δ 8.11 (d, J = 8.1 Hz, 
2H), 7.84 - 7.89 (m, 3H), 7.76 (t, J = 7.4 Hz, 2H), 7.69 (d, J = 7.6 Hz, 2H), 7.57 - 7.65 
(m, 4H), 7.39 (t, J = 7.3 Hz, 2H), 7.26 - 7.30 (m, 4H), 6.39 (s, 1H), 5.63 (d, J = 7.7 Hz, 
4H), 4.31 - 4.37 (m, 1H), 4.25 (d, J = 7.2 Hz, 2H), 4.17 (t, J = 7.1 Hz, 1H), 3.22 (ddd, 
J = 25.3, 14.6, 7.3 Hz, 2H). 
13
C NMR (125 MHz, d6-DMSO) δ 172.88, 159.70, 156.45, 
154.42, 152.39, 147.40, 144.18, 141.16, 134.72, 131.38, 131.32, 130.15, 129.58, 
128.08, 127.48, 126.94, 125.62, 125.38, 120.55, 117.05, 116.74, 115.09, 108.94, 
67.14, 66.23, 53.00, 47.04, 33.01. 
31
P NMR (121 MHz, d6-DMSO) δ -6.70. IT-TOF: 
m/z [M-H] 
-




nitrobenzyloxy)phosphoryloxy)-2-oxo-2H-chromen-4-yl)propanoic acid (3-1) 
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Prepared according to procedures for the preparation of comopound 3-2 using 
compound 3-1-2 (18 mg, 22 µmol), triethylamine and thiophenol (500 µmol each). 
The product was purified by preparative HPLC (9.8 mg, 65%).
1
H NMR (500 MHz, 
d6-DMSO) δ 8.08 (d, J = 8.2 Hz, 1H), 7.86 (t, J = 6.8 Hz, 2H), 7.79 - 7.81 (m, 1H), 
7.70 - 7.77 (m, 2H), 7.60 - 7.64 (m,  2H), 7.52 - 7.59 (m, 1H), 7.39 (t, J = 6.9 Hz, 2H), 
7.28 (dd, J = 15.0, 7.5 Hz, 2H), 7.20 - 7.21 (m, 2H), 6.33 (s, 1H), 5.41 (d, J = 7.8 Hz, 
2H), 4.30 - 4.36 (m, 1H), 4.23 - 4.26 (m, 2H), 4.15 - 4.20 (m, 1H), 3.21 (ddd, J = 25.3, 
14.6, 7.3 Hz, 2H). 
13
C NMR (75 MHz, d6-DMSO) δ 172.45, 159.47, 155.93, 153.98, 
152.08, 146.73, 143.61, 140.63, 134.09, 132.63, 132.52, 128.97, 128.65, 127.58, 
126.99, 125.94, 125.06, 124.68, 120.05, 116.62, 114.90, 113.75, 107.91, 65.71, 64.87, 
52.51, 46.51, 32.52. 
31
P NMR (121 MHz, d6-DMSO) δ -6.59. IT-TOF: m/z [M+H] 
+
 
calcd: 687.138, found: 687.106. m/z [M-H]
-
 calcd: 685.122, found: 685.088. 
 
6.6 Solid phase synthesis of three localization peptides 
6.6.1 General information 
All peptide synthesis described herein are carried out using standard Fmoc chemistry. 
HBTU, HOBt, and Fmoc-protected amino acids were purchased from GL Biochem 
(Shanghai, China). Fmoc-protecting amino acids with side chain protecting groups 
which normally could be deprotected by TFA are used. IRORI system and 
MacroKans
TM
 were used for the synthesis of individual peptide sequences. 
 
6.6.2 General procedure for solid phase synthesis 
Next step is following Scheme 3.3. 
Procedures for Fmoc deprotection a 
126 
 
The Fmoc-protected amino-functionalized resin was treated with 20% piperidine in 
DMF for 20 min at room temperature. After that, the resin was washed with DMF 
(3x), DCM (3x), DMF (3x) and DCM (3x). 
 
Procedures for condition b 
The Fmoc-protected amino acid or palmitic acid (4 equiv) was pre-activated using 
HOBT (4 equiv), HBTU (4 equiv), DIEA (8 equiv) in DMF for 10 min. Then the 
resin was put into the solution and shaken for 4 h or overnight. Next, the resin was 
washed with DMF (3x), DCM (3x) and DMF (3x). 
 
Procedures for condition c 
The Fmoc-protected unnatural amino acid, compound 3-11 (4 equiv) was pre-
activated using HOAT (4 equiv), HATU (4 equiv), DIEA (8 equiv) in DMF for 10 
min. Then the resin was put into the solution and shaken for 4 h or overnight. Next, 
the resin was washed with DMF (3x), DCM (3x) and DMF (3x). 
 
Procedures for condition d 
The Fmoc-protected amino-functionalized resin was treated with 2% DBU in DMF 
for 20 min at room temperature. After that, the resin was washed with DMF (3x), 
DCM (3x) and DMF (3x). If next step is using DCM as solvent, then the resin was 
washed with DCM (3x) again. 
 
Procedures for condition e 
The resin was swelled in DCM and washed with DCM. Then DIEA (10 equiv) was 
added to the reactor, followed by addition of acetic anhydride (5 equiv). The reaction 
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was shaken for 2 h. Then the resin was washed with DMF (3x), DCM (3x), DMF (3x), 
MeOH (3x), and dried in vacuo. 
 
Procedures for condition f 
The resin was swelled in DCM and washed with DCM. Then 1% TFA in DCM was 
added to the reactor. The reaction was shaken for 30 min, then washed with DMF (3x), 
DCM (3x) and DMF (3x). 
 
Procedures for condition g 
A cleavage cocktail TFA/TIS/DCM (95:2.5:2.5) was added to the resin and the 
reaction was stirred for 2 h. Subsequently, the resin was filtered off, followed by 
removal of the solvent in vacuo. The resulting residue was precipitated with cold 
diethyl ether and purified by preparative HPLC. 
 
Mitochondrion probe (pMito) 
Ac-X-GGGGFxrFxK-NH2  
IT-TOF-MS: Calcd: [M+2H]/2 = 678.804, found: 678.778 
  













Endoplasmic Reticulum (pER) 
Ac-X-GGGGKDEL-NH2  






IT-TOF-MS: Calcd: [M+2H]/2 = 630.800, found: 630.796 



























p-Hydroxyacetophenone (2.0 g, 14.7 mmol) was dissolved in acetonitrile (30 mL). 
K2CO3 (4.06 g, 29.7 mmol) and allyl bromide (2.13 g, 17.6 mmol) were added into the 
solution. The reaction was heated the reaction for 1 h at 50 °C, after which the organic 
solvent was removed under reduced pressure. The residue was dissolved in EtOAc 
and washed with water, brine. The organic layer was dried over Na2SO4 and the 
solvent was removed in vacuo to afford compound 4-5 (89%). 
1
H-NMR (300 MHz, 
CDCl3) δ 7.89 (d, J = 8.88 Hz, 2H), 6.90 (d, J = 8.88 Hz, 2H), 5.95 - 6.08 (m, 1H), 
5.39 (dd, J1 = 16.42, J2 = 1.47 Hz, 1H), 5.29 (dd, J1 = 10.51 Hz, J2 = 1.32 Hz, 1H), 
5.56 (td, J1 = 5.28 Hz, J2 = 1.47 Hz, 2H), 2.51 (s, 3H). 
13
C-NMR (75 MHz, CDCl3) δ 
196.5, 162.3, 132.4, 130.4, 118.0, 114.2, 68.7, 26.2. IT-TOF: m/z [M+1] 
+
 calcd: 
177.08, found: 177.09 
 
 
Methyl 4-(4-(allyloxy)phenyl)-4-hydroxy-2-oxobut-3-enoate (4-6-1) 
To a solution of compound 4-5 (2.0 g, 11.4 mmol) and dimethyl oxalate (1.47 g, 12.4 
mmol) in MeOH (in an ice bath) under a nitrogen atmosphere was added a freshly 
prepared NaOMe (12.5 mmol, 0.5 M in MeOH) in small portions. The reaction was 
subsequently refluxed for 24 h before being cooled down to room temperature. Upon 
filtration of the while precipitate formed, the solution was collected, concentrated in 
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vacuo to provide the desired product 4-6-1 (48%). 
1
H-NMR (300 MHz, CDCl3) δ 7.97 
(d, J = 8.85 Hz, 2H), 6.96 - 7.02 (m, 3H), 5.98 - 6.11 (m, 1H), 5.42 (dd, J1 = 17.26 Hz, 
J2 = 1.29 Hz, 1H), 5.32 (dd, J1 = 10.44 Hz, J2 = 1.23 Hz, 1H), 4.61 (d, J = 5.28 Hz, 
2H), 3.92 (s, 3H). 
13
C-NMR (75 MHz, CDCl3) δ 190.3, 167.8, 163.3, 162.9, 132.2, 
130.3, 127.7, 118.3, 114.9, 97.8, 69.0, 53.1 
 
 
Methyl 5-(4-(allyloxy)phenyl)isoxazole-3-carboxylate (4-6) 
Compound 4-6-1 (0.64 g, 2.4 mmol) and NH2OH∙H2O (0.17 g, 2.9 mmol) dissolved 
in MeOH was added a catalytic amount of TsOH∙H2O (0.01 g, 0.05 mmol). The 
reaction mixture was refluxed for 24 h. After being cooled down, the resulting white 
precipitate was collected by suction filtration and washed with a mixture of ice-cold 
MeOH and deionized water to provide the desired product 4-6 as a solid (80%). 
1
H-
NMR (300 MHz, CDCl3) δ 7.70 (d, J = 9.06 Hz, 2H), 6.97 (d, J = 9.06 Hz, 2H), 6.77 
(s, 1H), 6.00-6.09 (m, 1H), 5.41 (dd, J1 = 17.28 Hz, J2 = 1.47 Hz, 1H), 5.30 (dd, J1 = 
10.53 Hz, J2 = 1.17 Hz, 1H), 4.56 (d, J = 5.25 Hz, 2H), 3.97 (s, 3H) 
13
C-NMR (75 
MHz, CDCl3) δ 171.6, 160.5, 160.4, 156.5, 132.5, 127.4, 119.3, 118.0, 115.1, 98.4, 
68.7, 52.7. IT-TOF: m/z [M+1] 
+
 calcd: 260.08, found: 260.06 
 
 
5-(4-(Allyloxy) phenyl) isoxazole-3-carboxylic acid (4-7) 
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Compound 4-6 (1 g, 3.9 mmol) was dissolved in MeOH and water (1:1; 10 ml) in an 
ice bath. LiOH (0.47 g, 19.5 mmol) in 0.5 ml water was added slowly into the 
solution. After 2 h when TLC indicated the starting material was completely 
consumed, the solution was neutralized with 1 M HCl. The resulting white precipitate 
was collected, washed with water and chilled methanol to provide the desired 
compound 4-7 (89%). 
1
H-NMR (300 MHz, d6-DMSO) δ 7.87 (d, J = 8.70 Hz, 2H), 
7.24 (s, 1H), 7.10 (d, J = 8.55 Hz, 2H), 5.99 - 6.11 (m, 1H), 5.41 (dd, J1 = 17.26 Hz, 
J2 = 1.15Hz, 1H), 5.28 (dd, J1 = 10.53 Hz, J2 = 0.99 Hz, 1H), 4.65 (d, J = 5.10 Hz, 
2H). 
13
C-NMR (75 MHz, d6-DMSO) δ 170.8, 160.9, 160.1, 157.8, 133.2, 127.5, 119.0, 
117.8, 115.4, 99.3, 68.4. IT-TOF: m/z [M+1] 
+ 




To a solution of compound 4-7 (500 mg, 2.0 mmol) in CHCl3 was added t-BuOH (2 
mL, 20 mmol) and pyridine (806 mg, 10.0 mmol) in an ice bath. After 5 min, POCl3 
(406 mg, 2.6 mmol) was slowly added into the solution. The reaction was stirred for 1 
h. Dichloromethane and 10 mL dilute HCl were poured into the solution. The organic 
layer was separated, washed with dilute HCl (10 mL x 2), water (10 mL x 2), and 
brine (10 mL x 2), dried over Na2SO4. The solvent was removed and the residue was 
purified by silica gel chromatography (10% - 35% EtOAc in hexane) to afford 
compound 4-8 as a white solid (85%). 
1
H-NMR (300 MHz, CDCl3) δ 7.49 (d, J = 
8.85 Hz, 2H), 6.99 (d, J = 9.02 Hz, 2H), 6.72(s, 2H), 6.00 - 6.12 (m, 1H), 5.43 (dd, J1 
= 17.26, J2 = 1.5 Hz, 1H), 5.32 (dd, J1 = 10.53, J2 = 1.32 Hz, 1H), 4.59 (d, J = 5.25 Hz, 
2H), 1.63 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ 171.4, 160.5, 159.2, 158.1, 132.6, 
132 
 
127.5, 119.8, 118.1, 115.3, 98.6, 83.5, 68.9, 28.1. IT-TOF: m/z [M+1] 
+





O3 gas was bubbled into a solution of compound 4-8 (450 mg, 1.5 mmol) in 
DCM (10 mL) at -78 °C until the solution became blue. Excess O3 was purged out 
using argon. Then, zinc dust (340 mg, 5.2 mmol) and a mixture of glacial AcOH and 
water (17:3; 360 μL) were added to the solution in small portions with vigorous 
stirring. Subsequently, the reaction mixture was allowed to warm to room temperature, 
followed by stirring for a further 1 h. The reaction mixture was then neutralized and 
filter through Celite to remove any residual solids. The filtrate was extracted with 
DCM and the organic layer was washed with saturated NaHCO3 and brine, dried over 
Na2SO4 and concentrated in vacuo. The resulting crud product was purification by 
flash column chromatography (10% - 40% EtOAc in hexane) to afford the pure 
product 4-1 as an white solid (81%) 
1
H-NMR (300 MHz, CDCl3) δ 9.81 (s, 1H) , 7.68 
(d, J = 8.88 Hz, 2H), 6.94 (d, J = 8.88 Hz, 2H), 6.70 (s, 1H), 4.63 (d, J = 0.81 Hz, 2H), 
1.99 (s, 9H) δ 13C-NMR (75 MHz, CDCl3) δ 197.8, 170.8, 159.2, 158.9, 157.9, 127.5, 
120.5, 115.0, 98.8, 83.5, 72.4, 27.9. IT-TOF: m/z [M+1] 
+







4-Methylbenzophenone (3 g, 15.3 mmol) and N-bromosuccinimide (2.72 g, 15.3 
mmol) were dissolved in CCl4 (30 mL) solution. The reaction was placed under an IR 
lamp and the solution was refluxed for ~3 h when monitoring of the reaction by TLC 
indicated the complete consumption of the starting material. The resulting solution 
was cooled down and the solid filtered off. Upon concentration in vacuo to remove 
half of the solvent, the resulting solution was added hexane, and left standing for 
recrystalization to occur. The resulting solid was collected to give pure compound 4-9 
(78%). 
1
H-NMR (300 MHz, CDCl3) δ 7.77 - 7.80 (m, 4H), 7.60 (t, J = 7.30 Hz, 1H), 
7.46 - 7.51 (m, 4H), 4.53 (s, 2H) 
13
C-NMR (75 MHz, CDCl3) δ 195.9, 142.0, 137.4, 
137.3, 132.5, 130.5, 130.0, 128.9, 128.3, 32.2. IT-TOF: m/z [M+1] 
+
 calcd: 275.00, 




To a stirred solution of 4-9 (1.5 g, 5.5 mmol) in 16 mL mixture of acetone: H2O (3:1) 
in an ice bath was added NaN3 (0.7 g, 11 mmol; dissolved in water). After 1 h, some 
precipitates formed. Water (50 mL) was then added, and the resulting solution was 
filtered. The solid collected was washed with water and then dried in vacuo to afford 
compound 4-10 (96%). 
1
H-NMR (300 MHz, CDCl3) δ 7.80 (t, J = 8.49 Hz, 4H), 7.59 
(t, J = 7.30 Hz, 1H), 7.41 - 7.50 (m, 4H), 4.43 (s, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 
196.0, 139.8, 137.3, 132.5, 130.5, 130.0, 128.2, 127.7, 54.2. IT-TOF: m/z [M+1] 
+
 







4-10 (0.5 g, 2.1 mmol) dissolved in THF (10 mL) was added H2O (0.16 g) at room 
temperature. PPh3 was then added and the resulting solution was heated to 60 °C for 1 
h before being cooled down to 25 °C. Upon solvent removal under reduced pressure, 
the crude residue collected was subsequently purified by silica gel chromatography 
(30% EtOAc in hexane to 10% MeOH in DCM with 0.1% triethylamine) to give 
compound 4-11 (82%). 
1
H-NMR (300 MHz, CDCl3) δ 7.72 - 7.74 (d, J = 8.20 Hz, 
4H), 7.53 (t, J = 7.25 Hz, 1H) , 7.38 - 7.42 (m, 4H), 3.91 (s, 2H), 1.20(s, 2H) 
13
C-
NMR (75 MHz, CDCl3) δ 196.2, 147.5, 137.5, 135.9, 132.1, 130.2, 129.7, 128.1, 




6-formamidohexanoic acid (0.40 g, 2.5 mmol) was pre-activated with HOBT (0.37 g, 
2.75 mmol), HBTU (1.0 g, 2.75 mmol) and DIEA (0.38 g, 3 mmol) in 15 mL DMF. 
After 10 min, compound 4-11 (0.53g, 2.5 mmol) was added into the solution. The 
reaction was stirred further for 2 h. Upon DMF removal in vacuo, the resulting 
residue was purified by silica gel chromatography (10% to 40% EtOAc in hexane) to 
yield compound 4-12 (84%). 
1
H-NMR (300 MHz, CDCl3) δ 8.06 (s, 1H), 7.15 (t, J = 
8.05 Hz, 4H), 7.57 (t, J = 7.40 Hz, 1H), 7.45 (t, J = 7.24 Hz, 2H), 7.34 (d, J = 8.22 Hz, 
2H), 6.77 (br, 1H), 6.34 (br, 1H), 4.47 (d, J = 5.91 Hz, 2H), 3.25 (q, J = 6.66 Hz, 2H), 
2.24 (t, J = 7.39 Hz, 2H), 1.64 (qn, J = 7.45 Hz, 2H), 1.49 (qn, J = 7.11 Hz, 2H), 1.31 
135 
 
(qn, J = 7.27 Hz, 2H) 
13
C-NMR (75 MHz, CDCl3) δ 196.5, 173.3, 161.6, 143.3, 137.3, 
136.4, 132.5, 130.3, 129.3, 128.3, 127.3, 43.1, 37.7, 36.1, 28.9, 26.2, 25.0. IT-TOF: 
m/z [M+1] 
+




Compound 4-12 (1.0 g, 2.9 mmol) dissolved in anhydrous DCM in an ice bath was 
added triethylamine (1.86 g, 18.4 mmol) and POCl3 (0.91 g, 5.9 mmol). The solution 
was stirred for 30 min. Subsequently, 5% NaHCO3 was added and the reaction was 
stirred further for another 10 min. The resulting solution was extracted by DCM. The 
combine organic layer was washed with brine and dried over Na2SO4. The crude 
residue was purified by silica gel chromatography (5% to 30% EtOAc in hexane) to 
provide compound 4-2 (81%). 
1
H-NMR (300 MHz, CDCl3) δ 7.71 - 7.76 (m, 4H), 
7.58 (t, J = 7.38 Hz, 1H), 7.46 (t, J = 7.20 Hz, 2H), 7.35 (d, J = 8.04 Hz, 2H), 6.23 (br, 
1H), 4.49 (d, J = 5.91 Hz, 2H), 3.34 - 3.40 (m, 2H), 2.25 (t, J = 7.38Hz, 2H), 1.65 - 
1.75 (m, 2H), 1.48 - 1.50 (qn, J = 7.11 Hz, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 196.3, 
172.6, 155.9, 143.2, 137.4, 136.6, 132.5, 130.4, 129.9, 128.3, 127.4, 43.1, 41.3, 36.0, 
28.7, 25.9, 24.6. IT-TOF: m/z [M+1] 
+




6.8  Synthesis of TER-azide 
The acid (50 mg, 0.09 mmol; prepared based on reference 121) was pre-activated with 
HOBT (13.2 mg, 0.1 mmol), HBTU (37.2 mg, 0.1 mmol) and DIEA (18.55 mg, 0.1 
mmol) in DMF for 10 min. Subsequently, 3-azidopropan-1-amine (9 mg, 0.09 mmol) 
was added and the resulting mixture was stirred for 2 h. Upon DMF removal in vacuo, 
the residue was purified by flash chromatography (0.1% to 5% Methanol in DCM) to 
afford the desired rhodamine-N3 (85%). ESI: m/z [M+1] 
+
 calcd: 694.4, found: 694.3. 
 
6.8 MCR reaction 
6.8.1 General procedure for MCR reaction 
In 1.5 mL eppendorf tubes, a solution of amine (0.1 mmol, Figure 4.2) was added into 
400 μL MeOH. Then aldehyde 4-1 (0.1 mmol in 100 μL DMF) was added. After 1 h, 
isonitrile 4-2 (0.1 mmol in 100 μL MeOH) and 5-Hexynoic acid (0.1 mmol in 100 μL 
MeOH) were added into the mixture. The reaction was stirred for ~9 h. The crude 
residue was purified by semi-preparative reverse-phase HPLC. The product was next 
treated with 1 mL of a mixture of TFA/DCM (50/50) for 2 h. TFA/DCM was next 
removed under reduced pressure with a GeneVac HT-4X Series II parallel 
evaporation system, affording the final product which was sufficiently pure and could 
be directly used in subsequent screening experiments. Yield (in two steps): 20 - 30%. 
Both LCMS and 
1
H NMR were carried out to further characterize the final products 
and ensure the correct ID and purity (Table 6.1). 
137 
 
Table 6.1 Summary of AfBPs and their characterizations 
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H NMR Data 
P2 
1
H-NMR (500 MHz, d6-DMSO) δ 8.41 - 8.42 (m, 1H), 7.91 - 8.28 (m, 1H), 7.65 - 
7.72 (m, 7H), 7.55 (t, J = 7.55 Hz, 2H), 7.41 (d, J = 7.55 Hz, 2H), 7.11 - 7.29 (m, 6H), 
6.88 (m, 2H), 4.80 - 5.04 (m, 1H), 4.23 - 4.46 (m, 4H), 3.53 (m, 2H), 3.06 - 3.11 (m, 
2H), 2.78 - 2.85 (m, 3H), 2.11 - 2.21 (m, 6H), 1.69 (m, 2H), 1.50 - 1.51 (m, 2H), 1.39 
- 1.42 (m, 2H), 1.33 (m, 2H). IT-TOF: m/z [M+1] 
+





H-NMR (500 MHz, d6-DMSO) δ 8.41 (m, 1H), 7.82 - 8.20 (m, 1H), 7.65 - 7.72 (m, 
7H), 7.55 (t, J = 7.62 Hz, 2H), 7.41 (d, J = 8.20 Hz, 2H), 7.07 - 7.24 (m, 5H), 6.88 (m, 
3H), 4.75 - 4.90 (m, 1H), 4.22 - 4.36 (m, 4H), 3.03 (m, 2H), 2.76 (m, 1H), 2.50 (m, 
2H), 2.15 (m, 4H), 1.67 (m, 2H), 1.41 - 1.52 (m, 8H), 1.23 (m., 2H). IT-TOF: m/z 
[M+1] 
+
 calcd: 825.38, found: 825.34. 
 
 















H-NMR (500 MHz, d6-DMSO) δ 8.41 (m, 1H), 8.08 - 8.30 (m, 1H), 7.70 - 8.07 (m, 
7H), 7.66 (m, 2H), 7.42 (m, 2H), 7.28 (m, 2H), 7.14 (m, 2H), 6.83 - 6.88 (m, 3H), 
4.94 - 5.25 (m, 1H), 4.58 - 4.80 (m, 2H), 4.15 - 4.39 (m, 4H), 2.99 (m, 2H), 2.70 (m, 
1H), 2.34 - 2.40 (m, 1H), 2.25 (m, 1H), 2.14 - 2.18 (m, 4H), 1.67 - 1.80 (m, 2H), 1.52 
(m, 2H), 1.33 (m, 2H), 1.24 (m, 2H). IT-TOF: m/z [M+1] 
+






H-NMR (500 MHz, d6-DMSO) δ 8.42 (m, 1H), 8.02 - 8.2 (m, 1H), 7.65 - 7.72 (m, 
7H), 7.55 (t, J = 7.62 Hz, 2H), 7.41 (d, J = 8.20 Hz, 2H), 7.28 (m, 1H), 7.15 (m, 1H), 
6.98 (dt, J1 = 34.9, J2 = 8.77 Hz, 2H), 6.81 (m, 3H), 4.89 - 5.21 (m, 1H), 4.63 - 4.78 
(m, 2H), 4.09 - 4.37 (m, 4H), 2.98 (m, 2H), 2.68 (m, 1H), 2.23 - 2.32 (m, 2H), 2.08 - 
2.15 (m, 4H), 1.65 - 1.80 (m, 4H), 1.51 (m, 2H), 1.33 (m, 2H), 1.22 (m, 2H). IT-TOF: 
m/z [M+1] 
+





H-NMR (500 MHz, d6-DMSO) δ 8.42 (m, 1H), 8.02-8.28 (m, 1H), 7.66 - 7.72 (m, 
7H), 7.55 (t, J = 7.65 Hz, 2H), 7.41 (m, 3H), 7.20 - 7.32 (m, 2H), 7.07 (m, 1H), 6.82 
(m, 3H), 4.91 - 5.23 (m, 1H), 4.63 - 4.77 (m, 2H), 4.15 - 4.37 (m, 4H), 3.00 (m, 2H), 
2.70 (m, 1H), 2.23 - 2.34 (m, 2H), 2.14 (m, 4H), 1.66 - 1.68 (m, 2H), 1.52 (m, 2H), 
1.32 (m, 2H), 1.21 (m. 2H). IT-TOF: m/z [M+1] 
+






H-NMR (500 MHz, d6-DMSO) δ 8.42 (m, 1H), 7.96 - 8.22 (m, 1H), 7.63 - 7.96 (m, 
7H), 7.55 (t, J = 7.55 Hz, 2H), 7.41 (d, J = 8.20 Hz, 2H), 7.22 (m,1H), 7.04 - 7.15 (m, 
3H), 6.75 (m, 3H), 4.89 - 5.17 (m, 1H), 4.67 (m, 1H), 4.03 - 4.36 (m, 4H), 2.97 (m, 
2H), 2.68 (s, 1H), 2.24 - 2.40 (m, 2H), 2.08 - 2.14 (m, 4H), 1.67 - 1.76 (m, 2H), 1.51 
(m, 2H), 1.34 (m, 2H), 1,14 - 1,19 (m, 11H). IT-TOF: m/z [M+1] 
+






H-NMR (500 MHz, d6-DMSO) δ 8.41 (t, J = 5.80 Hz, 1H), 8.11 - 8.39 (m, 1H), 
7.67 - 7.71 (m, 7H), 7.54 - 7.58 (m, 4H), 7.40 - 7.47 (m, 4H), 7.32 (d, J = 7.55 Hz, 
1H), 6.84 (m, 2H), 4.96 - 5.30 (m, 1H), 4.77 - 4.91 (m, 2H), 4.16 - 3.37 (m, 4H), 2.93 
- 2.99 (m, 2H), 2.66 - 2.69 (m, 1H), 2.23 - 2.26 (m, 1H), 2.15 (m, 1H), 2.13 - 2.14 (m, 
4H), 1.68 - 1.79 (m, 2H), 1.50 (m, 2H), 1.32 (m, 2H), 1.22 (m, 2H). IT-TOF: m/z 
[M+1] 
+





H-NMR (500 MHz, d6-DMSO) δ 8.41 (m, 1H), 8.03 - 8.26 (m, 1H), 7.63 - 7.71 (m, 
7H), 7.55 (m, 2H), 7.41 (d, J = 8.20 Hz, 2H), 6.61 - 7.15 (m, 7H), 4.91 - 5.22 (m, 1H), 
4.61 - 4.78 (m, 2H), 4.13 - 4.37 (m, 4H), 3.57 - 3.65 (m, 3H), 2.99 (m, 2H), 2.67 (m, 
1H), 2.24 - 2.35 (m, 2H), 2.11 - 2.15 (m, 4H), 1.65 - 1.69 (m, 2H), 1.51 (m, 2H), 1.35 
(m, 2H), 1.23 (m, 2H). IT-TOF: m/z [M+1] 
+






H-NMR (500 MHz, d6-DMSO) δ 8.40 (m, 1H), 8.15 - 8.34 (m, 1H), 7.65 - 7.72 (m, 
7H), 7.34 - 7.57 (m, 8H), 6.81 (m, 3H), 4.96 - 5.31 (m, 1H), 4.50 - 4.91 (m, 2H ), 4.21 
- 4.50 (m, 4H), 2.94 - 2.99 (m, 2H), 2.70 (m, 1H), 2.34 (m, 1H), 2.23 (m, 1H), 2.13 (m, 
4H), 1.76 (m, 1H), 1.67 (m, 1H), 1.50 (m, 2H), 1.32 (m, 2H), 1.2 (m, 2H). IT-TOF: 
m/z [M+1] 
+





H-NMR (500 MHz, d6-DMSO) δ 8.42 (m, 1H), 8.08 - 8.31 (m, 1H), 7.65 - 7.72 (m, 
7H), 7.56 (t, J = 7.60 Hz, 2H), 7.41 (d, J = 8.20 Hz, 2H), 7.29 (m, 1H), 7.11 (m, 2H), 
6.98 (m, 1H), 6.83 (m, 2H), 4.92 - 5.24 (m, 1H), 4.65 - 4.74 (m, 2H), 4.17 - 4.37 (m, 
4H), 2.99 (m, 2H), 2.67 (m, 1H), 2.36 (m, 1H), 2.24 (m, 1H), 2.14 (m, 4H), 1.65 - 
1.78 (m, 2H), 1.51 (m. 2H), 1.34 (m, 2H), 1.24 (m, 2H). IT-TOF: m/z [M+1] 
+
 calcd: 





H-NMR (500 MHz, d6-DMSO) δ 8.43 (m, 1H), 7.97 - 8.23 (m, 1H), 7.65 - 7.72 (m, 
7H), 7.56 (t, J = 7.60Hz, 2H), 7.41 (d, J = 8.20 Hz, 2H), 6.61 - 6.82 (m, 6H), 5.77 - 
5.92 (m, 2H), 4.87 - 5.14 (m, 1H), 5.53 - 4.67 (m, 2H), 4.06 - 4.37 (m, 4H), 2.30 (m, 
2H), 2.64 (m, 1H), 2.23 - 2.37 (m, 2H), 2.14 (m, 4H), 1.66 - 1.68 (m, 2H), 1.51 (m, 
2H), 1.34 (m, 2H), 1.22 (m, 2H). IT-TOF: m/z [M+1] 
+







H-NMR (500 MHz, d6-DMSO) δ 8.41 (m, 1H), 8.02 - 8.15 (m, 1H), 7.61 - 7.72 (m, 
7H), 7.55 (t, J = 7.55 Hz, 2H), 7.41 (m, 3H), 7.12 - 7.22 (m, 2H), 6.93 - 7.03 (m, 1H), 
6.73 (m, 1H), 5.21 - 5.26 (m, 1H), 3.84 - 4.36 (m, 4H), 2.81 - 2.88 (m, 4H), 2.68 - 
2.71 (m, 2H), 1.98 - 2.18 (m, 8H), 1.52 - 1.63 (m, 4H), 1.40 (m, 2H), 1.25 (m, 2H). 
IT-TOF: m/z [M+1] 
+





H-NMR (500 MHz, d6-DMSO) δ 8.41 (m, 1H), 8.10 (m, 1H), 7.65 - 7.72 (m, 7H), 
7.55 (t, J = 7.55 Hz, 2H), 7.32 - 7.42 (m, 6H), 6.89 - 7.12 (m, 8H), 5.31 (m, 2H), 4.00 
- 4.36 (m, 4H), 3.02 (m, 2H), 2.68 (s, 1H), 2.07 - 2.17 (m, 6H), 1.61 (m, 2H), 1.52 (m, 
2H), 1.38 (m, 2H), 1.23 (m, 2H). IT-TOF: m/z [M+1] 
+





H-NMR (500 MHz, d6-DMSO) δ 8.40 (m, 1H), 8.15 (m, 1H), 7.65 - 7.72 (m, 7H), 
7.55 (m, 3H), 7.40 (m, 3H), 7.19 (s, 1H), 6.87 - 6.94 (m, 3H), 5.30 (m, 1H), 3.94 - 
4.37 (m, 4H), 3.07(m, 2H), 2.68 (s, 1H), 2.05 - 2.23 (m, 9H), 1.53 - 1.63 (m, 4H), 1.41 
(m, 2H), 1.27 (m, 2H). IT-TOF: m/z [M+1] 
+












ylamino) propan-2-yl)carbamate (5-5) 
FmocNH-Tyr(O
t
Bu)-COOH (1g, 2.17 mmol) was first activated by EDC (372 mg, 
2.40 mmol), HOBT (323 mg, 2.40 mmol) and DIEA (486 µL, 2.80 mmol) in DMF 
solution. Then the alkyne-based amine (460 mg, 2.3 mmol) was added into the 
solution. The solvent was evaporated after 1 h reaction. Then the residue was 
extracted by EA and washed by 10% citric acid, saturated NaHCO3 and brine. The 
product was purified by chromatography column (94%, 1.1 g). 
1
H NMR (500 MHz, 
CDCl3) δ 7.75 (d, J = 7.6 Hz, 2H), 7.55 (dd, J = 7.4, 3.1 Hz, 2H), 7.39 (t, J = 7.5 Hz, 
2H), 7.30 (t, J = 7.4 Hz, 2H), 7.07 (m, 2H), 6.91 (d, J = 8.2 Hz, 2H), 6.00 (s, 1H), 
5.54 (s, 1H), 4.33 - 4.40 (m, 3H), 4.18 (t, J = 6.7 Hz, 1H), 3.20 -3.30 (m, 2H), 2.96 - 
3.05 (m,  1H), 2.05 - 2.11 (m, 2H), 1.90 (s, 1H), 1.51 - 1.65 (m, 2H), 1.31 (s, 9H). 
13
C 
NMR (126 MHz, CDCl3) δ 170.80, 155.87, 154.39, 143.68, 143.66, 141.24, 131.18, 
129.70, 127.69, 127.04, 124.93, 124.20, 119.93, 83.16, 78.38, 69.24, 66.95, 56.50, 
47.08, 38.53, 38.16, 28.77, 27.75, 15.90. IT-TOF: m/z [M+H] 
+









The tBu group in 5-5 compound (0.3 mmol, 157 mg) was deprotected under TFA : 
DCM (1 : 1, 10 mL). After the reaction was finished, TFA and DCM were evaporated 
in vacuo. Piperidine (0.3 mL in 5 mL DMF, 3 mmol) was added into the resulted 
residue. After 30 min, DMF was also removed completely in vacuo. The residue was 
redissolved in DMF. BocNH-Phe-COOH (252 mg, 0.33 mmol) activated by EDC (51 
mg, 0.33 mmol), HOBT (44 mg, 0.33 mmol), DIEA (76 µL, 0.36 mmol) in DMF was 
dropwise added into the solution. DMF was evaporated after 1 h reaction. Then the 
residue was extracted by EA and washed by 10% citric acid, saturated NaHCO3 and 
brine. The product was purified by chromatography column (67%, 100 mg). 
1
H NMR 
(500 MHz, MeOD) δ 7.26 (t, J = 7.2 Hz, 2H), 7.17 - 7.21 (m, 3H), 6.98 (d, J = 8.0 Hz, 
2H), 6.70 (d, J = 8.3 Hz, 2H), 4.44 (t, J = 6.8 Hz, 1H), 4.23 - 4.26 (m, 1H), 3.19 - 3.28 
(m, 1H), 3.10 - 3.15(m, 1H), 3.1 (dd, J = 13.9, 5.2 Hz, 1H), 2.90 (d, J = 4.1 Hz, 2H), 
2.79 (dd, J = 13.6, 9.2 Hz, 1H), 2.22 (t, J = 2.6 Hz, 1H), 2.05 - 2.07 (m, 2H), 1.55 - 
1.62 (m, 2H), 1.35 (s, 9H). 
13C NMR (126 MHz, MeOD) δ 173.90, 173.07, 157.85, 
157.44, 138.39, 131.40, 130.34, 129.42, 128.50, 127.74, 116.32, 84.15, 80.91, 70.03, 
57.70, 56.09, 39.38, 38.84, 38.08, 29.18, 28.63, 16.53. IT-TOF: m/z [M+H] 
+
 calcd: 





yn-1-ylamino)propyl)phenyl ethenesulfonate (5-1) 
Compound 5-6 (50 mg, 0.1 mmol) and triethylamine (42 µL, 0.3 mmol) was dissolved 
in anhydrous DCM at 0 °C. And 2-chloro-1-ethane-sulfonylchloride (11 µL, 0.12 
mmol) in DCM was dropwise added into the solution. After 2 h, the reaction was 
concentrated and the crude product was purified by chromatography column (5-1, 48 
mg, 72%). 
1
H NMR (500 MHz, CDCl3) δ 7.21 - 7.31 (m, 3H), 7.15 (d, J = 7.0 Hz, 
2H), 6.82 - 7.14 (m,  4H), 6.60 - 6.66 (m, 2H), 6.42 (s, 1H), 6.33 (d, J = 16.6 Hz, 1H), 
6.14 (d, J = 9.9 Hz, 1H), 5.04 (s, 1H), 4.60 - 4.65(m, 1H), 4.30 - 4.31 (m, 1H), 3.12 - 
3.32 (m, 2H), 3.06 - 3.10 (m, 1H), 2.92 - 3.04 (m, 3H), 2.07 - 2.10 (m, 2H), 1.94 (t, J 
= 2.6 Hz, 1H), 1.55 - 1.61 (m, J = 6.9 Hz, 2H), 1.34 (s, 9H).
 13
C NMR (126 MHz, 
CDCl3) δ 171.21, 170.00, 155.73, 148.26, 136.05, 135.78, 131.98, 131.70, 130.71, 
129.18, 128.75, 127.18, 122.31, 83.25, 80.70, 69.12, 56.02, 53.82, 38.53, 37.84, 37.09, 
28.12, 27.77, 15.85. IT-TOF: m/z [M+H] 
+







Prepared according to the general procedure using TBDMS protected amino acid (634 
mg, 1.08 mmol), EDC (186 mg, 1.20 mmol), HOBT (161 mg, 1.20 mmol) and DIEA 
(243 µL, 1.40 mmol)  and 4-pentyn-1-amine (156 mg, 1.3 mmol). The product was 
purified by chromatography column (90%, 631 mg). 
1
H NMR (500 MHz, CDCl3) δ 
7.74 (d, J = 7.5 Hz, 2H), 7.70 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 6.9 Hz, 2H), 7.38 (t, J = 
7.4 Hz, 2H), 7.24 - 7.34 (m, 2H), 6.77 -  6.82 (m, 2H), 6.70 - 6.72 (m, 1H), 6.22 (s, 
1H), 6.03 (d, J = 8.1 Hz, 1H), 4.52 (d, J = 6.8 Hz, 1H), 4.39 (d, J = 6.2 Hz, 2H), 4.16 
(t, J = 6.4 Hz, 1H), 3.17 - 3.38 (m, 3H), 3.13 - 3.15 (m, 1H), 2.13 - 2.17 (m, 2H), 1.87 
(s, 1H), 1.56 - 1.68 (m, 2H), 1.00 (s, 9H), 0.24 (s,6H).
 13
C NMR (126 MHz, CDCl3) δ 
170.02, 161.06, 159.56, 156.06, 155.31, 151.68, 143.60, 141.30, 127.81, 127.12, 
125.64, 124.97, 120.03, 117.54, 113.06, 108.05, 83.29, 69.42, 67.23, 54.52, 47.04, 
38.93, 34.31, 27.65, 25.55, 18.24, 16.06, -4.41. IT-TOF: m/z [M+H] 
+





ylamino) propan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)carbamate (5-8) 
5-7 (100 mg, 0.15 mmol) was first treated with TBAF (1.5 mmol) in THF. After 30 
min, THF was evaporated and the residue was redissolved in DMF. BocNH-Phe-
COOH (137 mg, 0.18 mmol) activated by EDC (28 mg, 0.18mmol), HOBT (25 mg, 
0.18 mmol), DIEA (42 µL, 0.2 mmol) in DMF was dropwise added into the solution. 
DMF was evaporated after 1 h reaction. Then the residue was extracted with EA and 
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washed by 10% citric acid, saturated NaHCO3 and brine. The product was purified by 
chromatography column (55%, 48 mg). 
1
H NMR (500 MHz, MeOD) δ 7.75 (d, J = 
8.8 Hz, 1H), 7.22 - 7.24 (m, 2H), 7.18 (t, J = 6.8 Hz, 3H), 6.86 (dd, J = 8.8, 2.3 Hz, 
1H), 6.72 (d, J = 2.4 Hz, 1H), 6.10 (s, 1H), 4.64 (t, J = 7.1 Hz, 1H), 4.19 - 4.24 (m, 
1H), 3.16 - 3.20 (m, 1H), 3.08 (dd, J = 14.2, 8.2 Hz, 1H), 2.98 (dd, J = 13.7, 5.9 Hz, 
1H), 2.79 (dd, J = 14.71, 7.78 Hz, 1H), 2.23 (t, J = 2.63 Hz, 1H), 2.14 (td, J = 7.06, 
2.61 Hz, 2H), 1.38 (s, 9H). 
13C NMR (126 MHz, MeOD) δ 172.95, 170.57, 161.98, 
161.73, 156.45, 155.53, 153.06, 136.90, 128.85, 128.07, 126.42, 126.04, 113.14, 
111.51, 111.02, 102.40, 82.63, 79.55, 68.73, 56.39, 52.41, 38.25, 37.53, 33.58, 27.79, 
27.26, 15.19. IT-TOF: m/z [M+Na] 
+




yn-1-ylamino) propyl)-2-oxo-2H-chromen-7-yl ethenesulfonate (5-2) 
Prepared according to the general procedure compound 5-8 (40 mg, 0.07 mmol) and 
triethylamine (30 µL, 0.21 mmol) and 2-chloro-1-ethane-sulfonylchloride (8.2 µL, 0.9 
mmol). The crude product was purified by chromatography column (5-2, 34 mg, 
75%). 
1
H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 9.3 Hz, 1H), 7.29 (dd, J = 14.7, 7.4 
Hz, 2H), 7.10 -7.24 (m, 2H), 7.16 (d, J = 7.0 Hz, 2H), 6.72 (dd, J = 16.6, 10.0 Hz, 1H), 
6.67 (s, 1H), 6.49 (s, 1H),  6.45 (d, J = 16.6 Hz, 1H), 6.26 (d, J = 9.9 Hz, 1H), 6.22 (s, 
1H), 4.95 (s, 1H), 4.63 (dd, J = 14.2, 7.0 Hz, 1H), 4.28 (dd, J = 13.2, 6.5 Hz, 1H), 
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3.19 - 3.38 (m, 3H), 2.99 -3.08(m, 3H), 2.17 (td, J = 6.8, 2.5 Hz, 0H), 1.89 - 1.90 (m, 
1H), 1.61 - 1.66(m, 2H), 1.39 (s, 9H).
 13
C NMR (126 MHz, CDCl3) δ 171.64, 169.08, 
159.42, 154.36, 151.38, 150.73, 135.87, 132.65, 131.90, 129.08, 128.92, 127.39, 
126.27, 118.82, 117.75, 115.95, 111.25, 83.29, 81.16, 69.28, 56.35, 52.30, 39.01, 
37.57, 34.25, 28.23, 28.17, 27.67, 16.04. IT-TOF: m/z [M+Na] 
+





(fluoromethyl) phenyl)-1-oxo-1-(pent-4-yn-1-ylamino)propan-2-yl)carbamate (5-10) 
Prepared according to the general coupling reaction procedure using 5-9 (500 mg, 
0.63 mmol), EDC (117 mg, 0.75 mmol), HOBT (100 mg, 0.75 mmol) and DIEA (153 
µL, 0.88 mmol), 4-pentyn-1-amine (140 mg, 0.70 mmol). The product was purified 
by chromatography column (87%, 466 mg). 
1
H NMR (500 MHz, CDCl3) δ 8.08 (d, J 
= 8.2 Hz, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.67 (d, J = 7.6 Hz, 2H), 7.62 (t, J = 7.5 Hz, 
2H), 7.51 (d, J = 7.3 Hz, 2H), 7.46 (t, J = 7.7 Hz, 2H), 7.35 (t, J = 7.4 Hz, 2H), 7.32 
(d, J = 8.4 Hz, 2H), 7.24 - 7.28 (m, 3H), 7.16 (d, J = 6.1 Hz,1H), 6.36 (s, 1H), 5.66 (s, 
1H), 5.60 (d, J = 7.3 Hz, 2H), 5.37 (d, J = 47.4 Hz, 2H), 4.35 - 4.44 (m, 2H), 4.25 - 
4.32 (m, 1H), 4.10 - 4.14 (m, 1H), 3.22 - 3.35 (m, 2H), 3.97 - 3.11 (m, 2H), 2.05 - 
2.12 (s, 2H), 1.89 (s, 1H), 1.54 - 1.63 (m, 2H). 
13
C NMR (126 MHz, CDCl3) δ 170.49, 
155.85, 147.17, 146.63, 143.53, 141.15, 134.25, 134.07, 131.92, 131.44, 131.21, 
130.80, 129.13, 128.56, 127.65, 127.42, 126.98, 125.02, 124.84, 119.89, 83.21, 79.53 
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(d, J = 167.3 Hz, 1C, C-F), 69.19, 66.93, 66.91, 56.10, 46.98, 38.57, 37.81, 27.69, 
15.82. 
19
F NMR (282 MHz, CDCl3) δ -136.06 (t, J = 47.5 Hz, 1F).
 31
P NMR (121 
MHz, CDCl3) δ -6.40. IT-TOF: m/z [M+H] 
+






Compound 5-10 (100 mg, 0.12 mmol) was first treated with DBU (1.2 mmol) in 5 mL 
DMF to deprotect Fmoc group for 10 min. BocNH-Phe-COOH (106 mg, 0.14 mmol) 
activated by EDC (22 mg, 0.14 mmol), HOBT (20 mg, 0.14 mmol), DIEA (31 µL, 
0.15 mmol) in DMF was dropwise added into the solution. After 1 h, the residue was 
extracted with EA and washed by 10% citric acid, saturated NaHCO3 and brine. Then 
the crude product was treated with 2 mL 1 M thiophenol and triethylamine solution in 
acetonitrile for 1 h. Subsequently the solvent was evaporated and the product was 
purified by preparative HPLC (30%, 26 mg). 
1H NMR (500 MHz, MeOD) δ 8.05 (d, J 
= 7.8 Hz, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.39 - 7.49 (m, 2H), 
7.11 - 7.24 (m, 7H ), 5.35 - 5.45 (m, 4H), 4.47 (t, J = 7.0 Hz, 1H), 4.22 (dd, J = 9.0, 
5.3 Hz, 1H), 3.08 - 3.20 (m, 2H), 2.93 - 3.02 (m, 2H), 2.83 (ddd, J = 23.0, 13.7, 8.3 
Hz, 2H), 2.19 (t, J = 2.6 Hz, 1H), 2.04 - 2.09 (m, 2H), 1.52 - 1.60 (m, 2H), 1.33 (s, 
9H). 
13C NMR (126 MHz, MeOD) δ 171.83, 170.62, 155.61, 148.54, 145.87, 136.18, 
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133.40, 132.78, 131.17, 129.49, 128.85, 128.10, 127.30, 127.21, 127.17, 125.52, 
123.44, 118.68, 81.93, 78.90 (d, J = 165.0Hz, 1C, C-F), 78.68, 78.25, 67.86, 63.69, 
55.53, 53.79, 37.23, 36.77, 35.95, 26.99, 26.44, 14.33. 
19F NMR (282 MHz, MeOD) δ 
-135.95 (t, J = 47.8 Hz, 1F). 
31P NMR (121 MHz, MeOD) δ -6.67. IT-TOF: m/z 
[M+H] 
+






Prepared according to the general coupling reaction procedure using 5-11
 
(300 mg, 
0.35 mmol), EDC (65 mg, 0.42 mmol), HOBT (56 mg, 0.42 mmol) and DIEA (85 µL, 
0.50 mmol), 4-pentyn-1-amine (90 mg, 0.45 mmol). The product was purified by 
chromatography column (79%, 254 mg). 
1
H NMR (500 MHz, CDCl3) δ 8.12 (d, J = 
7.4 Hz, 2H), 7.94 (d, J = 7.94 Hz, 1H), 7.64 - 7.78 (m, 6H), 7.45 - 7.60 (m, 5H), 7.37 
- 7.40 (m, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.31 (s, 1H), 6.27 (s, 1H), 5.58 - 5.71(m, 7H), 
4.44 (d, J = 6.13 Hz, 2H), 4.37 - 4.40 (m, 1H), 4.18 (t, J = 6.5 Hz, 1H), 3.30 - 3.34 (m, 
2H), 3.06 - 3.26 (m, 2H), 2.14 - 2.18 (m, 2H), 1.85 (s, 1H), another 2H is inside of 
water peak (1.65 ppm). 
13
C NMR (75 MHz, CDCl3) δ 169.33, 158.95, 155.91, 153.43, 
153.04, 152.94, 152.28, 151.72, 150.65, 146.82, 143.51, 141.33, 134.25, 131.26, 
129.43, 128.86, 127.85, 127.14, 125.22, 124.86, 120.06, 116.28, 115.68, 115.62, 
104.98, 83.21, 77.20, 72.47 (d, J = 166.5 Hz, C-F), 69.39, 67.41, 67.15, 54.28, 47.09, 
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39.04, 27.59, 16.08. 
19
F NMR (282 MHz, CDCl3) δ -131.76 (t, J = 48.2 Hz, 1F). 
31
P 
NMR (121 MHz, CDCl3) δ -7.05. IT-TOF: m/z [M+H] 
+






Compound 5-12 (80 mg, 0.09 mmol) was first treated with DBU in DMF to deprotect 
Fmoc group for 10 min. BocNH-Phe-COOH (83 mg, 0.11 mmol) activated by EDC 
(17 mg, 0.11 mmol), HOBT (15 mg, 0.11 mmol), DIEA (31 µL, 0.15 mmol) in DMF 
was dropwise added into the solution. After 1 h, the residue was extracted with EA 
and washed by 10% citric acid, saturated NaHCO3 and brine. Then the crude product 
was treated with 1 mL 1 M thiophenol and triethylamine solution in acetonitrile for 1 
h. Subsequently the solvent was evaporated and the product was purified by 
preparative HPLC (25%, 18 mg). 
1
H NMR (500 MHz, d6-DMSO) δ 8.14 (d, J = 6.1 
Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.70 - 7.81 (m, 3H), 7.64 
(d, J = 8.8 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.15 - 7.23 (m, 5H), 6.95 (d, J = 8.3 Hz, 
1H), 6.19 (s, 1H), 5.50 (d, J = 48.2 Hz, 2H), 5.20 (d, J = 7.7 Hz, 2H), 4.58 (dd, J = 
13.88, 7.95 Hz, 1H), 4.08 - 4.12 (m, 1H), 3.16 - 3. 19 (m, 1H), 3.09 - 3.13 (m, 2H), 
3.00 (dd, J = 13.9, 8.2 Hz, 1H), 2.87 (dd, J = 13.8, 4.3 Hz, 1H), 2.75 (t, J = 2.47 Hz, 
1H), 2.65 - 2.72 (m, 1H), 2.12 (dd, J = 7.0, 4.7 Hz, 2H), 1.54 (td, J = 13.3, 6.6 Hz, 
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2H), 1.27 (s, 9H). 
13
C NMR (126 MHz, d6-DMSO) δ 171.56, 169.72, 159.32, 156.36, 
155.23, 153.10, 152.12, 146.49, 137.93, 135.18, 133.90, 130.24, 129.05, 128.41, 
128.10, 128.05, 127.97, 126.75, 126.14, 124.33, 120.24, 116.39, 113.22, 113.07, 
112.66, 83.85, 78.23, 73.46, 72.81(d, J = 166.5 Hz, C-F), 63.55, 56.02, 51.41, 37.78, 
37.35, 34.35, 28.03, 27.81, 15.27. 
19
F NMR (282 MHz, d6-DMSO) δ -135.28 (t, J = 
47.4 Hz, 1F).
31
P NMR (121 MHz, d6-DMSO) δ -5.45. IT-TOF: m/z [M-H] 
+
 calcd: 
807.25, found: 807.22 
 
6.10 Synthesis of trifunctional tag 
 
Scheme 6.1 Synthetic scheme of trifunctional tag 
 
Synthesis of 5-13 
The solution of Fmoc-Lys(Biotin)-OH (4.0 g, 6.7 mmol)
122
, HBTU (3.04 g, 8.0 mmol) 
and HOBt (1.08 g, 8.0 mmol) was stirred at room temperature for 10 min. 
Subsequently, N-Boc-propyldiamine (1.76 g, 10 mmol) and DIEA (2.36 mL, 13.6 
mmol) were added. After the reaction was stirred over night at room temperature, the 
product was precipitated in water as a yellowish solid. (3.5 g, 69%). 
1
H NMR (300 
MHz, d6-DMSO) δ 7.95-7.85 (m, 3H), 7.74 (s, 3H), 7.44-7.39 (m, 3H), 7.32 (t, J = 7.3 
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Hz, 2H), 6.76 (s, 1H), 6.42 (s, 1H), 6.35 (s, 1H), 4.49-4.22 (m, 4H), 4.11-4.09 (m, 1H), 
3.92-3.85 (m, 1H), 3.15-2.75 (m, 9H), 2.04 (t, J = 6.8 Hz, 2H), 1.68-1.10 (m, 23H). 
13
C NMR (75 MHz, d6-DMSO) δ 171.8, 162.7, 155.9, 155.6, 143.9, 143.8, 140.7, 
127.6, 127.0, 125.3, 120.1, 108.4, 77.4, 65.6, 61.0, 59.2, 55.4, 54.7, 46.7, 38.3, 37.4, 
36.2, 35.8, 35.2, 31.6, 30.8, 29.5, 28.9, 28.2, 28.0, 25.3, 23.0. 
 
Synthesis of 5-14 
The solution of compound 5-13 (3.5 g, 4.7 mmol) in piperidine-DMF (1: 4, 15 mL) 
was stirred at room temperature for 1 h. After the volatiles were removed under 
reduced pressure, water (~ 40 mL) was then added into the solution until no more 
precipitate formed. The precipitate was filtered and the filtrate was concentrated under 
reduced pressure to give the product as yellowish oil which was slowly changed to a 
yellowish solid. (2.2 g, 89%). The product was pure enough to use in next step.  
The crude product (1.8 g, 3.4 mmol) and DIEA (0.74 mL) in DMF were added into a 
solution of TER-acid (1.6 g, 2.2 mmol), HBTU (1.0 g, 2.6 mmol) and HOBt (0.36 g, 
2.8 mmol) in DMF (18 mL). After the reaction was stirred at room temperature 
overnight, the compound 5-14 was purified by prepHPLC. The purity of 5-14 was 
shown in the following LCMS. IT-TOF: m/z [M] 
+
























Synthesis of Trifunctional tag 
To the solution compound 5-14 (300 mg, 0.27 mmol) in DCM (10 mL) was added 
TFA (0.5 mL) and the reaction was stirred at room temperature for 1 h. The volatiles 
were removed under reduced pressure. The residual TFA was removed by azeotropy 
with toluene. After the solution of the residue above, DIEA (400 µL), HATU (137 mg, 
0.36 mmol) and 5-15 (0.11 g, 0.35 mmol) in DMF (10 mL) was stirred at room 
temperature overnight, the tag was purified by prepHPLC. IT-TOF: m/z [M+H]/2 
+
 

























6.11 Mass results 
Table 6.2 The complete list of P23 Labeled proteins
123 
identified from MCF-7 cell lysate. 
Name (Gene, Protein) M.W. Score Queries 
matched 
emPAI Family 
FKBP4 FK506-binding protein 4 52057 738 29 3.14 immunophilin protein family 
VAT1 Synaptic vesicle membrane protein VAT-1 homolog 42122 387 7 0.31 zinc-containing alcohol dehydrogenase family 
WARS Tryptophanyl-tRNA synthetase, cytoplasmic 53474 354 10 0.45 class-I aminoacyl-tRNA synthetase family 
CTSD Cathepsin D precursor 45037 338 13 0.46 peptidase family 
PSMD6 26S proteasome non-ATPase regulatory subunit 6 45787 313 16 1.1 proteasome subunit S10 family 
VDAC1 Voltage-dependent anion-selective channel protein 1 30868 289 9 0.85 eukaryotic mitochondrial porin family 
DCTN2 dynactin 2 44906 275 8 0.46 dynactin subunit 2 family 
SEC22B Vesicle-trafficking protein SEC22b 24896 271 7 1.13 synaptobrevin family 
PRKCSH Glucosidase 2 subunit beta precursor 60357 251 6 0.15  
SSB Lupus La protein 46979 245 7 0.35  
PCK2 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial 
precursor 
71447 242 7 0.25 phosphoenolpyruvate carboxykinase [GTP] 
family. 
HM13 Isoform 1 of Minor histocompatibility antigen H13 41747 229 10 0.58 peptidase family 
SLC7A5 Large neutral amino acids transporter small subunit 1 55659 223 6 0.11 amino acid-polyamine-organocation (APC) 
superfamily 
BCAP31 B-cell receptor-associated protein 31 34901 217 7 0.89 BCAP29/BCAP31 family 
BZW1 similar to basic leucine zipper and W2 domains 1 51420 208 15 0.55 BZW family 
YBX1 Nuclease sensitive element-binding protein 1 35903 208 5 0.17 may invovle in cancer 
TRIM28 Isoform 1 of Transcription intermediary factor 1-beta 90261 177 8 0.21 TRIM/RBCC family 
CTTN Src substrate cortactin 61896 175 7 0.32  
CAP1 Adenylyl cyclase-associated protein 1 52222 173 5 0.18 CAP family 
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Chloride intracellular channel protein 1 27248 169 4 0.41 chloride channel CLIC family. 
PSME1 Proteasome activator complex subunit 1 28876 150 11 1.4 PA28 family 
IDH2 Isocitrate dehydrogenase [NADP], mitochondrial precursor 51333 149 7 0.32 isocitrate and isopropylmalate dehydrogenases 
family 
RAB1A Isoform 1 of Ras-related protein Rab-1A 22891 149 6 0.51 Rab family 
SHMT2 Serine hydroxymethyltransferase, mitochondrial precursor 56414 147 5 0.22 SHMT family 
HEXA Beta-hexosaminidase alpha chain precursor 61106 145 9 0.32 glycosyl hydrolase 20 family 
AARS Alanyl-tRNA synthetase, cytoplasmic 107484 145 8 0.17 class-II aminoacyl-tRNA synthetase family 
SELENBP1 Selenium-binding protein 1 52928 144 8 0.38 selenium-binding protein family 
CS Citrate synthase, mitochondrial precursor 51908 141 4 0.18 citrate synthase family 
CD63 CD63 antigen 26474 140 10 0.81 tetraspanin (TM4SF) family 
LCP1 Plastin-2 70815 135 5 0.22 actin-binding proteins 
TMED10 Transmembrane emp24 domain-containing protein 10 precursor 25131 133 6 0.65 EMP24/GP25L family. 
Ribonuclease inhibitor 51766 131 3 0.12  
CDC37 Hsp90 co-chaperone Cdc37 44953 131 7 0.46 CDC37 family 
RAB10 Ras-related protein Rab-10 22755 129 5 0.51 Rab family 
Annexin A11 54697 127 7 0.3 Annexin family 
LAMP1 lysosomal-associated membrane protein 1 45367 126 6 0.32 LAMP family 
SLC9A3R1 Ezrin-radixin-moesin-binding phosphoprotein 50 39130 124 6 0.43 solute carrier family 
TXNDC4 Thioredoxin domain-containing protein 4 precursor 47341 121 3 0.2  
OLA1 Isoform 1 of Putative GTP-binding protein 9 44943 121 6 0.37 GTP1/OBG family 
PSMD11 Proteasome 26S non-ATPase subunit 11 variant (Fragment) 47790 120 3 0.19 proteasome family. 
PHB Prohibitin 29843 118 5 0.7 prohibitin family. 
SUCLG2 Succinyl-CoA ligase [GDP-forming] beta-chain, mitochondrial 
precursor 
46824 116 4 0.27 succinate/malate CoA ligase beta subunit family 
USP5 Isoform Long of Ubiquitin carboxyl-terminal hydrolase 5 96638 116 5 0.09 peptidase family 
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CAND1 Isoform 1 of Cullin-associated NEDD8-dissociated protein 1 137999 115 7 0.12 CAND family 
BASP1 Brain acid soluble protein 1 22680 111 5 0.74 BASP1 family 
VISA Isoform 1 of Mitochondrial antiviral-signaling protein 57063 110 4 0.16  
USP14 Ubiquitin carboxyl-terminal hydrolase 14 56489 109 4 0.22 peptidase family 
DERP12 38340 108 6 0.39  
VDAC3 Isoform 1 of Voltage-dependent anion-selective channel protein 3 30981 108 3 0.23 eukaryotic mitochondrial porin family 
VAPB Isoform 1 of Vesicle-associated membrane protein-associated 
protein B/C 
27439 107 6 0.77 VAMP-associated protein family 
AIFM1 Isoform 1 of Apoptosis-inducing factor 1, mitochondrial precursor 67144 107 5 0.15 FAD-dependent oxidoreductase family 
PICALM Isoform 2 of Phosphatidylinositol-binding clathrin assembly 
protein 
68892 106 2 0.09  
CNDP2 Cytosolic non-specific dipeptidase 41770 103 5 0.24 peptidase family 
BRI3BP BRI3-binding protein 27932 102 3 0.12  
PTPN1 Tyrosine-protein phosphatase non-receptor type 1 50505 101 5 0.25 protein-tyrosine phosphatase family 
ALDH7A1 Similar to Antiquitin 59020 99 2 0.1 aldehyde dehydrogenase family 
SRP54 Signal recognition particle 54 kDa protein 55953 99 4 0.23 GTP-binding SRP family 
YWHAB Isoform Long of 14-3-3 protein beta/alpha 28179 98 4 0.4 14-3-3 family 
YWHAE 14-3-3 protein epsilon 29326 98 4 0.38 14-3-3 family 
TACSTD1 Tumor-associated calcium signal transducer 1 precursor 35582 97 3 0.17 EPCAM family  
MARCKS Myristoylated alanine-rich C-kinase substrate 31707 96 3 0.22 MARCKS family. 
ANXA7 Isoform 1 of Annexin A7 52991 95 6 0.24 annexin family 
ARFIP1 Isoform A of Arfaptin-1 38632 92 3 0.24  
RANBP5 127 kDa protein 127923 91 5 0.08 importin beta family 
SERPINH1 Serpin H1 precursor 46525 91 3 0.2 serpin family 
PSMB5 Putative uncharacterized protein DKFZp686I0180 (Fragment) 28962 90 2 0.11 peptidase family 
RAD23B UV excision repair protein RAD23 homolog B 43202 90 8 0.39 RAD23 family 
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CLCC1 Isoform 1 of Chloride channel CLIC-like protein 1 precursor 62667 87 4 0.11 chloride channel MCLC family 
GNAS Isoform XLas-1 of Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms XLas 
111697 85 5 0.08 G-alpha family 
RAB3A Ras-related protein Rab-3A 25196 85 3 0.28 Rab family 
PSMC6 26S protease regulatory subunit S10B 44430 85 3 0.21 AAA ATPase family 
HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 57828 85 5 0.16 HMG-CoA synthase family 
SH3GLB2 Isoform 1 of SH3 domain GRB2-like protein B2 44175 84 4 0.21 endophilin family 
RUVBL1 Isoform 1 of RuvB-like 1 50538 84 5 0.25 RuvB family 
RAB11B Ras-related protein Rab-11B 24588 84 3 0.46 Rab family 
TOMM40 Isoform 1 of Probable mitochondrial import receptor subunit 
TOM40 homolog 
38211 83 4 0.34 Tom40 family 
ATP6V1A Vacuolar ATP synthase catalytic subunit A 68660 82 3 0.09 ATPase alpha/beta chains family 
OAT Ornithine aminotransferase, mitochondrial precursor 48846 81 3 0.19 class-III pyridoxal-phosphate-dependent 
aminotransferase family 
FUBP1 Isoform 1 of Far upstream element-binding protein 1 67690 80 5 0.18  
EIF4G1 EIF4G1 variant protein (Fragment) 178843 77 4 0.06  
TMPO Isoform Beta of Lamina-associated polypeptide 2, isoforms 
beta/gamma 
50696 77 3 0.18 LEM family 
CCT6A T-complex protein 1 subunit zeta 58444 77 2 0.12 TCP-1 chaperonin family 
ASAH1 Acid ceramidase precursor 45077 77 2 0.15 acid ceramidase family 
ATP1B3 Sodium/potassium-transporting ATPase subunit beta-3 31834 77 2 0.22 potassium ATPases subunit beta family 
FBP1 Fructose-1,6-bisphosphatase 1 37190 76 5 0.29 FBPase class 1 family 
PSMB3 Proteasome subunit beta type-3 23219 76 2 0.31 peptidase family 
SERPINB1 Leukocyte elastase inhibitor 42829 76 2 0.14 serpin family 
PCYOX1 Prenylcysteine oxidase 1 precursor 57003 75 4 0.22 prenylcysteine oxidase family 
CLPTM1 Isoform 2 of Cleft lip and palate transmembrane protein 1 79791 74 2 0.07 CLPTM1 family 
NCSTN Isoform 1 of Nicastrin precursor 79103 74 4 0.18 nicastrin family 
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GNS N-acetylglucosamine-6-sulfatase precursor 62840 74 3 0.15 sulfatase family  
ATP6V1H Isoform 1 of Vacuolar ATP syntha 56417 73 2 0.05 V-ATPase H subunit family 
ATP6AP1 Vacuolar ATP synthase subunit S1 precursor 52164 72 4 0.24 vacuolar ATPase subunit S1 family 
SNX2 Sorting nexin-2 58549 72 3 0.18 sorting nexin family 
ERP29 Endoplasmic reticulum protein ERp29 precursor 29032 72 4 0.54  
S100A11 Protein S100-A11 11847 72 3 0.66 S-100 family 
BAT3 Isoform 1 of Large proline-ric 120639 71 3 0.08  
F3B Isoform 1 of Eukaryotic translation initi 92833 71 2 0.04 eIF-3 subunit B family. 
TXNDC5;MUTED Thioredoxin domain-containing protein 5 precursor 48283 71 5 0.26 protein disulfide isomerase family 
CKAP4 Isoform 1 of Cytoskeleton-associated protein 4 66097 70 6 0.03  
RPL5 60S ribosomal protein L5 34569 70 2 0.2 ribosomal protein L18P family 
EIF2S2 Eukaryotic translation initiation factor 2 subunit 2 38706 69 2 0.16 eIF-2-beta/eIF-5 family. 
RTN4 Isoform 1 of Reticulon-4 130420 68 5 0.09  
PPT1 Palmitoyl-protein thioesterase 1 precursor 76216 68 4 0.13 palmitoyl-protein thioesterase family 
KYNU Kynureninase 52831 68 2 0.13 kynureninase family. 
UBQLN4 Ubiquilin-4 63869 67 2 0.05  
SCARB2 Lysosome membrane protein 2 54712 62 3 0.11 CD36 family 
FLJ22662 hypothetical protein LOC79887 63499 62 2 0.09 phospholipase B-like family 
LAP3 Isoform 1 of Cytosol aminopeptidase 56530 61 2 0.11 peptidase family 
IMMT Isoform 1 of Mitochondrial inner membrane protein 84026 61 4 0.11  
UQCRC2 Ubiquinol-cytochrome-c reductase complex core protein 2, 
mitochondrial precursor 
48584 59 2 0.12 peptidase family 
LAMP2 Isoform LAMP-2A of Lysosome-associated membrane 
glycoprotein 2 precursor 
45503 59 2 0.13 LAMP family 
RUVBL2 RuvB-like 2 51296 58 2 0.12 peptidase family 
PRKACA Isoform 2 of cAMP-dependent protein kinase, alpha-catalytic 
subunit 
39911 55 2 0.15 protein kinase superfamily 
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Chapter 7 Conclusion remarks 
 In summary, we developed some new unnatural amino acids which mimic 
pTyr in this study. Protein phosphorylation, targeted to tyrosine residues, plays a 
critical role in regulating many fundamental cellular processes including growth 
differentiation, metabolism, cell cycle progression, cell adhesion and migration, ion 
channel activity and immune response. Current knowledge of pTyr related proteins 
and domains have been mostly derived from experiments using gene knockout or 
overexpression techniques. However, these approaches do not provide an adequate 
view of the temporal, spatial and dynamic properties of proteins and domains in cell 
signaling. Given the large number and complexity of cellular system, we focused on 
novel pTyr mimic with better bioavaibility and new mechanism-based probes. 
 As described in Chapter 2, we synthesized a novel unnatural amino acid which 
mimics phosphotyrosine. The pTyr was replaced with a non-hydrolyzable isoxazole 
carboxylic acid. The new mimic possesses better cell permeability and hydrolytic 
stability. This unnatural amino acid can be readily incorporated into SH2 domain 
inhibitors, such as ISS 610 (a known STAT3 PPI inhibitor), to derive a new inhibitor 
which has better pharmacological properties without losing most of its inhibitory 
activity against STAT3. Its incorporation into a known STAT3 SH2 domain inhibitor 
further confirmed our design principle. This opens up opportunities to study the 
incorporation of this amino acid into other pTyr-containing higher biological active 
small molecules and proteins to further understand the studies of PTP biology. 
Furthermore, this mimic could potentially be incorporated into proteins using the 
nonsense suppression technology. 
172 
 
 In Chapter 3, since most of PTP fluorogenic substrates diffuse from the site of 
dephosphorylation making it not suitable for cell based assays, we synthesized the 
first self-immobilizing, fluorogenic unnatural amino acid that mimics pTyr. Using 
solid-phase peptide synthesis, it was subsequently incorporated into peptide-based 
localization probes which were applied in bioimaging and fluorescence-activated cell 
sorting. However, due to the highly pH sensitivity and low quantum yield of coumarin, 
the mimic could be modified to improve the properties. Nevertheless, as this study is 
based on an unnatural amino acid, the incorporation of this mimic to peptides, 
proteins and other biological active compounds could be explored to improve the 
recognition and specificity in detecting PTP activity in cellular systems. 
 Activity-based protein profiling (ABPP) has emerged as a powerful chemical 
proteomic approach for fingerprinting and identifying targets/off-targets of 
known/unknown drugs. ABPPs have already been widely used in PTP family, 
however, due to the high homology of PTP active site, the development of specific 
probes to target specific PTP still remains to be addressed. In Chapter 4, inspired from 
the Ugi reaction and the bidentate ligand concept developed by Zhang group, we 
rapidly assembled a small library of PTP probes to explore the fingerprinting of 
different PTPs and profiling its cellular targets. In future, ABPs could be assembled in 
other high-through put manner, like the microwave solid-phase synthesis to generate a 
large library with different scaffolds. Furthermore, other multi-component reactions 
(MCR) can also be used in ABPs development. The combination of MCR and ABPP 
will become another useful chemical tool in “Catalomic” field. 
 Moreover, in Chapter 5, we continued to develop new phosphotyrosine 
mimics and converted a known PTP1B inhibitor to four activity based probes. The 
four “clickable” and cell-permeable probes containing either sulfonate or quinine 
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methide-base reactive group were successfully synthesized. Subsequently, proteome-
wide profiling of potential cellular targets in the live MCF-7 cancer cells was 
performed. However, based on the pull-down experiments followed by mass 
spectrometry validation, PDI family proteins were found to be the major and specific 
targets of vinyl sulfonate probes not PTP family. As this VS probe is failed to be a 
suitable probe for PTP family, new probes should be done to further investigate PTPs 
function in cellular process. Furthermore, this VS probe gave a bright prospective 
view in developing new inhibitors of PDI for better understanding its role in 
biological systems. 
 It is hoped that the pTyr mimics and MCR assembling probe approach 
developed in this study, could provide valuable chemical biological tools for 
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